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Résumé:  
La démence d'Alzheimer est une maladie neurodégénérative caractérisée par une 
perte progressive et irreversible des fonctions cognitives et des compétences 
intellectuelles. La maladie d’Alzheimer se présente sous deux formes: la forme familiale 
ou précoce (EOAD) qui représente 5% des cas et elle est liée à des mutations génétiques 
affectant le métabolisme des peptides amyloïde; et la forme tardive ou sporadique 
(LOAD) qui représente 95% des cas mais son étiologie est encore mal définie. 
Cependant, le vieillissement reste le principal facteur de risque pour développer LOAD. 
Les changements épigénétiques impliquant des modifications des histones jouent un rôle 
crucial dans les maladies neurodégénératives et le vieillissement lié à l'âge. Des données 
récentes ont décrit LOAD comme un désordre de l'épigénome et ont associé ce trouble à 
l'instabilité génomique. Les protéines Polycomb sont des modificateurs épigénétiques qui 
induisent le remodelage de la chromatine et la répression des gènes à l'hétérochromatine 
facultative. Nous rapportons que les souris hétérozygotes pour une protéine Polycomb 
développent avec l'âge un trouble neurologique ressemblant à LOAD caractérisé par 
l’altération des fonctions cognitives, la phosphorylation de la protéine tau, l'accumulation 
des peptides amyloïde, et le dysfonctionnement synaptique. Ce phénotype pathologique 
est précédé par la décondensation de l’hétérochromatine neuronale et l'activation de la 
réponse aux dommages à l'ADN. Parallèlement, une réduction d’expression de polycomb, 
malformations de l'hétérochromatine neuronale, et l'accumulation de dommages à l'ADN 
étaient également présents dans les cerveaux de patients LOAD. Remarquablement, les 
dommages de l'ADN ne sont pas distribués de façon aléatoire sur le génome mais sont 
enrichis au niveau des séquences répétitives. Les conclusions présentées dans cette thèse 
ont identifié des modifications épigénétiques spécifiques qui conduisent à une instabilité 
génomique aberrante menant à la formation de LOAD. Ces résultats vont aider au 
développement de nouveaux traitements qui peuvent potentiellement ralentir la 
neurodégénérescence. 
 
Mots clés: Polycomb, Maladie d’Alzheimer tardive, instabilité génomique, 
hétérochromatine.  
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Abstract: 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder 
characterized by progressive and irreversible decline in cognitive functions and thinking 
skills. There are two types of AD: early-onset or familial AD (EOAD) that accounts for 
5% of cases and is linked to mutations affecting the amyloid metabolism and late-onset or 
sporadic AD (LOAD), which accounts for 95% of cases, however the etiology of this 
type remains poorly delineated with ageing presenting the main risk factor. Epigenetic 
changes involving histone modifications play a critical role in ageing and age- related 
neurodegenerative diseases. Recent evidence describing LOAD as an epigenetic disorder 
has accrued, associating this disorder to global genomic instability.  Polycomb group 
proteins are epigenetic modifiers initiating chromatin remodeling and gene repression at 
facultative heterochromatin. We report that mice heterozygous for a polycomb protein 
develop with advancing age a neurological disorder resembling LOAD characterized by 
impaired memory behaviour, tau phosphorylation, amyloid accumulation, and synaptic 
dysfunction. Interestingly, this phenotype was preceded by neuronal heterochromatin 
decondensation and activation of DNA damage response. Concomitantly, polycomb 
deficiency, de-compaction of neuronal heterochromatin, and accumulation of DNA 
damage machinery were also characteristic of LOAD brains. Remarkably, DNA damage 
was not randomly distributed on the genome but enriched at heterochromatin. The 
findings presented in this thesis identified specific epigenetic modifications that lead to 
aberrant genomic instability in LOAD and will aid in the development of novel 
therapeutics, which may potentially slow neurodegeneration. 
 
Keywords:  Polycomb, Late-Onset Alzheimer’s disease, genomic instability, 
heterochromatin.   
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CHAPTER 1 
 
 Chapter 1 is a review of the literature and is divided into three main sections. In 
the first section, I describe the molecular mechanisms of the ageing process along with 
the numerous theories established so far to explain this phenomenon. Moreover, I 
emphasize on ageing related pathologies specifically Alzheimer’s disease. The second 
section recapitulates the basic knowledge of chromatin formation and maintenance, 
highlighting the regulation of constitutive heterochromatin and its implication in genomic 
instability and neurodegeneration. In the third section, I introduce the Polycomb group 
complexes, which act as transcriptional repressors, and I will specifically describe the 
function of the Polycomb gene Bmi1 in the brain.  
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CHAPTER 1 
 
 
 
 
 
INTRODUCTION: SECTION 1 
 
 
 
 
 
 
Ageing & Alzheimer’s disease 
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1.1.1. Cellular and organismal ageing 
 
Ageing is defined as the progressive degeneration of tissue function that 
ultimately leads to mortality. This functional decline can ensue from 1) impaired activity 
of post-mitotic cells or 2) from inability to replenish those dysfunctional cells due to 
failure of stem cells to sustain replication and cell divisions. Analyzing the ageing 
phenomenon first arose from evolutionary theories, dating back to Darwin and Wallace. 
Theorists aimed to understand why natural selection permits the global recession in 
health and fitness, the promoters of prolonged longevity [1]. Interestingly, Medawar in 
1952 hypothesized that the driving force of natural selection decreases with age, due to 
exposure and submission of living organisms to extrinsic age-related causes of mortality. 
According to him, there is little or no advantage from guarding the germline from 
mutations that only confer damaging consequences at old stage [2]. Other elegant 
hypotheses have also been proposed, adjusting Medawar’s original theory, including 1) 
the notion of antagonistic pleiotropy [3]. In this model, germline mutations that present 
beneficial effects in the early stage of life will be selected, even if they will confer 
detrimental effects later in life; as well as 2) the disposable soma theory, which describes 
ageing as an evolutionary exchange of resources between procreation and maintenance of 
somatic tissue [4,5]. Nonetheless, all these theories converge on the unique concept that, 
unlike many developmental processes, ageing is not a programmed phenomenon. The 
fact that ageing is a consequence of the decline with time in natural selection is 
significant when molecular notions of ageing are taken into consideration. It is important 
to determine if ageing pathways will be conserved among eukaryotes, if stochastic events 
will precipitate associated pathology and, whether the pathology related to ageing can be 
tracked back to the same original molecular causes in all cases [1].  
Various studies have accrued to delineate ageing molecular pathways through 
analyses of invertebrate model organisms, mammals and mammalian cells in culture. 
Many different, yet intersecting mechanisms have been suggested such as reactive 
oxygen species (ROS) accumulation, caloric intake, growth signaling, telomere 
shortening, genomic instability, and heterochromatin loss. 
	  	   4	  
1.1.1.1.ROS:  
Considered as the most acclaimed theory of ageing, in 1950, Harman proposed 
that accumulation of reactive oxygen species highly contributes to organismal ageing [6]. 
Mitochondria are dynamic organelles that modulate nutrient usage to provide the cell 
with energy, even during dramatic changes in diet and development. These organelles are 
also, however, the main producers of toxic reactive oxygen species (ROS) within the cell 
[7]. ROS are intermediate oxygen metabolites with or without an unpaired electron, 
comprising superoxide anions (O2-), hydroxyl radicals (OH.), alkoxyl radicals (RO.), 
peroxyradicals (ROO.), hydrogen peroxide (H2O2), and the oxygen singlet (O2). Intrinsic 
oxygen radicals are the byproducts of incomplete oxygen reduction during normal 
mitochondrial respiration, generated by complexes I and III, glycerol 3-phosphate 
dehydrogenase, and alpha ketoglutarate dehydrogenase. Extrinsic ROS are caused by 
external sources such as ionizing radiation, pollutants, allergens, microbes, and drugs. 
Through a process called radiolysis ionizing radiation interacts with water, which 
comprises 60% of the human body, resulting in formation of damaging metabolites [8].  
ROS, at low doses, function as second messengers in various physiological cascades 
involved in cell proliferation and differentiation, gene expression, and regulation of 
immune responses. For instance, Grune et al. demonstrated that 40 different genes are 
activated by H2O2 in mammalian cells. However, accumulation of free radicals promotes 
oxidative stress and is deleterious for cellular macromolecules, causing lipid 
peroxidation, cross-linked sulphur bridges in proteins, single and double DNA strand 
breaks, nucleic acid adducts such as 8-oxoguanine (8-OHG) and DNA cross-linking [9]. 
Cells possess several mechanisms to detoxify free radicals and prevent their oxidative 
damage. The antioxidant defense system includes endogenous enzymatic and non-
enzymatic components such as superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPx), and glutathione (GSH), as well as exogenous antioxidants such as 
vitamin C, vitamin E, carotenoids, and polyphenols. Endogenous and exogenous 
antioxidants cooperate synergistically to preserve or re-establish redox homeostasis, for 
example during the regeneration of vitamin E by glutathione. Numerous studies have 
been carried out to either increase or decrease antioxidant activity and evaluate the effects 
on ageing. The conclusions, however, are highly equivocal with findings supporting 
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longevity associated either with increased activity or reduced activity, and other results 
supporting that neither increased nor reduced activity has effect on lifespan extension 
[10,11,12,13,14].  
The central nervous system (CNS) is highly vulnerable to oxidative imbalance because it 
is enriched of polyunsaturated fatty acids (PUFAs) and has a high metabolic oxidative 
rate, but in contrast it possesses a relative paucity of antioxidant system compared with 
other organs. These observations corroborate further the key role of oxidative stress in the 
ageing phenomenon [15].  
 
1.1.1.2 Calorie restriction/Sirtuins:  
In 1935, McCay et al observed that caloric restriction (CR), a dietary regimen, in 
rats slows ageing and extends median and maximal lifespan [16]. Similar findings have 
been demonstrated in a variety of species including yeast, spiders, flies, fish, and mice 
[17,18]. Some observational studies also reported the impact of prolonged CR on health 
and longevity in humans. For example, Kagawa et al. documented the prevalence of 
centenarians on the island of Okinawa in Japan. School children in Okinawa consume 
62% (i.e. 48% less) of the recommended intake of total energy in Japan. For adults, total 
protein and lipid intakes were similar, but energy consumption was 20% less than 
Japanese national average. Interestingly, the rates of mortality caused by cerebral 
vascular disease, malignancy, and heart disease were respectively 59%, 69%, and 59% in 
Okinawa, compared to those of the rest of Japan [19]. Lifespan extension by caloric 
restriction reflects an important deceleration of ageing emerged from evidence that 
restriction retards age-related changes in the properties of proliferative and non-
proliferative cells in many tissues and various organ systems. Several theories have 
accrued to elaborate the mechanisms by which CR exerts its effect on longevity. An 
initial hypothesis suggested that delayed sexual maturation is a possible explanation, until 
it was proven that CR introduced in older animals also extends lifespan. Decreased 
metabolic rate is another potential mechanism, resulting in reduction of free radicals 
generation and altering insulin sensitivity [20]. It was also demonstrated that CR modifies 
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gene expression profiles; for instance in yeast, CR up-regulates Sir2 activity, a member of 
the sirtuins gene family [21].  
Abraham Lincoln once stated that God must have valued the common people because he 
created so many of them. Mother Nature must have felt the same way regarding the 
sirtuins, a large family of proteins that acquired enormous fame when Sir2 (Silent 
information regulator 2) was shown to extend lifespan in multiple model organisms 
[22,23]. In yeast, Sir2 promotes longevity by suppressing the generation of toxic 
extrachromosomal rDNA circles (ERCs) [24]. Moreover, an extra copy of the Sir2 gene 
increases replicative lifespan by 50%, whereas deleting Sir2 shortens yeast lifespan [22]. 
The Caenorhabditis elegans homologue Sir-2.1 also prolongs worm lifespan by binding 
to the worm forkhead protein DAF-16 [25]. Concomitantly in Drosophila, increased 
dosage of Sir2 promotes longevity [23]. Even though, correlation between Sir2 and 
longevity was well established, its enzymatic activity remained elusive for several years 
until 1999 when Tanny et al. solved the mystery and demonstrated that Sir2 possess 
NAD-dependent ADP-ribosyltransferase activity [26]. Consequent studies revealed that 
Sir2 mediates another catalytic reaction, NAD-dependent histone deacetylation. During 
deacetylation, sirtuins cleave NAD and produce the novel metabolites, 2' and 3'-O-acetyl-
ADP-ribose, which are important regulators of physiology [27,28].  
Mammals possess seven Sir2 homologs (SIRT1–7) that bear a highly conserved NAD-
dependent sirtuin core domain [29]. Mammalian sirtuins have various cellular locations, 
target numerous substrates, and affect a wide range of cellular functions. SIRT1, SIRT6, 
and SIRT7 are nuclear proteins with SIRT1 being the most extensively studied sirtuin to 
date [30]. SIRT1 mutant mice can survive into adulthood but demonstrate a severe 
phenotype including small size, delayed bone mineralization, defective skeletal closure, 
delayed eyelid opening, and sterility. SIRT1 protects the cell against oxidative stress and 
DNA damage [30]. Several physiological processes affected during ageing and altered by 
CR are regulated by SIRT1, which deacetylates a broad number of substrates such as p53, 
Ku70, NF-κB, and forkhead proteins [31,32,33]. SIRT1 deacetylates histones H1K26, 
H3K9, H3K14, and H4K16 as well as reduces the methylation of H3K79 [27,34]. SIRT1 
also directs differentiation of muscle cells, adipogenesis, fat storage in white adipose 
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tissue, and metabolism in the liver, through regulation of nuclear receptor PPARγ and 
PGC-α hence linking SIRT1 with diets that promote longevity [30]. SIRT1 has also been 
described as a neuroprotective protein. Interestingly, CR guards against 
neurodegenerative pathology in mouse models for Alzheimer's and Parkinson's diseases 
[35,36]. SIRT1 induces survival in cultured neuronal cells and operates as an anti-
apoptotic factor through downregulation of p53 and FOXO [37, 38]. β-amyloid-induced 
death of microglia is counteracted by overexpression of SIRT1 or by treatment with Sir2-
activating polyphenol, resveratrol [39]. Overall, the above observations indicate that 
SIRT1 induction may be a novel strategy to treat neurodegenerative diseases.  
SIRT6 is a nuclear protein widely expressed in mouse tissues. SIRT6 KO mice manifest 
premature ageing symptoms including loss of subcutaneous fat and decreased bone 
density. SIRT6-/- mice die within 4 weeks after birth and exhibit a deficiency in one 
specific form of DNA repair, the base excision repair (BER).  SIRT6-/- MEFs show 
impaired proliferation, enhanced sensitivity to DNA damaging agents, genomic 
instability in the form of chromosomal translocations, and detached fragmented 
centromeres [40].  
SIRT3 protein is localized at mitochondria, which is particularly enthralling because 
mitochondrial dysfunction is highly associated with mammalian ageing and with various 
diseases including neurodegenerative disorders and cancer. Lifespan analysis of animals 
with different SIRT3 dosage levels has not yet been achieved; however, there is growing 
indication associating mitochondrial sirtuins with energy usage and human lifespan. For 
instance, human population studies revealed that polymorphisms within the SIRT3 gene 
are linked to longevity. The G477T transversion, which do not change the amino acid 
sequence, promotes survivorship of elderly males and may imply a haplotype 
contributing to longevity [41]. The same authors also reported that different number of 
tandem repeats (VNTR) enhancer within SIRT3 gene correlates with increased lifespan 
(i.e. >90 yr) [42]. In brown adipose tissue of obese mice, overexpression of SIRT3 
triggered upregulation of the uncoupling protein UCP1 in the mitochondrial inner 
membrane, which led to decreased energy expenditure and reduced oxidative stress. 
These observations suggest that SIRT3 may modulate longevity and raise the importance 
of performing lifespan experiments in mice that overexpress or lack SIRT3.  
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In conclusion, sirtuins have emerged as key anti-ageing genes in several model organisms 
(Figure 1). The NAD-dependence of these enzymes links them unavoidably to the 
metabolic activity of cells. In various models, sirtuins have been demonstrated to be 
regulated by and to mediate the effects of the dietary regimen CR. Moreover, mammalian 
sirtuins have been implicated in stress resistance and numerous metabolic pathways, 
including adipogenesis, gluconeogenesis, and insulin and glucose homeostasis. While it 
may be years before we know whether sirtuins regulate mammalian lifespan, current data 
suggests that these proteins are regulated by diet and in turn, regulate multiple facets of 
physiology, making them interesting therapeutic targets for metabolic and 
neurodegenerative diseases.  
                    
Figure 1: Sirtuins are NAD+-dependent deacetylases that target histones and other non-
histone substrates to regulate a wide range of cellular functions including cellular 
senescence, survival, DNA repair, metabolism, and cell cycle progression. The multi-
facets of sirtuins function earn them the title of key anti-ageing genes. Adapted from 
Oellerich M.F. and Potente M. (2012) Circulation Research 110; 1238-1251. 
 
 
 1.1.1.3 Growth/Target of Rapamycin (TOR) signaling: 
At first glance, ageing and growth are considered as mutually exclusive opposite 
events. Growth is described as synthesis of macromolecules from simple nutrients 
sustained by energy intake, and hence as increase of order and decrease of entropy. 
Ageing is synonymous to decay, meaning loss of order and greater entropy. However, 
interesting studies demonstrated that this rationale is erroneous and showed that reduced 
growth also decelerates the ageing process and prolongs lifespan. For instance caloric 
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restriction, as described in the paragraph above, inhibits growth and promotes longevity 
in various species from yeast to mice [43]. Rapamycin, an inhibitor of growth in yeast, 
decreases yeast aging. Repression of the growth-promoting insulin/IGF-1 signaling 
pathway extends lifespan, from worms to rodents. Therefore, growth and ageing are not 
antagonists but rather are complements of one another, determined by the same molecular 
pathway. In other words, excessive growth contributes to ageing and the molecular 
mechanism that drives both growth and ageing is the evolutionarily conserved TOR 
(target of rapamycin) pathway [43, 44]. 
TOR, as its name suggests, was originally identified in yeast as the target of the 
antifungal drug rapamycin, which is a natural secondary metabolite generated by soil 
bacteria to impede growth of fungal competitors. Interestingly, TOR is conserved 
structurally and functionally from yeast to human as crucial regulator of growth and 
metabolism [44]. In mammals, TOR (mTOR) modulates cell growth depending on 
nutrients (e.g., amino acids), growth factors (e.g., insulin, IGF-1), and cellular energy 
level (ATP) [45]. TOR activates anabolic processes such as transcription, translation, 
ribosome biogenesis, nutrient transport, as well as mitochondrial metabolism and in 
contrast inhibits catabolic activities such as mRNA degradation, ubiquitin-dependent 
proteolysis, and autophagy. TOR is an atypical serine/threonine kinase present in two 
functionally and structurally different multiprotein complexes: the rapamycin sensitive 
TORC1 and the rapamycin insensitive TORC2. mTORC1 regulates translation through 
phosphorylation of S6K and 4E-BP1; mTORC2 controls cell survival via phosphorylation 
of Akt/PKB [44, 45, 46, 47, 48].  
Budding yeast S. cerevisiae is a particularly convenient system for ageing analysis since 
1) it can be used to examine both replicative ageing (measured by the number of cell 
divisions) as well as chronological ageing (determined by the length of time a post-
mitotic cell can survive); and 2) because of yeast’s unicellularity where the cell is actually 
the organism and therefore it is a model for cell ageing and organismal longevity [49,50]. 
Inactivation of TORC1 signaling in yeast prolongs both replicative and chronological 
lifespan indicating that TOR engenders the ageing process regardless of physiological 
context (mitotic or post-mitotic cells). TOR also modulates longevity in multicellular 
organisms. Vellai et al. demonstrated that knocking down TOR in C. elegans doubles 
	  	   10	  
maximal lifespan [51]. Subsequently Jia et al. observed that worms deficient in raptor, a 
TORC1-specific subunit, also presented extended lifespan [52]. In Drosophila, TOR is 
essential during larval development and genetic inhibition of TOR pathway prolongs 
lifespan. Remarkably, the lifespan extension is detected upon down regulation of TOR 
signaling in the fat body, underlining the role of fat in ageing. Furthermore, inhibition of 
TOR signaling in the fat body not only lengthens the life of the fly but also decreases the 
size of the entire organism associating again growth and ageing [53,54,55,56]. In mice, 
reduced insulin/IGF-1 signaling in adipose tissue deactivates downstream mTOR 
pathway and increases lifespan. Moreover, IGF-1 deficiency promotes lifespan extension 
in rodents. Similarly, downregulation of mTORC1 or mTORC1 effector S6K prevents 
age-and-diet induced obesity in mice [57, 58].  
Numerous studies indicate that TORC1 regulates ageing through its downstream 
mechanisms such as autophagy, ribosome biogenesis, protein synthesis, transcription, and 
mitochondrial activity. TORC1 inhibits autophagy, which is defined by bulk degradation 
of proteins and organelles in lysosomes; autophagy is highly reduced in aging and age-
related diseases. Additionally, autophagy is required for lifespan extension in worms. 
These observations indicate that TORC1 favors the ageing phenomenon in part via 
inhibition of autophagy [59,60,61,62].  
TORC1 positively regulates ribosome and protein synthesis. Recent evidence showed that 
reduced ribosome biogenesis and repressed translation prolongs lifespan. Indeed, 
downregulation of ribosomal proteins and translation initiation factors promotes 
longevity in both yeast and worms. Therefore, TORC1 may drive the ageing process via 
activation of ribosome biogenesis and protein synthesis [63,64]. 
The nicotinamidase gene PCN1 is associated with longevity and is transcriptionally 
activated upon TOR inhibition. Remarkably, nicotinamidase converts nicotinamide to 
NAD+ that ultimately activates Sir2 denoting that TOR and sirtuins are part of the same 
longevity pathway [65,66]. Accumulation of aggregation-prone proteins is a 
neurodegenerative feature. Studies revealed that TOR engenders neurodegeneration in a 
Drosophila tauopathy model and that it is implicated in Alzheimer's disease by initiating 
Tau protein synthesis [67,68]. In contrast, rapamycin increases clearance of pathologic 
proteins reducing their neurotoxicity [69]. 
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Cell growth and division are the basic essential features of life. However, the growth-
regulating TOR signaling pathway appears to also bear the seeds of death. Ageing and its 
pathological manifestations present excessive growth-driven signaling when growth is no 
longer attainable. Therefore, ageing may be considered as prolongation of the same 
process that modulates developmental growth.  
 
1.1.1.4 Senescence: 
In 1961, Hayflick and Moorfield were first to describe cellular senescence 
through their observation that cultured normal human fibroblasts had limited ability to 
replicate and proliferate, becoming eventually permanently arrested [70]. This finding 
spawned two interesting hypotheses: 1) since cultured cancer cells proliferate 
indefinitely, cellular senescence is a mechanism to prevent cancer formation and hence 
acts as tumor suppressive process; 2) tissue renewal and repair degenerate with age and 
therefore cellular senescence was anticipated to recapitulate the ageing of cells. Studies 
have ultimately demonstrated that these two hypotheses coalesced and brought new 
insights into the fields of cancer and ageing [71,72].  
Hallmarks of cellular senescence consist of cell cycle arrest that occurs mostly in G1 
phase, up-regulation of cell cycle inhibitors mainly p21 and p16, silencing of E2F target 
genes by chromatin reorganization into discrete foci called senescence associated 
heterochromatin foci (SAHFs), induced expression of secretory proteins that alter the 
tissue microenvironment, apoptotic resistance, active metabolism, and enlarged 
morphology [72,73,74]. Cells undergo senescence in response to 1) dysfunctional 
telomeres and other genotoxic stresses that ultimately induce a DNA damage response 
mediated by the tumor suppressor protein p53; or due to 2) up-regulation of p16INK4A-pRb 
tumor suppressor pathway [75,76,77,78]. 
 Telomere shortening:  
Barbara McClintock and Herman Muller were the first investigators to demonstrate that 
chromosome ends consist of special structures required for chromosome stability [79,80]. 
Muller described these structures as telomere from the Greek for “end” telos and “part” 
meros. Telomeres are simple tandem non-coding DNA repeats (5’-TTAGGG-3’/5’-
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CCCTAA-3’) ending with single strand G-rich overhangs that fold into 3-dimensional 
structures termed “T-loops”, ensuring perfect capping of the chromosome termini [81]. 
Standard DNA polymerases cannot replicate the entire DNA ends, a process called the 
“end-replication problem”. Therefore, cells lose approximately 50 base pairs of telomeric 
DNA during each S phase, a phenomenon termed as telomere shortening [82]. Critically 
short telomeres are dysfunctional and only few such telomeres are sufficient to initiate a 
full senescence response in the affected cell [83,84]. 
Dysfunctional telomeres activate a DNA damage response (DDR) similar to that elicited 
by double strand breaks (DSB), leading to p53 up-regulation, p21 expression, and cellular 
senescence.  DDR enables cells to sense the damage and to respond by arresting cell 
cycle progression and initiating repair if possible. DDR consists of nuclear foci 
containing the phosphorylated form of the histone variant H2AX, which co-localize with 
activated kinases such as ataxia telangiectasia mutated (ATM) and checkpoint-2 (CHK2) 
[85,86,87]. Such foci when physically present at telomeres are referred to as telomere 
dysfunction induced foci (TIF) [88,89]. Occurrence of TIF increases in dermal fibroblasts 
of aged primates [90]. 
Telomere attrition can also be accelerated by suppression of telomerase expression. 
Telomerase is an enzyme required to circumvent telomere shortening and promotes de 
novo synthesis of telomeres by extending the 3′ end of chromosomes through addition of 
TTAGGG repeats. The human core enzyme consists of 3 essential components: the 
telomerase RNA element (hTERC) serving as template for telomere sequence synthesis, 
the telomerase reverse transcriptase (hTERT) bearing the catalytic subunit activity, and 
the ribonucleoprotein dyskerin (DKC1) ensuring proper folding and stability of 
telomerase RNA [91,92,93,94,95]. In adult humans, telomerase remains only expressed 
in germ cells as well as certain stem cells and its expression is regulated at transcriptional 
level, alternative splicing, assembly, subcellular localization, and posttranslational 
modifications. Analyses of model organisms and studies on patients with telomerase 
mutations have revealed that short telomeres engender dire consequences. Though the 
phenotypes are quite different, all comprise some forms of age-associated pathology, 
premature ageing and early death [96]. Mice carrying homozygous deletion of the RNA 
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component mTerc-/- or of the catalytic subunit mTert-/- manifest progeroid phenotype, 
specifically affecting organ systems with high rate of cell turnover. Genetic mutations in 
hTERC were identified in patients with dyskeratosis congenita (DKC). Affected 
individuals present short stature, suffer from hypogonadism and infertility, have defects 
in the skin and in the hematopoietic system, and eventually die of bone marrow failure 
[97,98,99]. Mutations in hTERT have been correlated to several forms of anemia and 
idiopathic pulmonary fibrosis, which is an adult-onset lethal disease of progressive lung 
scarring, followed by respiratory failure [100,101]. Human segmental progeroid 
syndromes such as Werner's syndrome (WS) and Hutchinson-Gilford progeria syndrome 
(HGPS) gave important insights to cellular senescence, and cells from such patients 
present greatly reduced in vitro lifespans [102, 103]. Although the genetic defects in WS 
and HGPS are quite distinct, the observed accelerated cellular senescence was found to 
be associated with increased rates of telomere shortening [96,103,104]. A significant 
number of age-associated pathologies, such as cardiovascular disease, osteoarthritis, 
diabetes and Alzheimer's disease have also been correlated with telomere shortening 
[104,105,106,107]. Moreover, individuals with short telomeres had a 3.18 fold higher 
mortality rate from heart diseases, and 8.54 higher mortality rate from infectious diseases, 
compared to those with relatively long telomeres [96].  
It is generally accepted that telomere attrition with age, which compromises the 
replicative lifespan of somatic cells in normal individuals, poses a barrier for the growth 
of aspiring malignant cells and hence operates as tumor suppressor mechanism; however, 
as a downside, it contributes to the collapse of cellular function and impaired organ 
maintenance. The intricate connection of telomere in both ageing and cancer ensures that 
pathways involving telomeres and telomerase will stay subject to intensive studies for 
many years to come. Understanding these pathways will help identify molecular targets 
for future therapies aiming to improve organ maintenance, tissue regeneration, and health 
in the growing population of the elderly.  
Upregulation of the CDKN2A gene (cyclin-dependent kinase inhibitor p16INK4a) 
p16 inactivates cyclin dependent kinases CDK4 and CDK6 maintaining the 
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retinoblastoma protein (pRB) in its active hypophosphorylated form and consequently 
blocking cell cycle progression in G1 [108]. The expression of p16 is triggered by a wide 
variety of stresses such as oncogene activation as well as DDR signals and has been 
therefore stated as potent biomarker of senescence [109,110,111,112]. The p16 pathway 
is crucial for generating SAHFs to silence the genes required for replication and 
proliferation. SAHFs necessitate several days to form and implicate transient interactions 
among chromatin-modifying proteins such as HIRA (histone repressor A), ASF1a (anti-
silencing function-1a) and HP1. Eventually, each SAHF includes portions of a single 
condensed chromosome, which is depleted for the linker histone H1 and enriched for 
HP1 and the histone variant macroH2A [71]. Although SAHFs are not found in all 
senescent cells, the p16–pRB pathway might establish chromatin conformations that are 
functionally equivalent to SAHFs in cells that do not develop these structures [71,74]. 
p16 expression is triggered by oncogenic RAS through activation of ETS transcription 
factors and is downregulated by the members of the polycomb family of repressors BMI1 
and CBX7 [113,114,115,116,117]. The regulation of p16 is particularly important in the 
age-related decline of stem and progenitor cells. Several studies demonstrated that the 
induction of p16 correlated with the in vivo senescence of hematopoietic stem cells 
[118,119,120]. In parallel, Bmi1 deficient mice displayed a striking loss of hematopoietic 
cells and cerebellar neurons, which were correlated with p16 overexpression as well as 
replicative failure of stem cells [120,121,122]. In contrast, increased regenerative ability 
was found in bone marrow, pancreatic islets and forebrain of mice lacking p16 
[123,124,125]. These observations underline the notion that age-associated upregulation 
of p16 restricts self-renewal and disturbs tissue homeostasis as well as associate p16-
dependent senescence in three hallmarks of ageing: decrements in neurogenesis, 
haematopoiesis and pancreatic function. Another interesting association between cellular 
senescence and ageing was provided by studies of mice lacking the p53-related gene p63 
[126]. Mutant animals displayed enhanced p16 expression, impaired stem cell renewal, 
widespread senescence, and accelerated ageing [127]. In humans, p16 overexpression 
was detected in ageing skin and kidneys [128,129]. Furthermore, upregulation of p16 has 
been observed in senescent human cardiomyocytes and hence has been proposed as 
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contributor to myocardial ageing [130,131,132].  
In conclusion, cellular senescence is one of several factors that influence or may promote 
ageing and in order to establish a direct cause-effect relationship between cellular 
senescence and ageing, in vivo deceleration of cellular senescence rates is required along 
with concomitant demonstration of increased maximum lifespan. 
1.1.1.5 DNA damage/repair: 
Within the intricate cellular machinery, biomolecules (proteins, lipids and nucleic 
acids) are exposed to damaging reactions e.g. hydrolysis which may contribute ultimately 
for ageing. However impairment of certain macromolecules may be more detrimental for 
the cell than damage to other constituents [133]. Severe accelerated ageing phenotype 
was observed in a battery of human syndromes and in mice with genetic defects in DNA 
metabolism, denoting that genomic damage is a main culprit in the ageing process. In 
general, all biomolecules are renewable except for nuclear DNA, which is the 
irreplaceable blueprint for RNA and protein coding information. Normal cellular function 
depends on the integrity of the genome that must be conserved during the entire 
organism’s lifetime and must be faithfully transmitted. Any acquired mutation in coding 
regions of DNA that was not properly repaired will trigger abnormal protein expression 
or function; moreover, chromosomal translocations or rearrangements induce apoptosis 
or senescence [134].  In order to preserve its genetic information, the cell developed 
complex maintenance network including numerous sophisticated systems to repair 
nuclear and mitochondrial DNA damage, checkpoint and effector machineries that allow 
cell survival or initiate senescence/cell death when DNA is severely impaired, as well as 
processes that guard the epigenetic code [135,136,137]. DNA damage is not only 
triggered by exogenous sources such as UV, ionizing radiation, and various chemicals but 
also by enemies from within the cell such as reactive oxygen species [138]. DNA lesions 
are greatly diverse and the immense size of the mammalian genome makes it more 
injury-prone, aggravating further the DNA problem. Some lesions are 1) mainly 
mutagenic promoting cancer formation; or 2) primarily cytotoxic initiating cell death or 
senescence and causing degenerative manifestations associated with ageing. Cytotoxic 
lesions are hard to repair and include double-strand breaks (DSBs) triggered by radiation 
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or ROS as well as inter-strand crosslinks induced by chemical agents such as cisplatin 
[139,140]. Apart from the sort of damage, the frequency of lesions and their position in 
the genome also affect the outcome. Despite the effort of the genome maintenance 
network in counteracting the wide range of potential threats, it cannot manage all the 
insults inflicted on the genome which will lead to gradual accumulation of DNA damage 
and eventually cellular malfunctioning, loss of organismal homeostasis, and ageing [141].  
Consistent with the role of DNA damage in ageing, various DNA repair pathways have 
also been associated to the ageing process. Studies of mouse mutants deficient in DNA 
repair mechanisms have revealed premature appearance of various symptoms of ageing 
indistinguishable from the same phenotypes normally occurring much later in life. Also, 
rare progeroid human disorders were correlated with genetic defects in DNA repair 
response systems [142,143,144,145]. The cell ensures the removal of damaged bases and 
the repair of the resulting single stranded (ss) DNA lesions via the nucleotide excision 
repair (NER) mechanism. On the other hand, the repair of DSBs is mediated by non-
homologous end joining (NHEJ) or by homologous recombination (HR). NER pathway 
represents a multi-step 'detect-excise-and-patch' repair system and is further divided into 
global genome (GG) NER and transcription coupled (TC) NER. Defects in TC-NER 
induce cell death, resulting from lesions that stall the RNA polymerase II, and underlie a 
variety of human progeroid disorders including Cockayne syndrome (CS) as well as CS-
like brittle hair disorder trichothiodystrophy (TTD). Both conditions along with their 
associated mouse models show many symptoms of premature ageing, including 
progressive neurodevelopmental delay, cachexia, kyphosis, retinal degeneration and 
deafness. XFE is another progeroid syndrome caused by a defect in XPF-ERCC1, an 
endonuclease required for NER as well as for DNA inter-strand crosslink (ICL) repair. 
ICLs covalently link both strands of DNA, preventing transcription and replication, and 
hence are extremely cytotoxic. Failing defense against such spontaneous lesions triggers 
cell death and senescence, culminating in accelerated ageing, as observed in both Ercc1 
and Xpf mouse mutants and the human XFE [146,147,148]. Ataxia telangiectasia is an 
autosomal recessive disorder characterized by the development of progressive cerebellar 
degeneration, skin abnormalities (telangiectasia, atrophy, pigmentary abnormalities and 
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hair greying), immunodeficiency and a wide range of malignant neoplasms. The disease 
is caused by various mutations in the ATM gene, which plays an essential role in DNA 
damage signaling, DNA repair and telomere maintenance. Fanconi anemia (FA) is an 
autosomal recessive disease resulting from mutations in Fanconi genes (encoding any of 
12 Fanconi anemia complementation group proteins). These proteins are required for 
DNA damage and repair pathways. The disorder is coupled with accelerated telomere 
shortening, and abnormalities in telomere replication or repair are thought to play a role 
in the pathogenesis, specifically in the progression of the disease to immunodeficiency 
and bone marrow failure. Other “progeroid” genes that have been implicated in DNA 
replication and repair are the family of genes encoding the RecQ DNA helicases. One of 
the functions of these proteins is to aid in the resolution and repair of broken or stalled 
replication forks. Helicases that could be involved include RecQ protein-like 2 (RecQL2), 
RecQL3, and RecQL4 with known mutations that give rise to Werner (WRN), Bloom 
(BLM), and Rothmund Thompson syndromes, respectively [148].  
Evidently, impairments in distinct DNA repair systems for cytotoxic lesions account for a 
bewildering but specific range of age-related pathologies, which may also explain the 
different segmental nature of progerias. It remains to know the sequence of events 
leading from DNA damage repair to the activation of longevity assurance pathways. It is 
likely that there are other protective mechanisms that can help postpone ageing. These 
include reduced production of metabolic byproducts through regulation of metabolism 
and oxidative phosphorylation, as well as improved anti-oxidant/detoxification defenses, 
which reduce the DNA damage load and its noxious effects. In addition, improved overall 
repair are predicted to extend lifespan next to other mechanisms, including epigenetic 
modifications and protein metabolism.  
 
1.1.1.6 Heterochromatin loss: 
In eukaryotes, the genomic DNA is organized in highly ordered chromatin 
structures. Chromatin is formed of nucleosomes, which are 146-7 base pairs of DNA 
wrapped around an octamer of four major core histone dimers H2A, H2B, H3, and H4 
[149,150]. Designated as nuclear architecture, chromatin is organized into two 
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structurally distinct domains: 1) Euchromatin refers to open loose conformation where 
nucleosomes are distant, is rich in gene concentration, and is transcriptionally active. 2) 
Heterochromatin indicates closed condensed conformation where nucleosomes are tightly 
packed and is inaccessible for transcription factors. Trimethylation of histone H3 at lysine 
9 (H3K9me3) and recruitment of chromodomain proteins such as heterochromatin protein 
1 (HP1) are hallmarks of heterochromatin assembly and maintenance. Heterochromatin is 
additionally subdivided into two compartments: 1) the constitutive heterochromatin, 
which includes large portions of noncoding repetitive DNA elements (centromeric, 
pericentromeric, telomeric, and intergenic regions), is localized to nuclear periphery and 
is transcriptionally impeded in all cell types; whereas 2) the facultative heterochromatin 
contains E2F target genes, regulates X chromosome inactivation, is present anywhere in 
the nucleus, and is formed in certain subset of cells [151,152,153,154]. The notion that 
long-term maintenance of nuclear architecture is required to enable permanent normal 
functioning of cells and tissues has reinvigorated interest in studying the association 
between chromatin malformations and the ageing process. Villeponteau was first to put 
forth the loss of heterochromatin model of ageing and proposed that heterochromatin 
domains formed in embryogenesis are disrupted with advancing age, leading to de-
repression of silenced DNA and aberrant expression patterns [155]. The detrimental 
effect of abnormal heterochromatin formation is demonstrated in the Hutchinson-Gilford 
progeria syndrome (HGPS), which is an autosomal dominant disorder caused by gain-of-
function mutation in the LMNA gene encoding for lamin A/C [101]. HGPS patients 
manifest premature ageing aspects including extreme short stature, aged facial features, 
alopecia, lipodystrophy, scleroderma, osteolysis as well as atherosclerosis and they pass 
away usually at the age of 12 years as a consequence of myocardial infarction or stroke 
[156]. Cells extracted from HGPS patients exhibit abnormal nuclear architecture 
characterized by reduced presence of H3K9me3 and HP1 markers at the constitutive 
heterochromatin leading to de-repression of pericentric satellite III repeats [157]. Misteli 
et al. further delineated the mechanism of heterochromatin loss observed in HGPS 
patients and demonstrated that defects in the NURD chromatin remodeling complex 
associated with reduced HDAC1 activity are key modulators of premature ageing [158]. 
As mentioned earlier, Werner syndrome (WS) is a rare progeroid autosomal recessive 
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disorder caused by loss of function mutations in the WRN gene encoding a member of 
the RecQ helicase family implicated in DNA repair, DNA recombination, and telomere 
maintenance [159]. WS patients develop normally until puberty, at which time they stop 
growing and start displaying multiple progressive premature ageing pathologies including 
hair graying, pattern baldness, skin atrophy, senile bilateral cataracts, type 2 diabetes, 
hypogonadism, osteoporosis, and atherosclerosis. Patients present a significantly 
decreased life expectancy and death occurs at an average age of 47 usually as a result of 
cancer or myocardial infarction. WS cells express a dysfunctional RecQ helicase activity 
initiating hyper-recombination, chromosomal aberrations, and hence genomic instability 
especially at repetitive loci of constitutive heterochromatin [160]. This finding indicates 
that the accelerated ageing observed in WS patients stem from inefficient repression of 
deleterious recombination events and global genomic instability at constitutive 
heterochromatin. Several reports on different organisms further validated the association 
between loss of heterochromatin and ageing. In C.elegans, peripheral heterochromatin 
was disrupted in aged cells [161]. Progressive loss of heterochromatin correlated with 
advancing age in Drosophila and lamin proteins were shown to influence the impaired 
nuclear morphology and decreased lifespan [162,163]. Moreover, loss-of-function HP1 
mutant flies manifest shortened lifespan however overexpression of HP1 in Drosophila 
extends lifespan and reduces the breakdown of muscle integrity that is characteristic of 
old animals [164]. Moreover, inhibiting the activity of Jumonji domain-containing 
protein 2A (JMJD2A), a histone demethylase that catalyzes demethylation of histone H3 
at lysine 9, significantly extended the lifespan of Drosophila [165]. In humans, aged skin 
fibroblasts exhibited nuclear defects similar to those seen in HGPS cells involving 
histone modifications and increased DNA damage [166]. Age related loss of 
heterochromatic epigenetic silencing was actually described 20 years ago. Indeed, the 
major satellite repeats that constitute the pericentromeric heterochromatic domains were 
found to be overexpressed in old cardiac tissue, suggesting a gradual loss of silencing of 
these elements [167]. One mechanistic explanation to that phenomenon was proposed by 
Haider et al. who reported that aged individuals display impaired activity in their histone 
modifying enzymes engendering decondensation of perinuclear constitutive 
heterochromatin [168]. 
	  	   20	  
As stated earlier, ageing is also linked to increased formation of senescence associated 
heterochromatin foci, which occur however in facultative heterochromatin to silence 
specific genes. SAHFs are formed in sequential manner consisting of chromosomes 
decondensation, followed by H3K9 methylation, and binding of HP1 proteins. Therefore, 
ageing is associated with global decrease in constitutive heterochromatin levels but 
accompanied with increase of heterochromatin formation at specific gene loci i.e 
facultative heterochromatin. This phenomenon is defined as heterochromatin 
redistribution [169] (Figure 2). Another example underlining heterochromatin 
redistribution is the finding that DNA methylation, which is required for heterochromatin 
formation, gets depleted globally with advancing age specifically at constitutively 
heterochromatic repetitive DNA segments, but becomes enriched at gene specific loci 
involved in cancer and senescence. Redistribution of DNA methylation has been ascribed 
to the differential regulation of the DNA methyltransferases: Dnmt1, which maintains 
DNA methylation patterns and Dnmt3, which is a de novo DNA methyltransferase. 
Reports revealed that in ageing, expression and activity of Dnmt1 decreases 
concomitantly with upregulation of Dnmt3 [170,171,172,173,174,175].  
In conclusion, these findings suggest that loss of global heterochromatin model for ageing 
is described as net reduction in constitutive heterochromatin and redistribution of 
heterochromatin markers (H3K9me3 and HP1) for facultative heterochromatin, ultimately 
leading to altered transcriptional patterns associated with ageing. As stated before, 
understanding the complex molecular interactions related to ageing engendered multiple 
ageing models including ROS insult, genomic instability, programmed senescence, 
telomere shortening, calorie intake and growth signaling. All of these models can be 
unified with heterochromatin disruption as the overarching theme. Persistent activation of 
DNA damage response instigates alterations in chromatin organization and nuclear 
architecture, eventually promoting the inexorable changes associated with ageing.  
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Figure 2: Heterochromatin redistribution during ageing, characterized by loss of 
constitutive heterochromatin demonstrated by decreased H3K9 methylation and 
delocalization of HP1. Conversely, facultative heterochromatin formation increases at 
specific loci, particularly at senescence-associated heterochromatin foci (SAHFs). 
Adapted from Tsurumi A and Li X.W. (2012) Epigenetics 7:7, 680-688. 
 
1.1.2. Alzheimer’s disease 
 
Alzheimer’s disease (AD), which was nearly anonymous to the public a 
generation ago, currently represents an enormous concern at individual level and is an 
imminent catastrophe for society. Greater than 35 million people worldwide are affected 
with Alzheimer's disease, a neurodegenerative protean disorder characterized by gradual 
progression from episodic memory problems to global decline of cognitive functions and 
learning skills, ultimately leading to death within 3 to 9 years after diagnosis. Sadly, 
patients affected with AD quickly learn that there is yet no efficient disease modifying 
treatment and that they are destined to experience the dire consequences. Nevertheless, 
scientific research is constantly attempting to vary this bleak situation [176].  
1.1.2.1.Forms of AD: 
There are two main forms of Alzheimer 's disease:  
Familial early-onset AD (EOAD)  
EOAD accounts for less than 5% of all AD patients and affects individuals under 65 
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years of age. This early-onset autosomal dominant form of AD is triggered by mutations 
in three genes (amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 
(PSEN2)) as well as by duplication of the APP gene. From therapeutic perspective, 
targeting solely the pathological mechanisms inducing familial early-onset AD makes the 
implicit assumption that this form is fundamentally identical to the common sporadic 
late-onset form [177,178].  
Sporadic late-onset AD (LOAD)  
LOAD symptoms appear in people of 65 year-old and over, accounting for 95% of AD 
cases. The genetics of the more common form of AD are not yet elucidated and are 
presently subject to active investigation. The only genetic variant that has been identified 
as a risk factor for LOAD is the ε4 allele of the apolipoprotein E (APOE) gene, however 
even after a decade from the discovery of its role in AD progression, no consensus 
mechanism of pathogenesis has yet emerged [179]. The primary risk factor of LOAD is 
advancing age with incidence doubling every 5 years after 65 years of age. Additional 
potential risk genes identified by gene-expression profiling and whole-genome 
association studies include the Aβ chaperone clusterin, the mitochondrial transporter 
TOMM40, and the Sortillin-related receptor that functions to partition amyloid precursor 
protein away from β-secretase and γ-secretase. However, their underlying mechanisms 
are various, and whether any of these factors promote amyloid accumulation and 
tauopathy in humans is yet unknown [180,181,182,183]. 
 1.1.2.2. AD hallmarks: 
Several molecular lesions have been detected in AD patients but the overarching 
hallmarks are accumulation of misfolded proteins in the brain including amyloid plaques 
and neurofibrillary tangles, synaptic dysfunction, oxidative damage, and energy failure. 
β-Amyloid 
Cerebral plaques are loaded with β-amyloid peptides (Aβ), which are metabolites of 36 to 
43 amino acids. Aβ40 peptides are much more predominant than the aggregation-prone 
and toxic Aβ42 monomers. β-amyloid peptides are produced from proteolysis of the 
amyloid precursor protein (APP) performed by the consecutive actions of the β-secretase 
beta-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) and the γ-secretase 
presenilin 1(PSEN1) (Figure 3). The “amyloid hypothesis” of AD states that imbalance 
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between production, clearance, and aggregation of Aβ peptides promotes their 
aggregation and therefore initiates Alzheimer's disease. Aβ monomers possess natural 
self-aggregation potential and coexist in multiple physical forms. Primitive form 
comprises soluble oligomers of 2 to 6 peptides that coalesce into intermediate assemblies, 
and then arrange themselves into fibrils and eventually β-pleated sheets to establish the 
insoluble fibers of advanced amyloid plaques. Soluble oligomers and intermediate 
assemblies were demonstrated to be the most neurotoxic forms of Aβ, disrupting synaptic 
function. Moreover, the severity of cognitive impairment in AD patients correlated with 
high levels of oligomers in the brain and not with total Aβ burden 
[184,185,186,187,188,189,190].  
In normal physiological levels, Aβ functions at the synaptic junction to dampen 
excitatory transmission and prevent neuronal hyperactivity. Maintaining steady-state 
levels of Aβ levels depends on the proteases neprilysin and insulin-degrading enzyme. 
Neprilysin is a zinc endopeptidase that degrades Aβ monomers and oligomers, however 
reduced expression of this protease triggers accumulation of cerebral Aβ. Insulin-
degrading enzyme is a thiol metalloendopeptidase that cleaves small peptides including 
insulin and monomeric Aβ. Mice lacking insulin-degrading enzyme present 50% 
reduction in Aβ processing. Conversely, upregulation of neprilysin or insulin-degrading 
enzyme counteracts plaque accumulation [191,192]. 
                                   
 
Figure 3: Processing of APP. Cleavage by α-secretase initiates nonamyloidogenic 
processing releasing a large amyloid precursor protein (sAPPα) ectodomain and an 83-
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residue carboxy-terminal fragment. C83 is subsequently digested by γ-secretase, 
liberating extracellular p3 and the amyloid intracellular domain (AICD). Amyloidogenic 
processing is started by β-secretase beta-site amyloid precursor protein–cleaving enzyme 
1 (BACE-1), releasing a shortened sAPPα. The remained C99 is also a γ-secretase 
substrate, generating Aβ and AICD. Soluble Aβ is prone to aggregation. Adapted from 
Querfurth H. and LaFerla F. Alzheimer’s disease, NEJM 2010; 362:328-44. 
 
Tau tangles 
 
Neurofibrillary tangles are filamentous inclusions present in neurons of AD patients and 
comprise abnormally hyperphosphorylated and aggregated form of tau [193] (Figure 4). 
Tau is a soluble microtubule binding protein that is highly abundant in axons and is 
essential for stabilizing neuron’s cytoskeleton as well as vesicle transport. Conversely 
hyperphosphorylated tau is insoluble, disintegrated from microtubules, and self-
aggregated into paired helical filament structures (PHF) [194]. Activation of several 
kinases such as stress activated JNK kinase induces tau phosphorylation [195]. 
Similarly to Aβ oligomers, intermediate assemblies of hyperphosphorylated tau are the 
neurotoxic forms, impairing axonal transport and cognitive function. It was proposed that 
formation of insoluble helical filaments is a protective process through the sequestration 
of toxic intermediate tau species [196,197]. Several mutations in the Tau gene have been 
identified in patients with frontotemporal dementia, another neurodegenerative disorder. 
However, no Tau mutations have been detected in AD patients and the degree of neuron 
loss is out of proportion to the amount of neurofibrillary tangles [198]. Experimental 
evidence suggests that Aβ accumulation precedes and favors tau aggregation. Moreover, 
Aβ-induced degeneration of cultured neurons and cognitive deficits in mice with an 
Alzheimer's disease–like phenotype entail the presence of endogenous tau [199,200]. 
The ageing associated pathologies, such as increased oxidative stress, defective protein-
folding function of the endoplasmic reticulum, as well as impaired proteasome-mediated 
and autophagic-mediated clearance of damaged proteins, accelerate the deposition of 
amyloid and tau proteins in Alzheimer's disease [201,202]. 
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Figure 4: Formation of Tau tangles. Upon phosphorylation, tau protein detaches from 
microtubules and self-aggregates in form of tangled clumps. Adapted from Querfurth H. 
and LaFerla F. Alzheimer’s disease, NEJM 2010; 362:328-44. 
 
Synaptic dysfunction 
Alzheimer's disease is described as a disorder of synaptic failure [203]. It is important to 
note though that ageing by itself promotes synaptic impairment, particularly affecting the 
dentate region of the hippocampus [204]. Synapses at the hippocampus start to 
degenerate in individuals with mild cognitive impairment (MCI), a transitional form 
between normal ageing and AD, and the remaining synaptic junctions will enlarge their 
sizes in order to compensate. In mild AD, there is 25% reduction in the expression of 
presynaptic vesicle protein synaptophysin, however with advancing pathology, synapses 
become excessively lost relative to neurons correlating with dementia progression 
[205,206]. Long-term potentiation assay, which is an experimental indicator of memory 
formation at synapses, is severely reduced in mice with Alzheimer's disease as well as 
after application of Aβ peptides on normal brain slices [207]. At the molecular level, 
impaired memory formation is caused by inhibition of crucial signaling molecules. 
Defective release of presynaptic neurotransmitters and postsynaptic glutamate-receptor 
ion currents ensues from endocytosis of N-methyl-D-aspartate (NMDA) surface receptors 
and endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid surface 
receptors [208,209]. These events further decline the synaptic activity through permanent 
depression of the currents after a high-frequency stimulus. Intraneuronal Aβ was shown 
to trigger early these synaptic deficits [210]. 
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Oxidative Stress 
Another hallmark of Alzheimer's disease is increased oxidative stress. Dysfunctional 
mitochondria generate oxidizing free radicals, triggering considerable oxidative damage 
in AD brains. Aβ peptides perturb mitochondrial function by directly impairing 
extracellular transport chain complex activities, blocking mitochondrial import channels, 
disrupting calcium storage, and highly increasing ROS levels. Moreover, the receptor for 
advanced glycation end products is required for mediating Aβ's pro-oxidant effects on 
neurons and microglial cells [213,214]. Similarly, Tau oligomers engender mitochondrial 
dysfunction and oxidative stress by decreasing the levels of NADH-ubiquinone 
oxidoreductase, which forms the mitochondrial electron transport chain complex I [215]. 
 Although animal models and most cross-sectional studies in ageing populations present 
an association between antioxidant intake and cognitive performance, randomized trials 
of antioxidants have generally failed in improving cognitive function in AD [216].  
DNA damage/Repair/ Cell-Cycle Reentry 
Accumulation of DNA damage is particularly deleterious in post-mitotic cells such as 
neurons, which cannot be renewed through cell proliferation. Mounting evidence 
suggests that AD neurons have elevated levels of oxidative DNA damage leading to slow 
build-up of DNA adducts such as 8-OHG, DNA single strand breaks, DNA-DNA and 
DNA-protein cross linking [217,218]. Suram et al. demonstrated that soluble Aβ 
oligomers have DNA nicking activities similar to nucleases, causing a direct DNA 
damage [219]. Markers of aberrant cell-cycle reentry were detected in AD neurons but 
are mostly prominent at the G1–S phase boundary with some evidence showing cell cycle 
progression till the G2 phase. These abortive cell cycle events may proceed to complete 
DNA replication, forming tetraploid neurons and activation of mitotic cyclins as well as 
cyclin dependent kinases [220,221]. However, mitoses are absent hence these inductions 
are not indicative of neuronal cell division but are either the prelude of programmed cell 
death or the mechanism required for repairing DNA damage. PARP-1 is a DNA binding 
protein that is activated by SSBs as well as DSBs and is required for DNA repair 
processes. PARP-1 activity is induced by Aβ and it is increased in AD brains [222]. The 
Mre11 DNA repair complex consisting of Rad50, Mre11, and Nbs1 proteins is reduced in 
the neurons of AD cortex [223]. The non-homologous end joining (NHEJ) mechanism is 
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the predominant DNA repair process in neurons and requires the kinase DNA-PK 
complex. Shakelford et al. demonstrated that the level of DNA-PK catalytic subunit was 
significantly decreased in AD extracts, indicating that NHEJ pathway is less efficient in 
AD patients [224].  
1.1.2.3.Models of disease and limitations: 
Animal models are the best systems to analyze which disease-modifying strategy 
to pursue. Unfortunately, there is no animal model designed to recapitulate all the main 
hallmarks of AD. For instance, transgenic mice based on the amyloid hypothesis of AD, 
such as Tg2576 that overexpresses a mutant form of APP and deposits Aβ in a temporal 
and spatial pattern similar to human AD do not develop neuronal tangles or major 
neuronal loss. Similarly, tau transgenic models such as Tg4510, which overexpresses a 
mutant form of tau, develop neurofibrillary tangles, brain atrophy and functional deficits, 
but do not show amyloid deposition. Moreover, the transgenic mouse models used in AD 
studies mainly represent EOAD pathology and not LOAD pathology since they are based 
on overexpressing genes related to amyloid or tau metabolism without taking into 
account the ageing risk factor. The success of treatments in animals designed to model a 
pathological pathway predicts only that the treatment may successfully interfere with the 
pathway in patients, not that interference with the pathway will have efficacy in AD 
[176].  
1.1.2.4.Biomarkers: 
AD is currently diagnosed only via clinical assessments and confirmed by 
postmortem brain pathology. However, neurodegeneration in AD is estimated to start 20 
to 30 years before the first clinical symptoms become apparent. Hence, the development 
of validated biomarkers for Alzheimer's disease is essential to improve early diagnosis, to 
differentiate AD from other dementias, and to accelerate the development of new 
therapies that will be most effective before pathological changes spread throughout the 
brain. Clinical diagnosis of AD is based on medical records, physical and neurological 
examination, laboratory tests, neuroimaging, and neuropsychological evaluation. 
Neuroimaging markers predict AD progression from a pre-AD state of mild cognitive 
impairment (MCI), and can be used to monitor efficacies of disease-modifying therapies. 
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Measurements of cerebrospinal fluid (CSF) markers including levels of Aβ40, Aβ42, 
total tau, and phosphorylated tau are also useful in predicting the risk of progression from 
MCI to AD [225].  
There is no single linear chain of events that could summarize the heterogeneity of 
pathways initiating Alzheimer's disease. Thus, developing a multi-targeted approach to 
prevent or symptomatically treat AD is indispensable. Some studies put forth the notion 
that other pathological conditions, but not amyloid or tangle deposition, account for 
dementia in the elderly (80 years of age or older). It remains probable that many of these 
mechanisms and models, including the amyloid hypothesis, are minimal or incorrect and 
that some critical ageing-related process is the disease trigger. 
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1.2.1. Chromatin 
 
The human cells contain enough DNA to extend from earth to sun more than 300 
times back and forth. How is that humongous DNA packaged so densely into 
chromosomes and squeezed into a microscopic nucleus?  
The nucleus is the most prominent organelle within the eukaryotic cell, ranging from five 
to seven microns in diameter. It is a double membrane bound structure, which isolates the 
genetic material from the cytoplasm of the cell. The nuclear lamina consists of 
intermediate fibers named lamins, which are cytoskeletal proteins localized in the inner 
side of the nuclear membrane and are required to attach and position the chromatin within 
the nucleus [226]. Chromatin defines the state in which DNA is packaged within the 
nucleus. The repeating fundamental unit of chromatin is the nucleosome, which is 
composed of 147 base pairs of DNA wrapped in 1.7 superhelical turns around an octamer 
of four core histones (H3, H4, H2A, H2B). The nucleosomal array, described as beads-
on-a-string fiber with a diameter of 11-nm, forms the first level of chromatin 
organization. Binding of linker histones (H1 or H5) wraps another 20 base pairs and 
further folds the nucleosomal arrays into a more compact 30-nm chromatin structure, 
which represents the second structural level of DNA organization. DNA coiling requires 
energy that is provided by histones mainly in the form of electrostatic interactions. Since 
DNA is negatively charged due to the phosphate groups in its phosphate-sugar backbone 
and the histones are positively charged proteins due to their lysine residues at the N-
terminal tails, hence they bind with each other very tightly leading to chromatin 
condensation. As a result, chromatin will compress into a much smaller spatial volume 
within the nucleus compared to unwound DNA [149,150]. Chromatin conformation is 
highly dynamic affecting nuclear architecture, DNA repair, genomic stability as well as 
gene expression patterns and is regulated by post-translational covalent modifications of 
histones or by displacement of histones via chromatin remodeling complexes. These two 
processes are reversible, so modified or remodeled chromatin can be restored to its 
compact state after transcription, replication, or DNA repair are complete [226]. Post-
translational modifications of histones include:  
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1) Methylation, acetylation, ubiquitylation, and sumoylation of lysine residues. 
2) Methylation of arginine residues. 
3) Phosphorylation of threonine and serine residues. 
4) ADP-ribosylation of glutamate.  
In the early twentieth century, Emil Heitz identified cytologically detectable differences 
in the staining of chromatin. He noted that certain regions remain visible throughout 
interphase whereas other parts become invisible after exit of mitosis. He suggested the 
terms heterochromatin and euchromatin, respectively [227]. I already discussed the 
differences between these two conformations earlier in this chapter, however in this 
section, I will expand more about the formation of constitutive heterochromatin 
describing its imperative role in genomic stability.  
 
1.2.2. Constitutive heterochromatin 
 
Eukaryotic and human genes contain some repetitive DNA sequences, however, 
the majority of highly repetitive DNA sequences are localized outside the coding 
information and are described as constitutive heterochromatin [228]. There are two main 
types of repetitive heterochromatic DNA (Figure 5):  
1) Highly repetitive sequences are short sequences of 5-10 bp, which are not 
interspersed with different non-repetitive sequences. The main family of highly tandem 
repeats includes satellite DNA. They are represented by monomer sequences, usually less 
than 2000-bp long, tandemly reiterated up to 105 copies per haploid animals and are 
present in certain sub-chromosomal compartments including centromeres, telomeres, as 
well as pericentromeric domains [229]. Satellite DNA forms 1 to 65% of the total DNA 
of numerous organisms including animals, plants, and prokaryotes. Satellites are large 
arrays of AT rich DNA sequence motifs, which evolved within and across the species 
through nucleotide changes and copy number variations. The precise function of satellite 
DNA remains unclear, although they are being increasingly utilized as a versatile tool for 
genome analysis, genetic mapping and for understanding chromosomal organization 
[230]. Some human satellite DNAs are implicated in the function of centromeres, whose 
DNA consists very largely of various families of satellite DNA. The centromere is an 
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epigenetically deﬁned domain. Its function is independent of the underlying DNA 
sequence; instead, its function depends on its particular chromatin organization, which, 
once established, has to be stably maintained through multiple cell divisions [231].  
2) Moderately or dispersed repetitive sequences include short (150 to 300-bp) 
sequences or long ones (5-kbp) amounting about 40% and 1-2% of the total genome, 
respectively. These repeats are dispersed throughout the euchromatin having 103 to 105 
copies per haploid genome, hence forming the intergenic heterochromatin. These 
sequences operate as regulators of gene expression. On the basis of their mode of 
amplification, repetitive DNA sequences may be tandemly arranged or interspersed in the 
genome [232].  
a. Interspersed repeats also named transposable elements are mobile DNA sequences 
that can migrate to different regions of the genome and account for more than 
40% of the total human DNA sequence [233]. There are primarily two types of 
transposable elements comprising DNA transposons and retrotransposons. DNA 
transposons are described as fossils since they are inactive in the human genome 
due to their high mutational rate. Retrotransposons are the most important and 
most abundant active transposable segments. In order to displace, reverse 
transcriptase converts the RNA transcript of the retrotransposon into cDNA, 
which will eventually integrate into the genome at a new location. The 
predominant families of retrotransposons are long interspersed nuclear elements 
(LINEs) and short interspersed nuclear elements (SINEs). LINEs are very 
successful autonomous transposons since they can make all the products needed 
for retrotransposition, including the essential reverse transcriptase. Human LINEs 
consist of three distantly related families: LINE-1, LINE-2, and LINE-3, however, 
LINE-1 (or L1) is the only family that continues to have actively transposing 
members. To integrate into genomic DNA, the LINE-1 endonuclease cuts a DNA 
duplex at the cleavage site TTTTA; hence the preference for incorporating into 
gene-poor AT-rich regions imposes a lower mutational burden and makes it easier 
for the host to accommodate them. However, LINE-1 occasionally promotes 
disease progression by disrupting gene function after insertion into an important 
conserved sequence [233,234,237]. The LINE-1 machinery is also responsible for 
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most of the reverse transcription in the genome, allowing retrotransposition of the 
nonautonomous SINEs and also of copies of mRNA, giving rise to processed 
pseudogenes and retrogenes. SINEs are retrotransposons that have been very 
successful in colonizing mammalian genomes, resulting in various interspersed 
DNA families, some with extremely high copy numbers. Unlike LINEs, SINEs 
cannot transpose independently and they are mobilized by neighboring LINEs. 
The human Alu family is the most prominent SINE family in terms of copy 
number originating from the short RNA component of the signal recognition 
particle 7SL RNA and occurring on average more than once every 3 kb. 
Interestingly, newly transposing Alu repeats show a preference for AT-rich DNA, 
but progressively older Alu repeats show a progressively stronger bias toward 
GC-rich DNA. The bias in the overall distribution of Alu repeats toward GC-rich 
and, accordingly, gene-rich regions must result from strong selection pressure. It 
suggests that Alu repeats are not just genome parasites but are making a useful 
contribution to cells containing them. Some Alu sequences are known to be 
actively transcribed and may have been recruited to a useful function. The 
BCYRN1 gene, which encodes the BC200 neural cytoplasmic RNA, arose from 
an Alu monomer and is one of the few Alu sequences that are transcriptionally 
active under normal circumstances. In addition, Alu repeats has recently been 
shown to act as a trans-acting transcriptional repressors during the cellular heat 
shock response [235,237]. 
b. Tandem repeats includes minisatellites and microstellites. Minisatellites 
comprises tandem copies of repeats that are 6-100 nucleotides in length. Alec 
Jeffrey first identified minisatellites in 1985, from the non-coding (intron) regions 
of the human myoglobin gene. Also named as variable number of tandem repeats 
(VNTR), majority of the minisatellites have a rich GC content and strong strand 
asymmetry. The degree of repetition varies from two to several hundreds. Repeat 
unit within a minisatellite usually presents small variations in sequence and 
mutations consist of gains or losses of one or more repeat units. Such mutations at 
hypervariable minisatellite loci are up to 1000 times more common than 
mutations in protein coding genes [236,237].  
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Figure 5: Schematic diagram representing the biological categories of the different DNA 
repetitive sequences. Adapted from Pathak D. and Ali S. (2012), Functional Genomics, 
ISBN: 978-953-51-0727-9. 
 
Constitutive heterochromatin has a characteristic histone-modification profile, which is 
distinguished by hypoacetylation and H3K9 trimethylation. Constitutive heterochromatin 
nucleation is directly associated with the presence of repetitive DNA elements and 
several lines of evidence denote the importance of non-coding RNAs and RNAi in this 
process. RNAi defines a post-transcriptional silencing mechanism that involves the Dicer 
protein (Dcr), Argonaute (Ago), and RNA-dependent RNA polymerase (RdRP). Briefly, 
RdRP generates double strand RNAs (dsRNAs) that will eventually be processed by 
Dicer into small interfering RNAs (siRNAs) [238,239,240].  A mechanistic insight into 
RNAi based heterochromatic silencing was demonstrated by purification of the RITS 
(RNA-induced transcriptional gene silencing) complex from Schizosaccharomyces 
pombe. RITS machinery includes Ago protein, siRNAs processed primarily from 
heterochromatic repeats, and the fission yeast HP1 homolog Chp1. Ago deficient yeast 
presented defects in chromosome segregation, implying heterochromatin malformation 
[241]. Yeast lacking Dicer present loss of siRNAs as well as delocalization of RITS from 
centromeric regions. Furthermore, RITS was shown to be required for initiating H3K9 
methylation at centromeric repeats [242,243].  Overall, these findings suggest that 
siRNAs wihin RITS complex provide specificity for RITS localization on the genome 
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and are needed for the subsequent recruitment of histone methyltransferases (HMTases) 
(Figure 6). DNA-binding proteins can also nucleate constitutive heterochromatin, 
working in parallel with RNAi-directed nucleation. For instance in S. pombe, 
transcription factors Atf1 and Pcr1 cooperate with the HDAC protein Clr3 to initiate 
heterochromatin [244]. Once nucleated, H3K9me3 mark serves as a molecular anchor 
tethering more HP1 proteins to chromatin, which in turn trigger further recruitment of 
HDACs and HMTases allowing heterochromatin to propagate to neighboring sequences, 
a process described as heterochromatinization. Moreover, studies have shown that Hp1 
also recruits Dnmt1 to methylate DNA at cytosine bases of CpG dinucleotides, a process 
highly associated to heterochromatin organization [245]. 
Constitutive heterochromatin contributes to several biological processes. It was first 
described to prevent illegitimate recombination between scattered repetitive DNA 
elements to protect genome integrity. Interestingly, control of transposable segments has 
been suggested as the original evolutionary benefit of heterochromatic silencing. 
Heterochromatin is important for the organization of nuclear domains. The peripheral 
localization of heterochromatin against the nuclear membrane favors the concentration of 
euchromatic active domains towards the center of the nucleus, allowing euchromatin to 
replicate and be transcribed with maximum efficiency. Heterochromatin is also required 
for normal function of centromeres and has been suggested that centromeric 
heterochromatin is necessary for the cohesion of sister chromatids, permitting normal 
segregation of mitotic chromosomes [228]. Mounting evidence indicates that 
heterochromatin operates as a dynamic platform controlling gene repression. Genes that 
are usually located in euchromatin can be silenced in cis and in trans when placed next to 
heterochromatic domains. 
Inactivation in cis 
Following chromosomal rearrangements, a euchromatic domain may be juxtaposed with 
a heterochromatic region. Rearrangement promotes the removal of normal barriers that 
protect the euchromatin, allowing for the heterochromatic structure to propagate in cis to 
the adjacent euchromatin and thus inactivating the genes enclosed therein. This 
mechanism has been identified in position effect variegation (PEV) in Drosophila and 
also in the inactivation of certain transgenes in mouse. 
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Inactivation in trans 
During cell differentiation, certain active genes are transposed into heterochromatic 
nuclear domains resulting in their silencing. Such a mechanism has been suggested to 
explain the co-localization in lymphocyte nuclei of the protein IKAROS and its 
downstream genes with centromeric heterochromatin [246]. 
Overall, although constitutive heterochromatin is apparently nebulous, isolated in the 
periphery of the nucleus, and previously considered as “Junk” DNA, growing evidence 
indicates that it is crucial in the organization and function of the genome.  
                                 
Figure 6: RNAi-mediated heterochromatin formation in fission yeast. RITS complex 
mediates heterochromatin assembly by associating with nascent transcripts via siRNA 
base-pairing, and with methylated H3K9 via the chromodomain of its Chp1 subunit. The 
chromosome-associated siRNA synthesis loop is essential for the spreading of H3K9 
methylation and silencing. The coupling of the siRNA synthesis loop to H3K9 
methylation forms a stable feedback loop that epigenetically maintains heterochromatin. 
Adapted from Buhler M. and Moazed D., Transcription and RNAi in heterochromatic 
gene silencing. Nature struct.mol. bio. 2007. 
 
1.2.3. Constitutive heterochromatin, genomic instability, and neurodegeneration 
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Correct formation of constitutive heterochromatin is critical to genome stability. 
Heterochromatin is usually refractory to DNA damage because of its condensed 
conformation and the protection given by its associated proteins. Per se, knockdown of 
heterochromatic proteins or induced decondensation of heterochromatin can sensitize 
cells to DNA damage [247]. Indeed, loss of HP1 renders nematodes highly sensitive to 
DNA damage [248]. In Drosophila, reduction of H3K9me2 levels through inactivation of 
the histone methyltransferase Su(var)3-9 favors genomic instability and constitutive DDR 
at the heterochromatin in both somatic and germ-line cells [249]. Moreover, flies lacking 
Su(var)3-9 exhibit reduced lifespan, muscle degeneration and loss of rRNA transcription 
silencing, whereas increasing heterochromatin formation through HP1 over-expression 
promotes longevity [163]. In mice, deletion of the SUV39h1/h2 methyltransferases leads 
to reduced viability, loss of H3K9me3 and genomic instability [250]. Interestingly, the 
neuroprotective SIRT1 protein was shown to regulate SUV39H1 through deacetylation 
during heterochromatin formation. Loss of SIRT1 affects H3K9me3 deposition and 
impairs HP1 localization [251]. Mice lacking the methyltransferase PRSET-7PA that is 
necessary for constitutive heterochromatin formation, display early embryonic lethality, 
defects in chromosomal condensation, and accumulation of DNA damage [252]. 
Neuronal cells from HP1β-deficient mice exhibit heterochromatin decondensation and 
genomic instability [253]. Inactivation of chromatin remodeling proteins, such as those of 
the NURD complex, result in DDR and cellular senescence that is preceded by 
heterochromatin alteration [158]. In human cells, downregulation of SU(V)39H1 via its 
methylation by SET7/9 leads to significant reduction in H3K9me3 levels, increased 
expression of satellite repeats, genomic instability, and inhibition of cell proliferation 
[254]. The HGPS syndrome associated with heterochromatin defects and introduced 
earlier in this chapter is also characterized by genomic instability. Cells from patients 
with ICF (Immunodeficiency, Centromeric instability and Facial anomalies) syndrome, a 
rare recessive disease that is linked to mutations of the gene DNMT3B, are characterized 
by mitotic catastrophe and genomic instability. DNA methylation mediated by DNMT3B 
is required for setting the histone code in pericentric and centromeric heterochromatin 
and loss of DNMT3B promotes the demethylation of GC rich satellite repeats causing 
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abnormal segregation of the sister chromatids, formation of multiradial figures, deletions, 
and micronuclei [255].  
Perturbations in constitutive heterochromatin and active restrotranspositions are reported 
to trigger neurodegenerative diseases through engendering genomic plasticity in neurons 
by initiating variation in genomic DNA sequences and by altering the transcriptome of 
individual cells. Fragile X-associated tremor/ataxia syndrome (FXTAS) is a 
neurodegenerative disease linked to fragile X premutation carriers. In an FXTAS 
Drosophila model, activation of a specific LTR retrotransposon, gypsy, modulates 
neurodegeneration [256]. Aberrant overexpression of Alu repeats is also found to directly 
cause age-related macular degeneration [257]. Mutations in DNMT1, which is crucial for 
the maintenance of methylation in constitutive heterochromatin, cause central and 
peripheral neurodegeneration in hereditary sensory and autonomic neuropathy (HSAN1) 
with dementia and hearing loss [258]. Mutations in ATRX (α-thalassemia X-linked 
mental retardation) cause several X-linked mental retardation syndromes featuring facial 
dismorphism, urogenital defects, and α-thalassemia [259]. ATRX protein resides 
predominantly in repetitive DNA sequences and impaired ATRX activity causes aberrant 
methylation pattern, genomic instability, and DDR [260].  Mutations in CREBBP (c-
AMP-responsive element binding protein (CREB) binding protein) gene cause Rubinstein 
Taybi syndrome, an autosomal dominant disorder of growth retardation, facial 
abnormalities, and mental retardation. CREBBP functions as a histone acetylase (HAT) 
promoting the decondensation of chromatin [261].  
In conclusion, all these findings and observations point to a surprisingly active role for 
constitutive heterochromatin malformation in genomic instability and neurodegeneration. 
The phenotypic variations associated with mutations in chromatin modifying complexes, 
even though all converging into heterochromatin decondensation and genomic instability, 
reflect the functional diversity, redundancy, and environmental modulation of the 
affected processes.  
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1.3.1. Polycomb complexes 
Polycomb group (PcG) proteins were originally identified in Drosophila 
melanogaster functioning as transcriptional repressors of homeotic (Hox) genes. PcG 
protein activity begins at gastrulation preventing homeotic gene reactivation at the time 
when the early repressors start to disappear [262]. Therefore PcG proteins operate as a 
maintenance system guarding the repressed state of target genes, which was already 
established early in development. This process results in variegated expression i.e. 
silencing of the gene in some cells but not in others, producing mosaic tissues. Several 
genome wide studies revealed widespread PcG roles in repressing hundreds of 
developmental decision makers and signaling factors [263,264,265,266]. Polycomb 
silencing function appears to be sensitive to dosage and involves cooperation of 
multiprotein complexes that selectively occupy chromatin sites [267]. These complexes 
include the PRC1, PRC2 and PhoRC groups and are described below.  
The PRC1 complex  
PRC1 complex biochemically purified from Drosophila melanogaster comprises a 
central core consisting of Polycomb (PC), Polyhomeotic (PH), Posterior sex combs 
(PSC), and RING1. The mammalian PRC1 complexes were identified using HeLa cells 
that express tagged protein components [268]. In mice and humans, some PcG proteins 
have several homologues that presumably operate as alternatives at different targets or in 
different tissues. The mammalian purified complexes consist of HPC (chromobox 
proteins CBX), HPH (1, 2 and 3), PCGF (BMI1 and its homologue MEL18), as well as 
RING1 (A and B), which are analogous respectively to the fly PC, PH, PSC and RING 
[269]. A common view has been that PRC1 targets chromatin via its PC chromodomain 
subunit CBX, which binds specifically to the PRC2 complex histone mark H3K27me3 
[270,271,272]. Recently, it has been shown that PRC1 complexes are further 
distinguished by comprising CBX subunits or not, dividing PRC1 family into CBX-
containing and CBX-lacking subgroups. Interestingly, PRC1 complexes lacking CBX 
proteins do not include the chromodomain subunit of PC, raising recent questions about 
the mode of PRC1 recruitment to chromatin. Indeed, genome wide ChIP analysis 
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revealed that CBX-comprising PRC1 co-localizes with H3K27me3 at chromatin whereas 
PRC1 missing CBX subunits are independent of this mark; and that loss of H3K27me3 
dislodges CBX-containing, but not CBX-lacking PRC1 complexes from chromatin 
domains [273,274]. Therefore, different PRC1 groups may target to chromatin by other 
mechanisms, with only CBX-containing complexes recruited via H3K27me3. 
Interestingly, emerging studies are implicating long non-coding RNAs (lncRNAs) in 
targeting PcG complexes to chromatin. A key example is the interaction of PRC1 with 
the lncRNA ANRIL to regulate the INK4A/ARF locus [275]. Other studies demonstrated 
conventional interactions of PRC1 with DNA binding factors such as Runx1 and REST, 
promoting PRC1 recruitment to genomic sites [276].  
The PRC2 complex 
A key function of PRC2 is trimethylation of histone H3 on K27, widely viewed as the 
operative chromatin mark initiating PcG silencing. The key catalytic subunit of PRC2 is 
the SET domain of the H3 methyltransferase Enhancer of zeste (E(Z)). However, when 
on its own, E(Z) has no histone methyltransferase activity and must be assembled with 
SUZ12 and EED to methylate H3K27 [277,278,279,280]. Moreover, knockout of SUZ12 
decreases the level of EZH2 protein, the mammalian E(Z), suggesting that formation of 
the complex stabilizes EZH2 [281]. Another PRC2 component includes P55 
(RBAP46/RBAP48), a histone-binding protein that is also associated with the chromatin 
assembly factor CAF1 [282]. Evidence identified JARID-2 as another prominent PRC2-
associated protein in embryonic stem cells. JARID-2 is member of the Jumonji (Jmj) 
family of histone demethylases, influencing PRC2 chromatin recruitment and modulating 
PRC2 histone methyltransferase activity [283]. In vivo, trimethylation of H3K27 
characterizes PcG target genes, which as mentioned earlier is specifically recognized by 
the PC chromodomain of PRC1 complex. In vitro, the PRC2 complex also methylates 
H3K9 and H3K9 trimethylation has been reported in vivo at PcG target genes [284]. 
Other studies showed that PRC2 could also methylate itself and other proteins such as 
GATA4 and histone H1 on K26, which has an amino acid context similar to that of 
H3K27 [285,286]. Therefore, while H3K27 methylation is a hallmark of PRC2 activity, 
this complex like the PRC1 group does not have monolithic composition and is unlikely 
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to have monolithic function. 
Other E(Z) complexes have been identified including PRC3 and PRC4 complexes, which 
differ biochemically by the presence of different isoforms of EED. PRC4 complex is 
assembled when EZH2 is overexpressed in cultured cells. It comprises an EED isoform 
that is only expressed in undifferentiated ES cells as well as the histone deacetylase 
SIRT1 [287].  
The PhoRC complex  
PHO and its closely related homologue, PHOL, are the only PcG proteins that are 
recognized to bind directly to DNA. These two D. melanogaster proteins are analogous to 
the mammalian factor Yin-Yang 1 (YY1), so called because it has both activating and 
repressive activities. Although it has been reported that PHO interacts molecularly with 
both PRC1 and PRC2 complexes in flies and mammals, it is not an important component 
of either of these two purified complexes [288]. The Drosophila PHO-containing 
complex, PhoRC, is implicated in homeotic gene silencing and contains an MBT-domain 
protein SFMBT (Scm-related gene containing four MBT domains). Although not 
previously recognized, SFMBT protein operates as a bona fide PcG protein and is 
required for PcG silencing. Its MBT repeats bind specifically to mono- and dimethylated 
H3K9 and H4K20. Widespread H3K9 and H4K20 methylation has been reported at the 
PcG target gene Ubx in Drososphila, providing other interactions to stabilize the binding 
of PcG proteins. These interactions provide a mechanistic insight for the spread of PcG 
silencing, by allowing polycomb complexes bound to a specific loci to interact with 
methylated nucleosomes and methylate any neighbouring nucleosomes that lack methyl 
marks [289]. 
PcG mechanisms of transcriptional repression 
PRC1 group promotes gene silencing through two distinct mechanisms including 
ubiquitylation of histone H2AK119 and polynucleosome compaction. RING1 in flies and 
RING1A and B in mammals have been shown to function as E3 ubiquitin ligases that 
orchestrate the mono-ubiquitylation of lysine 119 of histone H2A. The presence of BMI1, 
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which also encompasses a RING-domain, enhances the catalytic activity of RING1A and 
RING1B [290]. H2A ubiquitylation plays an important role in PRC1-mediated gene 
silencing, but the exact mechanism by which this specific ubiquitylation initiates 
repression is still unknown [290,291]. Moreover, recent studies conducted on RING1B-
mutant mouse cells along with presence or absence of RING1A defined two separate 
classes of PcG target genes: those that critically necessitate H2A ubiquitylation for 
silencing and those that display significant silencing without ubiquitylation. For instance, 
de Napoles et al. demonstrated that ubiquitylation-impaired RING1B renders PAX3 
almost totally derepressed, whereas numerous HOX genes are partially silenced [292]. 
Overall, these findings suggest that H2A ubiquitylation is a major contributor in PRC1 
repression, however there are other mechanisms that are also required such as 
polynucleosome compaction. Switch of the beads-on-a-string arrangement of nucleosome 
arrays into condensed knot-like structures is a non-enzymatic function of many PRC1 
family complexes. Compaction does not necessitate H2A ubiquitylation, as it is 
unaffected when mouse RING1B is made catalytically inactive [293]. In vertebrates, 
positively charged CBX subunits are the sole PRC1 components demonstrated to produce 
compaction. Since they also bind H3K27me3 thereby recruiting PRC1 complexes to 
regions containing this mark, they probably connect compaction with targeting by 
H3K27me3. Interestingly, densely packed nucleosomal arrays can trigger K27 methylation 
by PRC2 providing an attractive positive feedback loop between the compacted 
conformation and the covalent histone mark that is targeted by PRC1 complexes 
responsible for further compaction [294]. Unfortunately, the extent to which these 
findings reflect the situation in vivo is yet difficult to evaluate.  
Other proposed mechanisms of PcG silencing involve the primary chromatin fibre rather 
than higher order structures. For instance, when the well-defined polycomb response 
element (PRE) from the Ubx gene was placed in front of lacZ reporter driven by the heat 
shock-inducible hsp26 promoter, silencing did not mainly interfere with the binding of 
RNA polymerase II (RNA POL II) or of transcription factors, instead it blocked initiation 
of RNA synthesis by POL II. Another insight comes from the finding that chromatin 
insulators can block PcG silencing. One insulator placed between PRE and the promoter 
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inhibits silencing, however two insulators in tandem favor bypass of the block and lead to 
promoter silencing. This observation indicates that continuous DNA linkage is not 
required for silencing, and that the bound PcG complexes potentially loop out to contact 
the target promoter. The insulator also prevents the spreading of H3K27 trimethylation 
from the PRE concomitantly with the block imposed on silencing, suggesting that this 
chromatin mark might be directly involved in repression, or result from the same process 
that induces repression [295]. 
Biological functions 
In addition to the Hox clusters, PcG proteins regulate numerous genes especially key 
developmental regulators, and are centrally integrated in processes ranging from 
chromosome X inactivation to spermatogenesis, self-renewal of neural and 
haematopoietic stem cells, senescence and cell cycle progression [296,297,298]. PcG 
target genes encode transcriptional regulators, as well as morphogens, receptors and 
signalling proteins that are involved in all of the main developmental pathways. PcG 
complexes also modulate the majority of cell differentiation pathways, elucidating the 
concept that epigenetically stable silencing being established in the early embryo and 
preserved for the rest of development is not the common rule. This indicates that there are 
ways to bypass or overcome PcG silencing and switch target genes to the active state. In 
D. melanogaster, this can be accomplished by active transcriptional activity preceding the 
establishment of PcG silencing in the early embryo. Various studies revealed that 
transcription through the PRE interferes with PcG silencing, suggesting another potential 
mechanism for switching or resetting the epigenetic state [296]. According to this model, 
activation of neighboring transcription region that crosses the PRE promotes the 
derepression of silenced gene. Another suggested mechanism to bypass PcG silencing is 
massive production of an activator that is targeted to the repressed gene. For instance, 
PcG repression of Gal4–UAS reporter construct in the D. melanogaster embryo was 
counteracted by significant overexpression of Gal4. Larval imaginal discs, whose 
developmental identity has been established in the embryo and maintained by PcG 
silencing, can be influenced to change identity by cutting them and allowing them to 
regenerate. Studies have demonstrated that cells switching identity are subject to intense 
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signaling by strong morphogens such as Wingless/WNT, Decapentaplegic/transforming 
growth factor-β (DPP/TGF) and Hedgehog [296]. During wound healing in Drosophila, 
Lee et al. noted that JNK pathway is activated leading to downregulation of PcG genes. 
Similar mechanisms are suggested to operate in mammals and various signaling pathways 
in mammalian cells engender surprising effects on the PRC2 complex. Induction of 
integrins, T-cell receptor, platelet derived growth factor (PDGF) and related pathways 
favors re-localization of the PRC2 complex into the cytoplasm, where it appears to 
interact with the signal response pathway. PRC2 is required for the restructuring of the 
actin cytoskeleton in response to signaling. Covalent modifications of PcG proteins might 
be another way to dislodge them from target genes. Phosphorylation of PcG proteins 
promotes their dissociation from chromatin [295]. Activation of MAPKAP kinase 3, 
which is associated to PcG complexes, phosphorylates their components and causes their 
detachment from chromatin. Another mechanism involves PI3K–AKT, which enters the 
nucleus and phosphorylates EZH2. It is not established yet if these kinases are targeted to 
specific genes, thereby inducing local derepression rather than a global loss of silencing 
[295].  
In conclusion, PcG role in orchestrating patterns of gene transcription appears to be 
pervasive, mainly targeting genes critical in differentiation pathways. Many questions 
about PcG-mediated silencing remain to be determined, including the most essential one 
such as the mechanism of repression.  It will be interesting to delineate if repression is 
due to blockage of transcription initiation or transcription elongation. The effects of PcG 
complexes are fully accounted for by the chromatin modifictions, but it is entirely 
plausible that histone methylation and ubiquitylation patterns as well as the PcG-complex 
distribution are only devices to deliver the crucial function to the right places.  
1.3.2. Bmi1 
Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog), first identified as an 
oncogene that cooperated with c-Myc in the generation of murine lymphomas, plays 
essential roles in cell cycle regulation, cell immortalization, and cell senescence [299]. 
Bmi1 is a member of the PRC1 complex, which promotes chromatin compaction and 
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gene repression through its E3-mono-ubiquitin ligase activity mediated by Ring1a/b on 
histone H2A at lysine 119 (H2Aub) [300,301]. The human BMI1 gene is localized on 
short arm of chromosome 10 (10p11.23) and contains 10 exons and 9 introns. The human 
gene encodes a 37kDa protein consisting of 326 amino acids, whereas mouse Bmi1 gene 
encodes a protein of 45–47kDa [302].  
 
            RING               NLS                                      IE4F 
 
Figure 7: Schematic representation of human BMI1 gene (upper scheme) and BMI1 
protein (lower scheme). RING represents the ring finger domain; NLS represents the 
nuclear localization domain; and IE4F1 represents the interaction site with E4F1. 
Adapted from Cao L., Bombard J., et al., Bmi1 as a novel target for drug discovery in 
cancer. J. Cell Biochem. 2011. 112:2729-41. 
 
With respect to amino acid sequence, a high degree of homology is present 
between human BMI1 and murine Bmi1. BMI1 protein comprises a central helix-turn-
helix domain, which is essential for inducing telomerase activity, and a conserved RING-
finger domain near the NH2 terminus, which was shown to be important for the 
generation of lymphomas in Eµ-Bmi1 transgenic mice. BMI1 is predominantly localized 
at the nucleus, mediated by two nuclear localization signals (KRRR and KRMK) located 
in the C-terminal region of this protein [302,303]. BMI1 has a ubiquitous pattern of 
expression in almost all tissues and its expression levels are observed to be high in the 
brain, esophagus, salivary gland, thymus, kidney, lungs, gonads, placenta, blood, and 
bone marrow [303]. Bmi1-/- mice exhibit reduced post-natal growth and lifespan as well 
as defects in hematopoiesis, skeletal patterning, neurological functions, and cerebellar 
development [304,305,306]. Our group previously reported that Bmi1-null mice also 
display a premature ocular- and brain-aging phenotype associated with p53-mediated 
apoptosis and repression of anti-oxidant response genes in neurons [307]. 
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Bmi1 and stem cells: 
Hematopoietic stem cells (HSCs) and neuronal stem cells (NSCs) express high levels 
of Bmi1, which is required for efficient self-renewing cell divisions of adult HSCs as well 
as adult peripheral and central nervous system NSCs [308,309,310]. Indeed, 
transplantation of Bmi1–/– fetal liver cells led to only transient hematopoietic cell 
reconstitution, indicating that the transplanted mutant fetal liver HSCs failed to generate 
more HSCs. Similarly, the reduced self-renewal of Bmi1-deficient NSCs resulted in their 
postnatal depletion in vivo [311]. Moreover, BMI1 is reported to play a crucial role 
during the self-renewal and maintenance of prostate, intestinal, lung epithelial and 
bronchioalveolar stem cells [303]. 
Bmi1 and cancer: 
Bmi1 is associated with the initiation and progression of various types of tumor 
promoting cells and is overexpressed in numerous types of human cancers including 
mantle cell lymphoma, non-small cell lung cancer, B-cell non-Hodgkin's lymphoma, 
pancreatic adenocarcinoma, breast cancer, colorectal cancer, prostate cancer, and 
nasopharyngeal carcinoma. For example, in approximately 11% of cases of mantle cell 
lymphoma, the malignant cells have a three to seven-fold amplification of Bmi1 DNA 
and express high levels of the protein [312,313]. Consistent with its implication in the 
progression of carcinomas, various studies have demonstrated that Bmi1 is required for 
the self-renewal of cancer stem cells through multiple pathways. For example, in a mouse 
model of AML, Bmi1 was essential for the proliferation and maintenance of leukemic 
stem cells (LSCs). Bmi1-expressing LSCs were able to induce leukemia progression 
when transplanted into irradiated mice, whereas Bmi1-deficient LSCs had limited 
proliferative capacity and were unable to trigger malignant formation [314]. One 
mechanism by which Bmi1 overexpression drives transformation is through preventing 
senescence and activation of telomerase. There is evidence that Bmi1 regulates 
telomerase expression in human mammary epithelial cells (MECs) and may play a role in 
the development of human breast cancer. Overexpression of Bmi1 immortalizes MECs 
and is associated with human telomerase reverse transcriptase (hTERT) expression, which 
leads to induction of telomerase activity. Deletion analysis of the Bmi1 protein suggested 
that the RING finger, as well as the conserved helix-turn-helix domain, was required for 
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its ability to induce telomerase and immortalization [315]. Another mechanism is via 
promoting stem-like properties associated with induction of epithelial–mesenchymal 
transition (EMT) favoring invasion and metastasis [316]. A recent report demonstrated 
that in head and neck cancer, BMI1 upregulates the mitotic kinase Aurora A leading to 
chromosome instability and EMT through stabilization of Snail [317]. Our group also 
demonstrated that BMI1 confers radioresistance to cancerous stem cells in glioblastoma 
through recruitment of DNA damage machinery [318]. Operating as an important 
modulator in tumorigenesis, Bmi1 can be used as a valuable marker for the assessment 
and prognosis of different cancers as well as a potent target candidate in cancer stem cells 
for cancer therapy. Indeed, Wang et al. successfully examined 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine nanoparticles carrying small inhibitory RNA to target BMI1 and 
demonstrated an inhibition in the growth of chemoresistant ovarian tumors implanted in a 
xenograft mouse model [319]. Moreover, Siddique et al recently showed that targeted 
inhibition of BMI1 by adopting gene therapy approach led to reduced invasive potential 
and tumorigenic potential of prostate cancer cells [319].  
Bmi1 and senescence: 
Several lines of evidence point to a clear role for Bmi1 in preventing senescence. In 
human fetal lung fibroblasts, Bmi1 is downregulated when the cells undergo replicative 
senescence, but not quiescence. Bmi1 overexpression extends replicative lifespan in 
mouse and human fibroblasts [320]. WT mouse embryo fibroblasts (MEF) enter 
senescence after 8 passages in culture, whereas Bmi1-/- fibroblasts undergo senescence 
after 3 passages. Moreover, re-expression of Bmi1 rescued the premature senescent 
phenotype and increased MEF lifespan. Furthermore, unlike human 
fibroblasts, Bmi1 could immortalize MEFs. One key target of Bmi1 is the Ink4a/Arf locus 
that encodes two structurally and functionally distinct proteins: the p16Ink4a and 
the p19Arf  (p14ARF in humans) proteins [320]. p16Ink4a  is an inhibitor of the cell cycle 
while p19Arf regulates p53 stability. As stated earlier, p16Ink4a regulates the retinoblastoma 
activity. During the cell cycle, pRB is hyperphosphorylated by the cyclin D/cyclin-
dependent kinases 4 and 6 complex, disabling its inhibition of E2F transcription factor 
and allowing transcription of E2F target genes that are important for the G1/S transition. 
In the absence of Bmi1, p16Ink4a is upregulated resulting in hypophosphorylated pRB, 
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which binds to E2F and inhibits E2F-mediated transcription leading to cell cycle arrest 
and senescence. p19Arf  also plays an important role in senescence though sequestering 
mouse double minute 2 (MDM2). MDM2 is an E3 ubiquitin ligase that targets p53 for 
proteasomal degradation. Thus, by repressing MDM2, ARF stabilizes p53 favoring cell 
cycle arrest in G1 and G2/M phases or apoptosis. Lifespan extension by Bmi1 is mediated 
partially by suppression of the p16Ink4a-dependent senescence pathway and requires the 
RING finger and helix-turn-helix domains of Bmi1. Indeed, deletion of RING finger 
region induced p16Ink4a expression and premature senescence [321,322]. Mice 
lacking Bmi1 showed induction of both p16Ink4a and p19Arf in various hematopoietic and 
neuronal tissues. Point mutations and deletion of p16Ink4a and p19Arf are frequently found 
in many types of human cancers, involving them as key regulators of immortalization 
and/or senescence checkpoints. Interestingly, Ink4a/Arf locus is upregulated not only in 
senescing cultured cell lines but also in several tissues of ageing animals. Concomitantly, 
Itahana et al. showed that Bmi1 levels are reduced in senescent diploid fibroblasts 
[303,322,323].  
Bmi1 and CNS: 
Several studies associated the important function of Bmi1 in the central nervous system 
(CNS). Bmi1 null mice exhibit smaller brains with profound defects in cerebellar growth 
after 2 weeks of age [306]. They also develop generalized astriogliosis, ataxia, and 
epilepsy in the first month after birth [304]. Our group reported that Bmi1 is highly 
expressed in neurons and that Bmi1 mutant mice manifest a progeroid phenotype at 4 
week-old. This progeroid phenotype is characterized by lens cataracts formation, 
apoptosis of cortical neurons, and increase of reactive oxygen species (ROS) 
concentrations, due to p53-mediated repression of antioxidant response (AOR) genes. We 
also found that Bmi1 expression progressively declines in the neurons of ageing mouse 
and human brains and that Bmi1-deficient neurons were hypersensitive to β-amyloid-
induced apoptosis [307,324]. Conversely, Bmi1 overexpression in cortical neurons 
conferred robust protection against DNA damage-induced cell death or mitochondrial 
poisoning, and resulted in suppression of ROS through activation of AOR genes [324]. 
Since Bmi1 regulates key genes implicated in senescence and ageing and Bmi1 genetic 
deficiency recapitulates aspects of physiological brain aging, it is of interest to determine 
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if Bmi1 is implicated in ageing related diseases and test if Bmi1 overexpression is a 
potential therapeutic modality against neurodegeneration. 
Bmi1 regulation (Figure 7): 
Evidence revealed that Bmi1 is regulated at the transcriptional and post-translational 
levels. BMI1 is positively regulated by c-MYC, E2F1, sp1, and FoxM1 at the 
transcriptional level [319]. BMI1 can be ubiquitylated by the E3 ubiquitin ligase 
CULLIN3/Speckle-type POZ protein (SPOP) in vitro, however this ubiquitylation does 
not affect BMI1 protein levels and most likely has no bearing on protein stability [325]. 
Bmi1 can also be phosphorylated leading to its dissociation from chromatin [326, 327]. 
Moreover, the nature of phosphorylation sites is important for Bmi1 function. Indeed, 
Kim et al. reported that in the progeroid Ataxia-telangectasia mutated disorder, the 
defective proliferation of Atm-/- NSCs was due to Bmi1 downregulation, mediated by its 
phosphorylation via p38 MAP-kinase. Conversely, Bmi1 downregulation could be 
rescued by Akt phosphorylation, which renders Bmi1 resistant to the proteasomal 
degradation, leading to its stabilization and accumulation in the nucleus [328]. Treatment 
of breast cancer cells with histone deacetylase inhibitors (HDACi) downregulates the 
expression of BMI1, associated by a decrease in histone 2A lysine 119 ubiquitination 
(H2AK119Ub) [329]. Few observations hint on the role of miRNAs in Bmi1 regulation. 
For instance, miRNA 200c was shown to downregulate BMI1 in breast cancer [330]. 
miRNA-218 initiates apoptosis by downregulating BMI1 in colon cancer [331]. miR-
128a inhibits the growth of medulloblastoma cells by reducing BMI1 expression, which 
resulted in changes of the intracellular redox state of the tumor cells, thus promoting 
cellular senescence [319]. 
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Figure 8: Schematic representation of different mechanisms regulating Bmi1 expression 
and its downstream signaling pathways. Adapted from Cao L., Bombard J., et al., Bmi1 
as a novel target for drug discovery in cancer. J. Cell Biochem. 2011. 112:2729-41. 
 
 
Since we demonstrated that Bmi1 deficiency promotes progeria and ageing, we 
hypothesized that it is also implicated in ageing-related neurodegenerative disorders such 
as late onset Alzheimer’s disease. Furthermore, since Bmi1 acts as a chromatin remodeler 
via its mediated H2A ubiquitylation, we speculate that this pathological phenomenon is 
due to altered chromatin formation. We used aged Bmi1 heterozygous mice to analyze for 
LOAD hallmarks and defective chromatin structure.  
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This function is PRC2-independent and requires ubiquitylation of histone H2A. 
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SUMMARY 
 
Mono-ubiquitination of histone H2A at lysine 119 (H2Aub) is associated with the 
inactive chromatin at pericentromeric satellite repeat-DNA, X chromosome and silenced 
developmental genes. The Polycomb Repressive Complex 1 protein BMI1 was shown to 
promote H2Aub and transcriptional repression at developmental and tumor suppressor 
genes. We report here that BMI1 deficiency results in defective heterochromatin 
formation and activation of repeat-DNA sequences in mouse and human cells. BMI1 
localized at intergenic and pericentromeric satellite repeat-DNA and was required for 
H2Aub deposition and H3K9me3 loading in an EZH2- and H3K27me3-independent 
manner. BMI1 co-purified with architectural heterochromatin proteins and with 
H3K9me3. Notably, H2Aub and heterochromatin defects associated with BRCA1 
deficiency could be rescued by BMI1 over-expression. These findings uncover a critical 
function for BMI1 in heterochromatin formation and maintenance in mammalian cells. 
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INTRODUCTION 
 
Chromosomes are structurally organized in distinct sub-compartment as 
determined by the local DNA sequence and chromatin organization. Euchromatin defines 
“open” chromatin regions containing actively transcribed genes. In contrast, 
heterochromatin defines “close” chromatin regions containing protein-encoding genes 
(the facultative heterochromatin) or not (the constitutive heterochromatin) 1. The 
constitutive heterochromatin is found at the center and ends of chromosomes and is 
mostly constituted of repetitive DNA sequences 1. Numerous (about 10,000) repetitive 
A/T rich DNA elements of 231 bp are also found in the pericentric heterochromatin of 
mouse and human chromosomes. Furthermore, about 40% of the mammalian genome is 
constituted of retro-elements located in intergenic regions of chromosomes 2, 3. Active 
repression of repetitive elements of retroviral origins is important to maintain genomic 
stability as these can self-replicate and randomly integrate the genome. During mitosis, 
repetitive elements can also recombine by non-homologous recombination, resulting in 
chromosomes deletion, translocation and fusion 4. 
Polycomb group proteins form large multimeric complexes that are involved in 
gene silencing through modifications of chromatin organization 5. They are classically 
subdivided into two groups, namely Polycomb Repressive Complex 1 (PRC1) and PRC2 
6. The sequential histone modifications induced by the PRC2 complex (which includes 
EZH2, EED and SUV12) and the PRC1 complex (which includes BMI1, RING1a and 
RING1b) allows stable silencing of gene expression in euchromatin and facultative 
heterochromatin 7-9. The PRC2 contains histone H3 tri-methylase activity at lysine 27 
(H3K27me3) while the PRC1 contains histone H2AK119ub (H2Aub) ligase activity 7-9. 
Cells deficient for Bmi1 proliferate poorly owing to de-repression of the Ink4a/Arf locus. 
Mice lacking Bmi1 also display neurological abnormalities, depletion of neural stem 
cells, increased reactive oxygen species and premature aging 10-12. 
Although Polycomb group proteins have not been directly implicated in 
constitutive heterochromatin formation or maintenance in mammalian somatic cells, 
several line of evidences support this possibility: 1) Immuno-gold localization of BMI1 
by electron microscopy in U-2 OS cells revealed high enrichment in electron-dense 
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heterochromatin, consistent with BMI1 immuno-localization at pericentric 
heterochromatin in some human cell lines 13-16; 2) co-inactivation of Eed and Ring1b in 
mouse embryonic stem cells resulted in activation of intergenic retro-elements 17; 3) 
inhibition of Eed and Ring1b in mouse embryonic stem cells resulted in re-activation of 
major satellite repeat-DNA in the parental allele of mouse embryos up to the 8 cells 
stage, thus until the end of the maternal-embryo transition 18. 
 We show here that Bmi1-null mice present constitutive heterochromatin 
anomalies in neurons characterized by reduced chromocenters size and number, 
decreased accumulation of heterochromatin protein 1 (HP1) and Ring1b at genomic 
repeats, and activation of intergenic retro-elements and satellite repeats. Bmi1 is enriched 
at constitutive heterochromatin in both mouse and human cells and required for H2Aub 
deposition and H3K9me3 loading at repeat-DNA sequences. BMI1 co-purifies with 
architectural heterochromatin proteins and histones H2Aub and H3K9me3. Loss- and gain-
of-function studies revealed that BMI1 and BRCA1 display functional redundancy for 
H2Aub deposition at repeat-DNA sequences. 
MATERIALS AND METHODS 
 
Animals 
Mice were used in accordance with the Animal Care Committee of the Maisonneuve-
Rosemont Hospital Research Center (Approval ID #2009-40; #2009-42; # 2011-23). 
 
Neuronal cultures 
Embryonic day 18.5 cortices were dissected in oxygenated HBSS. Following meninges 
removal, cortices were cut to ~1mm3 pieces, and incubated at 37ºC for 15 min in 2 ml 
TrypleEx solution (Invitrogen). Afterwards, enzymatic solution was discarded, and cortex 
pieces dissociated in HBSS with a 1 ml tip (10 times up and down). After dissociation, 
cells were plated at 1.5 x 105 cells/well on poly-L-lysine-coated 6-well plates or 8-well 
cultures slides (BD Biosciences). Cells were maintained in normal medium composed of 
Neurobasal-A Medium (Invitrogen), Glutamax-I (Gibco), gentamycin (50 µg/ml; Gibco), 
B27 supplement (Gibco), NGF (50 ng/ml; Invitrogen) and BDNF (0.5 ng/ml; Invitrogen). 
Neurons were nucleofected with plasmid DNA using the Mouse Neuron Nucleofector Kit 
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according to manufacturer’s instructions (Amaxa Biosystems). 
 
Chromatin Immunoprecipitaion (ChIP) assay 
ChIP was performed using the ChIP Assay kit (Upstate). Cells were homogenized at RT 
according to the manufacturer’s protocol and sonicated on ice for 10 sec at 30% 
amplitude to shear the chromatin (Branson Digital Sonifier 450, Crystal Electronics, On. 
Canada). Sonicated materials were immunoprecipitated using 2 µg mouse anti-BMI1, 
mouse anti-Ubiquityl H2A clone E6C5, mouse anti-RING1B, and mouse anti-HP1 
(Millipore), rabbit anti-H3K9me3, and rabbit anti-H3K27me3 (Abcam), rabbit anti-
BRCA1 (SantaCruz), and rabbit anti-mouse IgG (Upstate) antibodies. Fragments were 
then amplified by real-time PCR in triplicates. Human primers sets used were as follow: 
MCBOX (F) 5’-AGGGAATGTCTTCCCATAAAAACT-3’; (R) 5’-
GTCTACCTTTTATTTGAATTCCCG-3’; SATIII (F) 5’-
AATCAACCCGAGTGCAATCNGAATGG-3’; (R) 5’-
TCCATTCCATTCCTGTACTCGG-3’; SATa (F) 5’-
AAGGTCAATGGCAGAAAAGAA-3’; (R) 5’-CAACGAAGGCCACAAGATGTC-3’; 
ACTIN (F) 5’-CCTCAATCTCGCTCTCGCTC-3’; (R) 5’-
CTCTAAGGCTGCTCAATGTCA-3’; ß-GLOBIN (F) 5’-
GGCTGTCATCACTTAGACCTC-3’; (R) 5’-GGTTGCTAGTGAACACAGTTG-3’;5’. 
Mouse primers sets used were as follow: MajSAT 5′- 
GGCGAGAAAACTGAAAATCACG-3′, 5′-CTTGCCATATTCCACGTCCT-3′; 
MinSAT 5′- TTGGAAACGGGATTTGTAGA-3′, 5′-
CGGTTTCCAACATATGTGTTTT-3′; LINE 5′-TGGCTTGTGCTGTAAGATCG-3′, 5′-
TCTGTTGGTGGTCTTTTTGTC-3′; SINE1 5′-GAGCACACCCATGCACATAC-3′, 5′-
AAAGGCATGCACCTCTACCACC-3′; Actin 5’-TCGATATCCACGTGACATCCA-3’; 
5’-GCAGCATTTTTTTACCCCCTC-3’; HoxA7 5’-GTGGGCAAAGAGTGGATTTC-
3’; 5’-CCCCGACAACCTCATACCTA-3’; β-major 5′-
CAGTGAGTGGCACAGCATCC-3′; 5′-CAGTCAGGTGCACCATGATGT-3′. ChIP-
qPCR data was analyzed according to the Percent Input method. First, the raw Ct of the 
diluted 1% input fraction is adjusted by subtracting 6.64 cycles (i.e. log2 of the dilution 
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factor 100). Subsequently, the percent input of each IP fraction is calculated according to 
this equation: 100*2(Adjusted Input Ct-Ct(IP). 
 
Real-time RT-PCR 
Mouse cortices or human cells were diced and RNA was isolated using TRIzol reagent 
(Invitrogen). Reverse transcription (RT) was performed using 1 µg of total RNA and the 
MML-V reverse transcriptase (Invitrogen). Real-time PCR was carried in triplicates using 
Platinum SYBRGreen Supermix (Invitrogen) and Real-time PCR apparatus (ABI prism 
7002). 
 
Micrococcal nuclease and DNase sensitivity assays 
One million (106) cells were harvested at the log phase growth and used in either nuclease 
sensitivity assay. Cells were permeabilized (0.02% l-α-lysolecithin, 150 mM sucrose, 35 
mM HEPES, 5 mM KH2PO4, 5 mM MgCl2, 0.5 mM CaCl2) on ice for 90 s than washed 
in ice cold PBS. The cell pellet was resuspended in nuclease buffer (150 mM sucrose, 50 
mM Tris–HCl (pH 7.5), 50 mM NaCl, 2 mM CaCl2) on ice, and nucleases were added. 
Digestions were performed at 24°C. Reactions were stopped by adding digestion stop 
buffer (20 mM Tris.Cl (pH7.4), 0.2 M NaCl, 10 mM EDTA, 2% SDS) and 0,1 mg/ml 
RNaseA for 30 min at 37°C. DNA was extracted by phenol/chloroform and visualized on 
0.8% native agarose gel/ethidium bromide. 
 
Plasmid constructs and viruses 
Sequence-specific oligonucleotides stretch shRNA designed to target the BMI-1 ORF 
(accession #: BC011652): were synthetized. Oligo#1 (nt 1061-1081) 5’-CCTAATACT 
TTCCAGATTGAT-3’, and oligoScramble (nt 573-591) 5’- GGTACTTCATTGA 
TGCCAC-3’ were used in this study. These sequences are followed by the loop sequence 
(TTCAAGAGA) and finally the reverse complements of the targeting sequences. The 
double stranded shRNA sequences were cloned downstream of the H1P promoter of the 
H1P-UbqC-HygroEGFP plasmid using Age1, SmaI, and XbaI cloning sites. The shRNA-
expressing lentiviral plasmids were cotransfected with plasmids pCMVdR8.9 and 
pHCMV-G into 293FT packaging cells using Lipofectamin (Invitrogen) according to the 
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manufacturer's instructions. Viral containing media were collected, filtered, and 
concentrated by ultracentrifugation. Viral titers were measured by serial dilution on 293T 
cells followed by microscopic analysis 48 hr later. For viral transduction, lentiviral 
vectors were added to dissociated cells prior to plating. Hygromycin selection (150 
µg/ml) was added 48 h later. shBRCA1 constructs (MISSION shRNA) are from Sigma, 
and siRING1B (FlexiTube siRNA) are from Qiagen. 
 
Proteomics 
293T cells were transfected with the EFv-CMV-GFP (GFP-293T) or EFv-BMI1-Myc-
CMV-GFP (Myc-293T) plasmids. Protein extracts were subjected to 
immunoprecipitation using an anti-Myc antibody. Immunoprecipitates were resolved by 
SDS-PAGE and LC-MS analysis was performed. 
BMI1 Overexpression 
Full-length human BMI1 cDNA (2611 base pairs) was cloned by RT-PCR from normal 
human retina RNA extracts. The DNA fragment was cloned into a lentiviral vector to 
generate the EF-1a-BMI1.CMV-GFP construct. 
 
Fixation, sectioning, and immunolabeling 
For fixation, tissues were immersed for 1 h at room temperature in 4% paraformaldehyde 
(PFA)/3% sucrose in 0.1 M phosphate buffer, pH 7.4. Samples were washed three times 
in PBS, cryoprotected in PBS/30% sucrose, and frozen in CRYOMATRIX embedding 
medium (CEM) (Thermo Shandon, Pittsburgh, PA). Otherwise, tissues were fixed in 10% 
buffered formalin and embedded in paraffin according to standard protocols. 5 to 7 µm 
thick sections were mounted on Super-Frost glass slides (Fisher Scientific) and processed 
for immunofluorescence or immunohistochemistry staining. For immunofluorescence 
labeling, sections were incubated overnight with primary antibody solutions at 4ºC in a 
humidified chamber. After three washes in PBS, sections were incubated with secondary 
antibodies for 1 h at room temperature. Slides were mounted on coverslips in DAPI-
containing mounting medium (Vector Laboratories, CA). For immunohistochemistry 
labeling, formalin-fixed paraffin-embedded slices were analyzed by using the Vectastain® 
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ABC kit (Vector) according to the manufacturer instructions. Peroxidase substrates used 
are the Vector® VIP (Pink) (Vector), and DAB (brown) (Sigma). Observations were 
made under a fluorescence microscope (Leica DMRE, Leica Microsystems) and images 
were captured with a digital camera (Retiga EX; QIMAGING; with OpenLab, ver.3.1.1 
software; Open-Lab, Canada). Antibodies used in this study were mouse anti-BMI1, 
mouse anti-Ubiquityl H2A clone E6C5, mouse anti-RING1B, and mouse anti-HP1 
(Millipore), rabbit anti-H3K9Ac, rabbit anti-H3K9me3, and rabbit anti-H3K27me3 
(Abcam). Secondary antibodies used were FITC-conjugated donkey anti-mouse and 
rhodamine-conjugated donkey anti-rabbit (Chemicon). 
 
Electron microscopy 
Tissues were fixed overnight in 3% glutaraldehyde. After fixation with 2% osmium 
tetraoxide for 3 h, tissues were dehydrated through a graded series of ethanol (30–100%) 
and propylene oxide, and were embedded in epoxy resin LX-112 (Ladd Research). 
Sections were cut at 0.1 µm and stained with uranyl acetate and lead citrate. An Hitachi 
H7600 transmission electron microscope was used to capture images. 
 
Immunoprecipitation and Western blot 
Cells were resuspended in the K solution (20mM sodium phosphate, 150mM KCl, 30mM 
sodium pyrophosphate 0,1% NP-40, 5mM EDTA, 10mM NaF, 0,1mM Na3VO4 into 
CompleteMini protease inhibitor cocktail solution (Roche Diagnostics)) and sonicated. 
Whole-cell extracts were immunoprecipitated with 2ug of IgG, BMI1 and p-ATM 
antibodies following Catch and Release v2.0 kit (Millipore) and used in Western blot 
experiments. For Western blot, cellular extracts were homogenized in the Complete Mini 
Protease inhibitor cocktail solution (Roche Diagnostics), followed by sonication. Protein 
material was quantified using the Bradford reagent. Proteins were resolved in 1x Laemelli 
reducing buffer by SDS-PAGE electrophoresis and transferred to a Nitrocellulose 
blotting membrane (Bio-Rad). Subsequently, membranes were blocked for 1h in 5% non-
fat milk-1X TBS solution and incubated overnight with primary antibodies. Membranes 
were then washed 3 times in 1X TBS; 0.05% Tween solution and incubated for 1h with 
corresponding horseradish peroxidase-conjugated secondary antibodies. Membranes were 
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developed using the Immobilon Western (Millipore). Blots were quantified using the 
Image quant program. 
 
Statistical analysis 
Statistical differences were analyzed using Student's t-test for unpaired samples. Two 
way-ANOVA test was used for multiple comparisons with one control group. In all cases, 
the criterion for significance (P value) was set as mentioned in the figures. 
RESULTS 
 
Heterochromatin formation is perturbed in Bmi1-deficient neurons 
In most eukaryotes, constitutive heterochromatin perturbations result in genomic 
instability and premature ageing/senescence, which are hallmarks of the Bmi1-null 
phenotype 19-25. We performed immuno-histochemistry (IHC) on cortical sections from 
WT and Bmi1-/- mice at post-natal day 30 (P30) using antibodies against histone H3 tri-
methylated at lysine 9 (H3K9me3), a mark of constitutive heterochromatin, and histone H3 
acetylated at lysine 9 (H3K9ac), a mark of open chromatin. We observed reduced 
H3K9me3 labeling in Bmi1-/- neurons together with increased H3K9ac labeling (Fig. 1a). 
Labeling for HP1 as well as for KAP1, HDAC1 and DEK1 was also reduced in Bmi1-/- 
neurons, suggesting heterochromatin anomalies (Fig. 1a and data not shown). 
Quantitative analysis revealed that the number of H3K9me3-positive chromocenters was 
reduced in Bmi1-/- neurons, while neuron’s nuclear diameter was increased (Fig. 1b). 
Consistently, electron-dense chromocenters were smaller and the nuclear matrix was 
generally irregular in Bmi1-/- neurons, as evaluated by transmission electron microscopy 
(Fig. 1c). Deficiency in constitutive heterochromatin formation can directly affect repeat-
DNA sequences expression and indirectly perturb DNA methylation at imprinted genes, 
and Bmi1 was previously shown to form a complex with the DNA methyltransferase 
Dnmt1 and its co-factor Dmap 26. Consistently, quantitative RT-PCR (qPCR) analysis of 
Bmi1-/- mouse cortices or cultured e18.5 neurons revealed increased expression of 
intergenic LINE elements and pericentric repeat-DNA sequences (Fig. 1d, e). 
Furthermore, analysis of our previously published micro-array data using e18.5 Bmi1-/- 
	  	   101	  
neurons revealed that the majority of the top 10 most up-regulated genes are imprinted 
genes (Fig. 1f) 10. Because post-natal neurodegeneration may account for the observed 
heterochromatin anomalies in Bmi1-/- mice, we analyzed the cortex of WT and Bmi1-/- 
embryos at e18.5. We found that H3K9me3 and HP1 staining were reduced in Bmi1-/- 
neurons, while that of H3K9ac was unaffected (Fig. 1g). Comparable anomalies were also 
observed in Bmi1-/- retinas at P30 where H3K9me3 levels and electron-dense chromatin 
were reduced in photoreceptor cells, while H3K9ac levels were unaffected (Fig. 1h, i).   
 
Bmi1 accumulates at satellite DNA and is required for H2Aub and H3K9me3 
deposition in mouse neurons 
The E3 ubiquitin ligase BRCA1 was shown to be required for pericentric 
heterochromatin formation, satellite repeat repression and genomic stability through 
ubiquitylation of H2A at heterochromatin 27, raising the possibility that Bmi1 mediates 
repression of repeat-DNA through H2Aub deposition. To test this, we performed 
Chromatin Immuno-Precipitation experiments (ChIP) on cultured WT and Bmi1-/- e18.5 
neurons. Bmi1 and Ring1b were found to accumulate at all genomic repeats analyzed as 
well as at Hoxa7 locus (a known Bmi1-target gene) (Fig. 2). In contrast, while 
enrichment for H3K27me3 was observed at the Hoxa7 locus in WT neurons and slightly 
reduced in Bmi1-/- neurons, H3K27me3 enrichment at repeat-DNA was negligible in both 
WT and Bmi1-/- neurons. Importantly, we found that Bmi1-deficiency resulted in 
depletion of Ring1b and HP1 at genomic repeats, but not of BRCA1. In some instances, 
BRCA1 enrichment was also increased in Bmi1-/- neurons (Fig. 2). Notably, enrichment 
for H2Aub and H3K9me3 at genomic repeats was highly reduced in Bmi1-/- neurons when 
compared to WT, suggesting that deficient H2Aub deposition could underlie the observed 
heterochromatin compaction defect (Fig. 2). 
 
BMI1 is required for heterochromatin compaction in human cells 
To test for conserved function across species, BMI1 was inactivated in human 293T cells 
using a small hairpin RNA (shBMI1) 28. This resulted in increased expression of the 
BMI1 target gene p16Ink4a and of McBox and SATIII repeats (Fig. 3a). Conversely, BMI1 
over-expression resulted in reduction of p16Ink4a and repeat-DNA sequences expression 
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(Fig. 3b). We performed ChIP experiments on shScramble and shBMI1 virus-infected 
cells. We found that BMI1 and RING1B accumulated at genomic repeats and the 
HOXC13 control locus in shScramble cells, and these were depleted in shBMI1 cells 
(Fig. 3c). BMI1 knockdown in human cells also led to reduce HP1 accumulation as well 
as H3K9me3 and H2Aub deposition at all repeat-DNA sequences. This was accompanied 
by increased BRCA1 enrichment only at ALU sequences (Fig. 3c). Nuclease 
hypersensitivity is a classical phenotype of cells deficient in heterochromatin 
condensation 29. Micrococcal nuclease (MNase) assays can be used to obtain information 
about the location of nucleosomes along DNA strands and chromatin compaction level 30-
32. We used native chromatin extracts isolated from control and shBMI1 293T cells in 
MNase and DNaseI experiments and found that cells knockdown for BMI1 were 
hypersensistive to both nucleases, indicating reduced heterochromatin compaction (Fig. 
3d). 
 
RING1B knockdown does not affect H2Aub deposition at constitutive 
heterochromatin 
Considering that BMI1 is enriched together with RING1B and H2Aub at constitutive 
heterochromatin, we tested whether the BMI1 knockdown heterochromatin phenotype 
could be mimicked by RING1B knockdown in 293T cells (Supplementary Fig. 1a). We 
observed that while RING1B accumulation at pericentric and intergenic heterochromatin 
and at HOXC13 was highly reduced in siRING1B-treated cells, H2Aub reduction was 
only detected at HOXC13. Likewise, RING1B knockdown did not significantly affect 
BMI1 and HP1 accumulation and H3K9me3 deposition at all tested regions 
(Supplementary Fig. 1b). These results suggested a possible dissociation between 
constitutive heterochromatin and HOXC13 for RING1B-dependent H2Aub deposition, 
and revealed that RING1B knockdown is not sufficient to reproduce the BMI1 
knockdown heterochromatin phenotype.       
 
BMI1 localization at constitutive heterochromatin is EZH2 and H3K27me3-
independent 
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To investigate the possibility that BMI1 localization at constitutive heterochromatin was 
PRC2 and H3K27me3-dependent, we performed ChIP experiments on 293T cells 
knockdown for EZH2 using a previously characterized lentiviral construct 28. In control 
cells, EZH2 and H3K27me3 enrichment was negligible at pericentric and intergenic 
heterochromatin but robust at the PRC2-target loci HOXC13 (Supplementary Fig. 2). In 
contrast, enrichment for BMI1 and H2Aub was significant at both pericentric and 
intergenic heterochromatin and at HOXC13 (Supplementary Fig. 2). In EZH2 knockdown 
cells, we observed reduced EZH2 and H3K27me3 enrichment at HOXC13 but with no 
measurable effect on BMI1 or H2Aub enrichment at constitutive heterochromatin and 
HOXC13, altogether indicating that BMI1 accumulation and H2Aub deposition can be 
EZH2 and H3K27me3-independent (Supplementary Fig. 2).     
 
BMI1 co-purifies with architectural heterochromatin proteins and histone H3K9me3 
To identify novel BMI1-associated proteins, we infected 293T cells with a lentivirus 
expressing a Myc-tagged BMI1 fusion protein or a control virus expressing GFP. After 
immuno-precipitation (IP) with an anti-Myc antibody, samples were separated on a 1D 
gel and sequenced by LC-MS (Fig. 4a). In the BMI1-myc sample, we identified several 
unique peptides corresponding to proteins involved in heterochromatin organization, 
including DEK1, HP1a (also called CBX5) and Lamins (Fig. 4a) 29, 33-35. To confirm 
these results, we performed IP experiments on control and BMI1 virus-infected cells. We 
observed that BMI1 co-precipitated with RING1B but not with EZH2 (Fig. 4b). Co-
precipitation of BMI1 with KAP1, DEK1 and HP1 was also observed (Fig. 4b). Notably, 
while BMI1 was found to co-precipitate with histones H3K9me3, H3 (total), H1 and 
H2Aub, co-precipitation was not observed with histones H3K9me2, H3K27me2 and 
H3K27me3 (Fig. 4b). To further investigate the relationship of BMI1 with H3K9me3, we 
performed co-localization studies in 293T cells. This revealed that ~79 +/- 20% of the 
endogenous BMI1 signal co-localized with H3K9me3 (Fig. 4c). To test whether BMI1 
knockdown could perturb the subnuclear distribution of heterochromatin proteins, we 
performed cellular fractionation experiments in control and shBMI1 virus-infected 293T 
cells 29. In these assays, the SDS fraction is thought to contain chromatin-bound proteins 
and compacted heterochromatin. In controls cells, BMI1 was detected in the 450nM NaCl 
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and SDS fractions (Fig. 4d). Likewise, BRCA1 and H3K9me3 were only found in the 
100nM-450nM NaCl and SDS fractions, while modest HP1 distribution was also 
observed in the nucleosol fraction (Fig. 4d). In shBMI1 cells, the distribution of HP1 and 
H3K9me3 was highly reduced in the SDS fraction and apparently displaced in other 
fractions, while distribution of H3 and BRCA1 was not affected (Fig. 4d). Taken 
together, these results revealed co-purification of BMI1 with architectural 
heterochromatin proteins and H3K9me3, co-localization of BMI1 with H3K9me3, and 
BMI1 requirement for HP1 and H3K9me3 distribution in the SDS-soluble nuclear fraction.  
 
BMI1 and BRCA1 display redundancy in heterochromatinization  
Since the PRC1 and BRCA1 display H2Aub activity and that BRCA1 enrichment and 
distribution at heterochromatin is not affected upon BMI1 depletion, we tested whether 
BMI1 and BRCA1 displayed functional redundancy in heterochromatinization.  To 
confirm previous findings, we first performed BRCA1 knockdown in 293T cells 
(Supplementary Fig. 3b). In control cells, we observed BRCA1 enrichment at pericentric 
and intergenic heterochromatin and weak accumulation at HOXC13 (Supplementary Fig. 
3a). In BRCA1 knockdown cells, HP1 accumulation as well as H2Aub and H3K9me3 
deposition were reduced by ~50% at pericentric and intergenic heterochromatin. 
Comparable reduction for these marks was also observed at HOXC13 (Supplementary 
Fig. 3a). BRCA1 knockdown was also accompanied by increased expression of repeat-
DNA sequences (Supplementary Fig. 3c), thus confirming previous findings 27. Notably, 
BMI1 and RING1B enrichment was increased at all tested regions in BRCA1 knockdown 
cells (Supplementary Fig. 3a), suggesting that BMI1 and BRCA1 are mutually 
independent and/or compete for accumulation at heterochromatin. To test for possible 
redundancy, stably infected shBMI1 cells were transfected with an shBRCA1 plasmid, 
generating double knockdown (DKN) cells. Notably, while H3K9me3 enrichment was 
reduced by 55-70% in DKN cells at all tested chromatin regions, enrichment for HP1 and 
H2Aub was further reduced by 80-90% in DKN cells (Fig. 5a), thus revealing an additive 
effect. In DKN cells, these chromatin modifications also correlated with an additive 
effect on ALU and Sata expression, while no additive effect was observed for SatIII and 
McBox expression (Fig. 5b). To test whether BMI1 could compensate for BRCA1 
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deficiency, we over-expressed BMI1 in control and shBRCA1-treated cells. In control 
cells, we found that BMI1 over-expression could not displace endogenous BRCA1 
enrichment on the chromatin at all tested regions (Fig. 6a). However, accumulation of 
both endogenous BMI1 (shBRCA1 cells) and transgenic BMI1 (shBRCA1 + BMI1-Myc 
cells) proteins at pericentric and intergenic heterochromatin, as well as at HOXC13, was 
enhanced following BRCA1 knockdown (Fig. 6a). A similar but less dramatic trend was 
also observed for RING1B. Most notably, while BMI1 over-expression could increase 
H2Aub and H3K9me3 deposition as well as HP1 accumulation at all tested regions in 
control cells, it could also rescue the corresponding heterochromatin anomalies in 
shBRCA1 cells (Fig. 6a). Importantly, BMI1 over-expression in shBRCA1 cells resulted 
in normalization of ALU, McBox, Sata and SatIII expression (Fig. 6b), altogether 
suggesting that BMI1 over-expression can rescue the BRCA1-deficient heterochromatin 
phenotype 
 
DISCUSSION 
 
We showed here that Bmi1-deficiency in mouse neurons and BMI1 knockdown in human 
cells result in anomalies in constitutive heterochromatin compaction. These anomalies 
were accompanied by transcriptional activation of intergenic retro-elements and 
pericentromeric satellite repeats. Using ChIP analysis, we observed that loss of BMI1 
function was associated with reduced H2Aub and H3K9me3 deposition at constitutive 
heterochromatin, and that knockdown of RING1B was not sufficient to reproduce this 
phenotype. Using ChIP, IP and microscopy analyses, we found that BMI1 accumulates at 
constitutive heterochromatin, co-purifies with architectural heterochromatin proteins and 
histones H2Aub and H3K9me3, and co-localizes with H3K9me3. In contrast, EZH2 and 
H3K27me3 were not enriched at constitutive heterochromatin, did not co-purify with 
BMI1, and BMI1 accumulation and H2Aub deposition were EZH2 and H3K27me3-
independent. Using gain- and loss-of-function studies, we showed that BMI1 and BRCA1 
were mutually independent for accumulation at constitutive heterochromatin and 
displayed functional redundancy for H2Aub deposition and heterochromatinization. 
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 We provided substantial evidences that BMI1 deficiency results in defective 
heterochromatin formation. Notably, this phenotype was also associated with increased 
nuclear diameter and an irregular nuclear lamina (see Fig. 1). These anomalies are 
particularly interesting considering our identification of LaminA/C, Lamin B2 and 
Importin as putative BMI1-co-purifying proteins and the recent demonstration that loss of 
heterochromatin foci can result in disruption of the nuclear lamina 35. It is also notable 
that RING1B knockdown could not mimic the BMI1-deficient phenotype. More 
particularly, while H2Aub levels were reduced at HOXC13 in RING1B knockdown cells, 
this was not accompanied by a corresponding reduction in HP1 and H3K9me3 levels, as 
observed in BMI1 knockdown cells. Furthermore, there was not apparent effect on H2Aub 
levels at constitutive heterochromatin. This finding leaves us open with many 
explanations, the most likely one being functional compensation by RING1a for H2Aub 
deposition, as shown in other context 17, 36-38. 
 Using ChIP analysis, we found BMI1 enrichment at pericentric and intergenic 
heterochromatin (all data being normalized to one repeat sequence using the input data) 
in mouse and human cells. This was also confirmed by BMI1 co-purification and co-
localization with H3K9me3. Considering that there is about 10 000 pericentric repetitive 
DNA sequences in the mouse genome, and that 40% of the human genome is constituted 
of intergenic retro-elements, our results argue that a large fraction of the BMI1 protein 
pool is bound to constitutive heterochromatin. Consistently, previous findings revealed 
that BMI1 localizes at pericentric heterochromatin and electron-dense heterochromatin in 
human cells 14, 16. Likewise, our cell fractionation assay revealed that a large portion of 
the BMI1 protein pool is bound to the SDS chromatin fraction, which is predicted to 
correspond to constitutive heterochromatin. Interestingly, we also observed that: 1) BMI1 
did not co-purify with EZH2 or H3K27me3, 2) EZH2 and H3K27me3 were not enriched at 
constitutive heterochromatin, and 3) BMI1 accumulation at constitutive heterochromatin 
and HOXC13 was EZH2 and H3K27me3-independent. These results are in agreement with 
recent findings, implying that previous models proposing a strict hierarchy in PRC 
activity may be only applicable to specific loci 39. 
 How BMI1- and BRCA1-mediated H2Aub deposition at repetitive DNA 
sequences can translate into heterochromatinization (i.e. H3K9me3 loading and 
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heterochromatin compaction) is an intriguing issue. One possibility is that H2Aub induces 
allosteric changes in the histone H3 lysine tri-methyltransferases SUV39H1/2 to promote 
their activity, such as proposed for H2Bub and H3K4 methylation 40, 41. This would be 
consistent with our findings that BMI1 co-purifies with architectural heterochromatin 
proteins, and with previous observations that PRC1 components can interact with 
SUV39H1 15. Alternatively, BMI1 may directly or indirectly regulate the transcription of 
H3 lysine methyltransferases or demethylases, thus also operating in trans. We also 
showed that co-inactivation of BMI1 and BRCA1 induces more severe H2Aub, H3K9me3 
and HP1 depletion at constitutive heterochromatin than single BMI1 or BRCA1 
deficiencies, and that BMI1 over-expression could rescue the BRCA1-deficient 
heterochromatin phenotype. These results suggest that BMI1 and BRCA1 are 
functionally redundant for H2Aub deposition at constitutive heterochromatin. The 
observation that BMI1 and BRCA1 proteins accumulation is mutually independent and 
that BMI1 levels are increased in BRCA1-deficient cells (and reciprocally) also indicate 
that both proteins possibly bind to the same substrate to catalyze H2Aub deposition. 
 In conclusion, we showed that BMI1 is associated with constitutive 
heterochromatin and required for heterochromatin formation and maintenance in mouse 
and human cells. Since BMI1 is highly expressed in several cancers, it will be of prime 
interest to investigate the function of BMI1 on cancer cell’s heterochromatin structure. At 
the opposite, BMI1 deficiency is associated with premature aging, genomic instability 
and DNA damage accumulation 42-44, raising the possibility that the heterochromatin de-
compaction phenotype we unraveled here could account for some of these effects. 
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FIGURE LEGENDS 
 
Figure 1. Heterochromatin compaction defects in Bmi1-deficient neuronal cells 
(a) Paraffin-embedded brain sections from P30 WT and Bmi1-/- mice were analyzed by 
immuno-histochemistry (IHC). Labeled cells are neurons located in the upper cortical 
layers of the cerebral cortex. Scale bar, 10 µm. (b) Quantification of the total number and 
number of large H3K9me3-positive chromocentres. Note that neuron’s nuclear diameter is 
increased in Bmi1-/- mice. Where n = 3 brains for each genotype. *P < 0.05, **P < 0.01. 
(c) Transmission electron microscopy analysis of cortical neurons in P30 WT and Bmi1-/- 
mice. Note the reduction in electron-dense chromocenters in Bmi1-/- neurons. (d) Whole 
cortices or  (e) e18.5 neurons from WT and Bmi1-/- mice were analyzed by qPCR for 
satellite repeats and intergenic retro-elements expression. P16Ink4a was used as positive 
control. Note the up-regulation of minor and major satellite repeats in Bmi1-/- neurons. 
Where n = 3 independent samples for each genotype. *P < 0.05, **P < 0.01. (f) Analysis 
of DNA micro-array data revealed up-regulation of several imprinted genes in e18.5 
Bmi1-/- neurons relative to WT. (g) Paraffin-embedded brain sections from e18.5 WT and 
Bmi1-/- embryos were analyzed by IHC. Most labeled cells are cortical neurons. Scale bar, 
50 µm. (h) Immuno-fluorescence analysis of frozen retinal sections from P30 WT and 
Bmi1-/- mice. The outer nuclear layer of the retina, which contains the cell body of 
photoreceptors, is shown. (i) Photoreceptors from P30 WT and Bmi1-/- mice were 
visualized by transmission electron microscopy. Note the reduction in electron-dense 
chromocenters in Bmi1-/- photoreceptors. 
 
Figure 2. Bmi1 accumulates at repeat-DNA sequences and is required for H2Aub 
and H3K9me3 deposition 
WT and Bmi1-/- neurons were analyzed by ChIP for proteins enrichment at satellite 
repeats, intergenic retro-elements and HoxA7 (positive control gene). Note the 
accumulation of Bmi1 and Ring1b at all repeat-DNA sequences. While HP1 
accumulation and H2Aub and H3K9me3 deposition were reduced in Bmi1-/- neurons at 
all tested loci, Brca1 accumulation was either unaffected (Minor and Major satellites) or 
increased (Line, Sine and IAP 
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). Note the near absent accumulation of Brca1 at HoxA7 in both WT and Bmi1-/- neurons.  
 
Figure 3. Bmi1 is required for heterochromatin compaction in human cells 
(a, b) 293T cells were infected with shScramble or shBMI1 viruses (a) or with viruses 
expressing either GFP or the BMI1-myc fusion protein and GFP (b). (b) Gene expression 
was analyzed by qPCR, and where n = 3 independent cultures. *P < 0.05, **P < 0.01. (c) 
293T cells knockdown for BMI1 were analyzed by ChIP for proteins enrichment at 
satellite repeats, intergenic retro-elements and HoxC13 (positive control). (d) 293T cells 
were infected with shScramble or shBMI1 viruses and treated or not with MNase (0.4U at 
24°C for different time periods) or DNaseI at the indicated concentrations for 20 minutes 
at 24°C. Note the nuclease hypersensitivity phenotype of shBMI1-treated cells. 
 
Figure 4. BMI1 co-purifies with architectural heterochromatin proteins and 
H3K9me3 
(a, b) 293T cells were infected with EFv-CMV-GFP or EFv-BMI1-Myc-CMV-GFP 
viruses. Protein extracts were subjected to IP using an anti-Myc antibody, and 
immunoprecipitates were resolved by SDS-PAGE and analyzed either by LC-MS/MS (a) 
or Western blot (b). (a) Note the co-purification of BMI1 with several heterochromatin 
proteins and with Lamins. (b) Note the preferential co-purification of BMI1 with histone 
H3K9me3 (*). (c) 293T cells were labeled with BMI1 and H3K9me3 antibodies, 
counterstained with DAPI, and analyzed by quantitative confocal microscopy. Note the 
co-localization of BMI1 with H3K9me3-positive chromocenters. (d) 293T cells were 
infected with shScramble or shBMI1 viruses and cell’s compartments were fractionated. 
Note HP1 and H3K9me3 reduction (*) in the SDS fraction of shBMI1-treated cells. 
 
Figure 5. BRCA1 and BMI1 display redundant activities for H2Aub deposition at 
heterochromatin 
(a, b) 293T cells were infected with shScramble or shBMI1 viruses. After selection with 
hygromycin, cells were transfected or not with an shBRCA1-encoding plasmid, (a) and 
analyzed by ChIP. Note the severe reduction in H2Aub and H3K9me3 deposition and HP1 
accumulation at all tested loci in shBMI1/shBRCA1 cells. (b) Cells were analyzed by 
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qPCR. Note the combined effect of shBMI1/shBRCA1 on ALU expression (when 
compared to shBMI1 or shBRCA1 alone).   
 
Figure 6. BMI1 over-expression can rescue BRCA1-knockdown heterochromatic 
phenotype 
(a, b) 293T cells stably expressing BMI1-myc or not were transfected with shScramble or 
shBRCA1 plasmids and analyzed by ChIP (a), and q-PCR (b). (a) Note the enrichment 
for both endogenous and exogenous BMI1 in shBRCA1-treated cells at all tested loci. 
Note also that BMI1-myc over-expression can prevent the reduction in H2Aub and 
H3K9me3 deposition and HP1 accumulation in shBRCA1-treated cells at all repeat-DNA 
sequences. (b) BMI1-myc over-expression also normalizes repeat-DNA sequences 
expression in shBRCA1-treated cells. 
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CHAPTER 3: 
  
 Chapter 3 is the article reporting that aged Bmi1+/- mice develop a neurological 
disorder resembling LOAD. Moreover, this study reveals that Bmi1 is required for the 
genomic stability of constitutive heterochromatin in neurons and that loss of Bmi1 
triggers activation of DNA damage response at repetitive DNA sequences.  
 I am first author on this article. I contributed majorly to conception of the study 
and I performed 90% of the experiments as well as the writing of the manuscript.   
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ABSTRACT 
 
Late-onset or sporadic Alzheimer’s disease (LOAD) is the most prevalent form of 
dementia, but its origin remains poorly understood. The Bmi1 protein is part of the 
Polycomb Repressive Complex 1, which catalyzes histone H2A ubiquitylation (H2Aub) 
for repression of senescence-associated and developmental genes. We show here that 
Bmi1+/- mice develop normally but present with age a neurological disorder resembling 
LOAD. This phenotype was preceded by a reduction in H2Aub and H3K9me3 levels, 
neuronal heterochromatin de-compaction and DNA damage response (DDR). BMI1 
deficiency, reduced H2Aub and H3K9me3 levels, heterochromatin de-compaction, and 
DDR were characteristic of LOAD but not of elderly control or familial Alzheimer’s 
disease brains. In Bmi1+/- mice and LOAD patients, DNA damage preferentially 
accumulated at heterochromatin. Consistently, Bmi1 co-localized with H3K9me3 and 
was enriched at heterochromatin together with H2Aub. We conclude that BMI1 
deficiency and heterochromatic genome instability are hallmarks of LOAD. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is characterized by progressive memory and behavioral 
impairment owing to degeneration of limbic and cortical areas of the brain. Pathological 
hallmarks are the presence of amyloid plaques, neurofibrillary phospho-TAU tangles and 
synaptic dysfunction 1. Early-onset (familial) AD (EOAD) has been linked to mutations 
in AMYLOID PRECURSOR PROTEIN, PRESENILIN1/2, while the E4 allele of 
APOLIPOPROTEIN or allelic variants of SORL1 represent risk factors for EOAD and 
late-onset (sporadic) AD (LOAD) 2, 3. Despite these findings, the etiology of LOAD, 
which account for ~95% of AD cases, remains poorly understood 4. The probability to 
develop LOAD increases dramatically with age, suggesting that aging-related 
mechanisms may account for disease progression or origin 5. 
Nucleosomes are the basic building unit of chromatin and are comprised of  147 
bp of DNA wrapped around a histone octamer 6. Euchromatin defines “open” chromatin 
regions mostly containing actively transcribed genes. In contrast, heterochromatin defines 
“closed” chromatin regions either containing protein-encoding genes (the facultative 
heterochromatin) or not (the constitutive heterochromatin) 6. Constitutive 
heterochromatin encompasses a large part of the mammalian genome, is localized at 
intergenic, pericentric, centric and telomeric regions of chromosomes, is comprised of 
repetitive DNA sequences, and generally enriched for histone H3 trimethylated at lysine 
9 (H3K9me3). 
Bmi1 is a component of the Polycomb Repressive Complex 1, which promotes 
chromatin compaction and gene repression through its E3-mono-ubiquitin ligase activity 
mediated by Ring1a/b on histone H2A at lysine 119 (H2Aub) 7, 8. Bmi1-/- mice present 
reduced post-natal growth and lifespan together with cerebellar degeneration 9. Bmi1-
deficient cells undergo premature senescence owing in part to up-regulation of the Ink4a 
locus 10. The Bmi1 protein is also recruited to DNA break sites where it promotes DNA 
damage response (DDR) and repair 11, 12. We previoulsy showed that Bmi1 is required to 
prevent brain aging and p53-mediated repression of antioxidant response genes in 
neurons 13. 
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We show here that while mice lacking one Bmi1 allele develop normally, they 
display an age-dependent brain pathology resembling LOAD. Analysis of disease 
progression revealed that it was preceded by structural and molecular alterations of the 
neuron’s constitutive heterochromatin. These alterations were associated with preferential 
DDR at constitutive heterochromatin. Bmi1 co-localized with H3K9me3 in wild type 
(WT) neurons, and Bmi1 and H2Aub were enriched at H3K9me3-associated 
heterochromatin in neuronal extracts. Deficient BMI1 expression, heterochromatin 
anomalies and DDR at heterochromatin were found in LOAD but not in elderly control or 
EOAD brains. Our results suggest that Bmi1 is required for neuronal heterochromatin 
compaction and stability in mice, and that deficient BMI1 expression and 
heterochromatic genome instability are characteristics of LOAD. 
 
 
MATERIALS AND METHODS 
 
Human samples 
Paraffin-embedded human brains were obtained from the department of pathology of 
Maisonneuve-Rosemont Hospital. Post-mortem human cortices were provided by the 
Douglas Hospital Brain Bank and used accordingly to the Maisonneuve-Rosemont 
Hospital Ethic Committee. All samples were confirmed by histopathological analysis as 
non-demented controls or “classical” EOAD or LOAD cases (see Supplementary table 1). 
 
Animals 
Mice of the C57BL/6 strain were used in accordance with the Animal Care Committee of 
the Maisonneuve-Rosemont Hospital Research Center (Approval ID #2009-40; #2009-
42; # 2011-23). For behavioral and LTP studies, mice were randomized using numbers to 
avoid bias. Behavioral studies were performed in the morning during the light cycle. 
 
Antibodies 
Rabbit anti-p53 (Santa Cruz Biotechnology), rabbit anti-p-JNK (Invitrogen), mouse anti-
synaptophysin (Sigma), mouse anti-amyloid clone DE2B4 (Abcam), rabbit anti-amyloid 
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clone FCA3542 (Calbiochem), mouse anti-p-TAU clone AT-8 (Thermo scientific), 
mouse anti-p-TAU clone PHF1 (a gift from Dr. Davies, Albert Einstein College of 
Medicine), rabbit anti-BACE1 (Covance), mouse anti-NeuN (Chemicon), rabbit anti-
cleaved caspase-3 (Cell Signaling), mouse anti-Bmi1 clone F6 (Millipore), mouse anti-
Bmi1 (Abcam), mouse anti-p-ATM (Novus), rabbit anti-p-ATR (Santa Cruz 
Biotechnology), rabbit anti-H3K9me3 (Abcam), mouse anti-H2Aub clone E6C5 
(Millipore), mouse anti-HP1 (Millipore), mouse anti-β-actin (Sigma), mouse anti-tubulin 
(Sigma), mouse anti-H3 (Upstate), and rabbit anti-mouse IgG (Upstate).  
 
Amyloid fractions 
Cortices were minced and homogenized in a 10ml TBS 1x/protease inhibitor cocktail 
solution (Roche Diagnostics), using a tissue grinder. The homogenates were sonicated 
and ultra-centrifuged at 175,000g for 1h at 4°C. The supernatants were collected as the 
soluble cellular fraction. The dense pellet was re-homogenized in a 10ml TBS 1x/Triton 
1%/ protease inhibitor cocktail solution, followed by sonication and centrifugation at 
100,000g for 1h at 4°C. The supernatants were recuperated as the insoluble cellular 
fraction. 
 
Immunohistochemistry 
For paraffin fixation, tissues were immersed for 1 h at room temperature in Formalin or 
4% paraformaldehyde/3% sucrose in 0.1 M phosphate buffer, pH 7.4. Samples were 
washed three times in PBS, cryo-protected in PBS/30% sucrose, and embedded in 
paraffin according to standard protocols. 5 to 8 µm thick sections were mounted on 
Super-Frost glass slides (Fisher Scientific) and processed for immunohistochemistry 
staining. Paraffin-embedded slices were analyzed by using the Vectastain® ABC kit 
(Vector) according to the manufacturer instructions. Peroxidase substrates used are the 
Vector® VIP (Violet) (Vector), and DAB (brown) (Sigma). Observations were made 
using the Zeiss imager Z2 microscope and images were captured with a digital camera. 
Pyramidal neurons from the frontal cortex were used to quantify the number of 
chromocenter/neuron. When required, neuronal cell identity was determined by the 
morphology (using phase contrast imaging), the large nuclear diameter (when compared 
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to astrocytes), and the presence of chromocenters and of a large nucleolus. 
 
Western Blot 
Total cortical extracts were homogenized in the Complete Mini Protease inhibitor 
cocktail solution (Roche Diagnostics), followed by sonication. Protein material was 
quantified using the Bradford reagent. Proteins were resolved in 1x Laemelli reducing 
buffer by SDS-PAGE electrophoresis and transferred to a Nitrocellulose blotting 
membrane (Bio-Rad). Subsequently, membranes were blocked for 1h in 5% non-fat milk-
1X TBS solution and incubated overnight with primary antibodies. Membranes were then 
washed 3 times in 1X TBS; 0.05% Tween solution and incubated for 1h with 
corresponding horseradish peroxidase-conjugated secondary antibodies. Membranes were 
developed using the Immobilon Western (Millipore). Blots were quantified using the 
Image quant program. 
 
Neuronal cultures 
After dissociation of e18.5 cortices, cells were plated at 1,5 x 105 cells/well on poly-L-
lysine-coated 8-well cultures slides (BD Biosciences). Cells were maintained in normal 
medium composed of Neurobasal-A Medium (Invitrogen), Glutamax-I (Gibco), 
gentamycin (50 µg/ml; Gibco), B27 supplement (Gibco), nerve growth factor (50 ng/ml; 
Invitrogen) and BDNF (0,5 ng/ml; Invitrogen). For inhibitory assays, we added 2 µM of 
DMSO, 2 µM of ATM/ATR inhibitor (CGK733; Millipore) or 10 µM of ATM inhibitor 
(KU55933; KuDOS Pharmaceuticals) to the cell culture medium for 16 hours. NAC was 
added daily at 5mM into the culture medium for 7 days. 
 
Chromatin Immunoprecipitaion (ChIP) assay 
ChIP was performed using the ChIP Assay kit (Upstate). Briefly, 50 mg of cortical tissue 
was frozen for 1 hour and than homogenized at RT according to the manufacturer’s 
protocol. The tissue was sonicated on ice for 10 sec at 30% amplitude to shear the 
chromatin (Branson Digital Sonifier 450, Crystal Electronics, On. Canada). Sonicated 
materials were immunoprecipitated using designated antibodies. Fragments were then 
amplified by real-time PCR in triplicates. Human primers sets used were as follow: 
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MCBOX (F) 5’-AGGGAATGTCTTCCCATAAAAACT-3’; (R) 5’-
GTCTACCTTTTATTTGAATTCCCG-3’; SATIII (F) 5’-
AATCAACCCGAGTGCAATCNGAATGG-3’; (R) 5’-
TCCATTCCATTCCTGTACTCGG-3’; SATa (F) 5’-
AAGGTCAATGGCAGAAAAGAA-3’; (R) 5’-CAACGAAGGCCACAAGATGTC-3’; 
ACTIN (F) 5’-CCTCAATCTCGCTCTCGCTC-3’; (R) 5’-
CTCTAAGGCTGCTCAATGTCA-3’; ß-GLOBIN (F) 5’-
GGCTGTCATCACTTAGACCTC-3’; (R) 5’-GGTTGCTAGTGAACACAGTTG-3’;5’. 
Mouse primers sets used were as follow: MajSAT 5′- 
GGCGAGAAAACTGAAAATCACG-3′, 5′-CTTGCCATATTCCACGTCCT-3′; 
MinSAT 5′- TTGGAAACGGGATTTGTAGA-3′, 5′-
CGGTTTCCAACATATGTGTTTT-3′; LINE 5′-TGGCTTGTGCTGTAAGATCG-3′, 5′-
TCTGTTGGTGGTCTTTTTGTC-3′; SINE1 5′-GAGCACACCCATGCACATAC-3′, 5′-
AAAGGCATGCACCTCTACCACC-3′; Actin 5’-TCGATATCCACGTGACATCCA-3’; 
5’-GCAGCATTTTTTTACCCCCTC-3’; HoxA7 5’-GTGGGCAAAGAGTGGATTTC-
3’;5’-CCCCGACAACCTCATACCTA-3’;β-major 5′-CAGTGAGTGGCACAGCATCC-
3′; 5′-CAGTCAGGTGCACCATGATGT-3′. ChIP-qPCR data was analyzed according to 
the Percent Input method. First, the raw Ct of the diluted 1% input fraction is adjusted by 
subtracting 6.64 cycles (i.e. log2 of the dilution factor 100). Subsequently, the percent 
input of each IP fraction is calculated according to this equation: 100*2(Adjusted Input Ct-Ct(IP). 
 
Real-time RT-PCR 
Mouse cortices were diced and RNA was isolated using TRIzol reagent (Invitrogen). 
Reverse transcription (RT) was performed using 1 µg of total RNA and the MML-V 
reverse transcriptase (Invitrogen). Real-time PCR was carried in triplicates using 
Platinum SYBRGreen Supermix (Invitrogen) and Real-time PCR apparatus (ABI prism 
7002). Primer sets used were as described 13.  
 
Statistical analysis 
Statistical differences were analyzed using Student's t-test for unpaired samples. Two 
way-ANOVA test was used for multiple comparisons with one control group. In all cases, 
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the criterion for significance (P value) was set as mentioned in the figures. Significance 
was assessed using an unpaired two-sided Student's t-test in figures 1-4 and 6 and 7, as 
these all represent comparisons of independent samples of equal size and variance 
following a normal distribution. For figures 5 and 8, where several groups were 
compared, significance was assessed by ANOVA and adjusted for multiple comparisons 
using the Bonferroni correction. 
 
RESULTS 
 
Bmi1+/- mice display aging features and neurological symptoms 
Alopecia and weight loss are common characteristics of premature aging in mice and we 
previously reported that Bmi1+/- mice presented reduced median and maximal lifespan 13. 
We observed that Bmi1+/- mice between the ages of 15-20 months (defined here as old 
mice) exhibited alopecia and reduced body size when compared to age-match WT 
littermates (Fig. 1a, b). These features were not present in 3- and 12-month old Bmi1+/- 
mice (Fig. 1a, b). We performed the paw-clasping test to verify if alopecia-affected 
Bmi1+/- mice presented pathological reflexes. Instead of limb extension as in WT mice, 
Bmi1+/- mice displayed an irregular clasping behavior characterized by the dragging of 
the fore paws towards the trunk and asymmetry in limb position (Fig. 1c), thus suggestive 
of a neurological syndrome. The Bmi1 gene operates as a central regulator of the 
p19Arf/p53 and p16Ink4a/pRb axes, which promote apoptosis and senescence 10. Although 
senescence is thought not to occur in neurons, increased SA β-galactosidase activity and 
expression of the senescence-associated genes p19Arf and p16Ink4 have been described in 
cortical neurons of aged p73+/- mice and Bmi1-/- pups 13, 14. To test for neuronal 
senescence, we compared the cortex of 24-month old (defined here as very old) WT and 
15-month old Bmi1+/- mice for SA β -galactosidase activity. Very old WT mice were used 
to compensate for possible premature aging in Bmi1+/- mice. Yet, robust SA β-
galactosidase staining was observed in pyramidal neurons (layers 2 and 3 of the frontal 
cortex) of Bmi1+/- mice when compared to WT, together with a 2-fold increase in the 
number of SA b-galactosidase-positive neurons (Fig. 1d, e). Expression of p16Ink4 is 
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considered as a biomarker of aging 15. Consistently, we observed increased p16Ink4  (~25 
fold) and p19Arf (~5 fold) expression in Bmi1+/- mice compared to WT (Fig. 1f), 
suggesting that old Bmi1+/- mice display premature brain aging. 
 
Bmi1+/- mice show altered spatial memory and reduced long-term potentiation  
To test if cognitive functions were perturbed, we examined healthy 15-months old WT 
and Bmi1+/- littermates for spatial learning and memory aptitude. For the Morris water 
navigation task, mice were trained for 4 days (traning) and then evaluated on their 
capacity to remember the platform location (probe test). Bmi1+/- mice performed poorly 
in this assay during both the training period and probe test, as demonstrated by the 
increased time (latency) required to reach the platform (Fig. 2a, b). Although the 
swimming speed of Bmi1+/- mice was reduced (0.25 m/s for WT and 0.20 m/s for Bmi1+/-
), it was sufficiently close to that of WT mice to exclude this variable as the cause of the 
highly increased latency (Fig. 2a). Bmi1+/- mice also exhibited an anxious phenotype as 
demonstrated by an increased thigmotactic behavior while performing the task (Fig. 2a). 
The Barnes maze test is based on mice aversion to open enlightened spaces. Bmi1+/- mice 
were more prone to visiting non-target holes while searching for the hole with the escape 
box and the latency of escape was also increased (Fig. 2c). These results suggested that 
otherwise healthy Bmi1+/- mice present impaired spatial memory formation and increased 
anxiety.        
Using the same animals, we tested if impairment of spatial memory formation was 
related to an impairment of long-term potentiation (LTP), a cellular model for spatial 
memory formation 16. LTP of the Schaffer collateral pathway was induced in the CA1 
region of the hippocampus in both WT and Bmi1+/- mice. We found that inducing LTP 
(100 Hz, 100 pulses) enhanced fEPSP slope in WT mice at 60 minutes after tetanus 
(Percent potentiation: 48.9 ± 5.2%, data from 6 slices and 3 mice). Compared with fEPSP 
recorded before tetanus (baseline), WT slices displayed significant potentiation (P = 
0.036; paired Student’s t-test) (Fig. 2d, e). Slices from Bmi1+/- mice exhibited weaker 
potentiation than WT (11.7 ± 11.2%, data from 6 slices, 4 mice; Bmi1+/- vs. WT: P = 
0.045, Student’s t-test) and failed to show significant potentiation when compared to 
baseline at 60 minutes after tetanus  (P = 0.357; paired Student’s t-test) (Fig. 2f). Our 
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findings suggested that Bmi1 hemi-deficiency significantly impaired LTP formation, and 
LTP deficits have been observed in transgenic mouse models of AD that exhibit spatial 
memory impairment 17, 18. 
 
Bmi1+/- mice present neuropathological features resembling AD 
We previously showed that most neuronal anomalies present in Bmi1-/- mice were 
mediated by p53 activity 13. We therefore analyzed p53 expression and found that when 
compared to old WT, p53 levels were increased in the brain of old Bmi1+/- mice, 
suggesting the presence of a brain pathology (Fig. 3a). Hallmarks of AD are 
accumulation of p-TAU in neuron’s perikarya, extra-cellular amyloid plaque formation, 
reduced synaptophysin immunoreactivity and neuronal loss. By immunoblot using 
antibodies that recognize p-TAU at Ser202 (AT-8) or Ser396 (PHF1), we observed the 
presence of p-TAU accumulation in Bmi1+/- cortices (Fig. 3a). By immunohistochemistry 
(IHC), we observed p-TAU immunoreactivity in the neuron’s perikarya of old WT and 
Bmi1+/- mice. However, large p-TAU deposits in “ghost-like” neurons and strong 
immunoreactivity in track fibers of the cortical white matter were only observed in 
Bmi1+/- mice (Fig. 3b). These pathological features correlated with increased p-JNK and 
reduced synaptophysin levels (Fig. 3a). Accumulation of p-JNK and p-TAU (S202) was 
not observed in very old WT mice (Fig. 3c). Cleavage of APP by the β -secretase BACE1 
is the first step in the sequential production of β-amyloid, and BACE1 levels are 
increased in sporadic AD 19. Notably, we observed increased BACE1 levels in Bmi1+/- 
cortices (Fig. 3a). Soluble amyloid oligomeres of ~10-12kda are believed to perturb 
synaptic and mitochondrial functions in AD and these were shown to accumulate in the 
neuronal cytoplasm of AD patients and of transgenic mice carrying the APPE693-deleted 
mutation 20, 21. By immunoblot using the FCA3542 antibody, which recognizes the mouse 
and human 1-42 amyloid peptide, a 10-12kda band was revealed in 15-month old Bmi1+/- 
mice, but not in old WT mice (Fig. 3d-input 20%). After immunoprecipitation using a 
mouse monoclonal antibody (DE2B4) that recognizes the mouse and human amyloid 
peptide, the presence of the 10-12kda band was also observed with FCA3542 in 15-
month old Bmi1+/- mice and 6-month old APP transgenic mice carrying the AD-related 
Swe/Iowa/Nevada mutations (APPTG), but not in old WT mice (Fig. 3d). By IHC on 
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cortical sections, we observed intra-neuronal immunoreactivity for β-amyloid in old 
Bmi1+/- mice, but not in WT littermates (Fig. 3e). Amyloid accumulation was also not 
observed in very old WT mice (Fig. 3f). To evaluate the possibility of neuronal loss, we 
calculated the total number of cortical neurons per section in the frontal cortex using a 
pan-neuronal marker (NeuN). When compared to WT littermates, old Bmi1+/- mice 
displayed a ~20% reduction in NeuN-positive neurons (Fig. 3g). To measure cell death, 
we quantified the number of neurons positive for activated caspase-3 in the frontal cortex. 
This revealed a ~2 fold increase in the frequency of apoptotic neurons in old Bmi1+/- mice 
(Fig. 3h), altogether suggesting ongoing neurodegeneration resembling AD in Bmi1+/- 
mice.  
 
Cortical neurons of Bmi1+/- mice present heterochromatin anomalies and a DDR 
involving the ATM and ATR kinases 
In most eukaryotes, constitutive heterochromatin perturbations result in genomic 
instability and premature aging or reduced lifespan 22-27. Hence, we reasoned that the 
pathological brain aging phenotype observed in Bmi1+/- mice could result from 
heterochromatin alterations. To test this, we performed immunoblot analysis on old WT 
and Bmi1+/- cortices using antibodies against histone H2Aub, the main target of 
Bmi1/Ring1b activity, and histone H3K9me3, which marks constitutive heterochromatin. 
As expected, H2Aub levels were reduced in Bmi1+/- mice when compared to WT. Most 
notably, we also observed reduced H3K9me3 levels (Fig. 4a, b). Of note, Bmi1 levels in 
the brain of old Bmi1+/- mice were also below the 50% reduction expected from deleting 
one Bmi1 allele (Fig. 4a, b). In mammalian cells, a core of proteins is involved in 
constitutive heterochromatin formation. This involves tri-methylation of H3K9me1/2 by the 
SUV39h1/2 methyltransferases, which form a complex with heterochromatin protein 1 
(HP1) 6, 27. To test for an abnormal heterochromatin structure, we performed IHC on 
cortical sections using antibodies against H3K9me3 and HP1. We observed that in contrast 
to WT neurons, where 2-3 large chromocenters were present, Bmi1+/- neurons had smaller 
and more numerous chromocenters, suggesting heterochromatin de-nucleation (Fig. 4c-
e). One prediction of heterochromatin de-nucleation is activation of a DDR, owing to 
genomic instability. The Ataxia Telengectasia Mutated (ATM) and Ataxia Telengectasia 
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and RAD-3 Related (ATR) kinases work at the apex of the DDR, operate as sensors of 
chromatin and DNA damage, and are activated by phosphorylation and auto-
phosphorylation at specific residues 28. By immunoblot analysis, we observed increased 
activation of phospho-ATM at Serine 1981 (p-ATM) and phospho-ATR at Serine 428 (p-
ATR) in the cortices of old Bmi1+/- mice when compared to WT (Fig. 4f). By IHC, we 
also observed accumulation of the histone variant γH2AX, a mark of DNA damage, in 
cortical neurons of old Bmi1+/- mice, suggesting a primarily neuronal DDR (Fig. 4g) 29. 
To test if the observed heterochromatin anomalies preceded apparition of other 
pathological marks, we performed immunoblot analysis on cortices from 90-day old WT 
and Bmi1+/- mice. This revealed that p53, p-ATM, p-ATR, γH2AX, p-JNK, p-TAU and 
amyloid were not yet detectable in young Bmi1+/- mice (Supplementary Fig. 1a). In 
contrast, H2Aub and H3K9me3 levels were reduced by ~50% in these mice (Fig. 4h, i). 
Furthermore, neuron’s chromocenters were smaller and more numerous than in WT 
(Supplementary Fig. 1b, c). These findings revealed that heterochromatin anomalies in 
Bmi1+/- mice are present before the appearance of other pathological marks. 
 
Bmi1 is enriched at heterochromatin in WT mice and required to prevent DNA 
damage accumulation at heterochromatin in Bmi1+/- mice 
To test where Bmi1 and DDR proteins were localized on the genome, we performed 
chromatin immuno-precipitation (ChIP) experiments using Bmi1, H2Aub, H3K9me3, p-
ATR, gH2AX and IgG antibodies on old WT and Bmi1+/- mice. As positive control for 
Bmi1 enrichment, we analyzed the Hoxa7 locus (a known target of Bmi1), while the b-
globin locus was used as negative control 13. We found that Bmi1 was highly enriched 
together with H3K9me3 and H2Aub at pericentric (Minor and Major satellite repeats) and 
intergenic (LINE) constitutive heterochromatin in WT cortices (Fig. 5a). In contrast, 
Bmi1, H3K9me3 and H2Aub enrichment was highly reduced in Bmi1+/- cortices (Fig. 5a). 
We also found that p-ATR and gH2AX enrichment was nearly absent for all tested 
regions in WT cortices (Fig. 5b). In contrast, while there was no enrichment for gH2AX 
and p-ATR at euchromatin (b-actin), silent facultative heterochromatin (b-globin), or 
bivalent facultative heterochromatin (Hoxa7) in Bmi1+/- cortices, important accumulation 
(up to 100 fold difference relative to WT) was found at constitutive heterochromatin (Fig. 
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5b, c). These findings suggested that Bmi1 and H2Aub are highly enriched at constitutive 
heterochromatin in WT mouse brains and that DDR in Bmi1+/- mouse brains 
predominantly occurs at constitutive heterochromatin. 
 
Bmi1 is required for proper H3K9me3 distribution and co-localizes with H3K9me3 in 
neurons 
We performed confocal microscopy imaging analyses on cortical sections from 45-day 
old WT and Bmi1+/- mice to further investigate heterochromatin anomalies. We observed 
reduced and fragmented H3K9me3 immunostaining in Bmi1+/- pyramidal neurons (Fig. 
6a). DAPI staining was also fragmented, but to a lesser extend (Fig. 6a). While H3K9me3 
and DAPI signals co-localized in WT neurons, their co-localization was poor in Bmi1+/- 
neurons (Fig. 6a). Quantitative analysis of the data revealed that H3K9me3 distribution in 
WT neurons was very close to a bell curve (normal distribution), while that of Bmi1+/- 
neurons resembled an imperfect bell curve, and where maximal H3K9me3 intensity was 
reduced (Fig. 6b, c). DAPI staining distribution was also affected in Bmi1+/- neurons, and 
where the bell curve was fragmented and compressed (Fig. 6b, c). To confirm Bmi1 
enrichment at heterochromatin, we performed IF analyses on cortical sections from WT 
mice. We observed co-expression of Bmi1 and H3K9me3 in the nuclei of pyramidal 
neurons, and where 90-96% of the Bmi1 signal co-localized with H3K9me3 (Fig. 6d). 
 
Heterochromatin anomalies are present at the onset of neurogenesis 
To evaluate when heterochromatin anomalies could be first detected, we performed ChIP 
analysis on cultured embryonic day 18.5 (e18.5) cortical neurons. This method yields a 
nearly pure neuronal cell population after 7 days in vitro 13. We found enrichment for 
Bmi1, H2Aub and H3K9me3 at the chromatin of Minor and Major satellite repeats as well 
as LINE intergenic retro-element in WT neurons, and this was significantly reduced in 
Bmi1+/- neurons (Supplementary Fig. 2a). Importantly, Bmi1 also accumulated at the 
chromatin of its target gene, Hoxa7, but not at the chromatin of b-globin (Supplementary 
Fig. 2a). These results established that heterochromatin anomalies in Bmi1+/- mice are 
present at the onset of neurogenesis, and confirmed Bmi1 and H2Aub enrichment at 
heterochromatin in neurons. 
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The ATM/ATR kinases operate upstream of p53 and p-TAU 
The Chk1 and Chk2 kinases can target TAU for phosphorylation at specific residues 30. 
Likewise, ATM and ATR can target p53 for phosphorylation and stabilization 31, 32. To 
test if we could establish a cause an effect relationship between DDR and the neuronal 
pathology, we analyzed cultures of e18.5 neurons. Using antibodies against p-ATM and 
p-Chk1 (a downstream target of ATR), we found that DDR was not detectable in WT or 
Bmi1+/- neurons. In contrast, it was readily observed in Bmi1-null neurons, suggesting a 
gene dosage effect (Supplementary Fig. 2b). Notably, p-TAU accumulation was also 
observed in Bmi1-null neurons, but not in WT or Bmi1+/- neurons (Supplementary Fig. 
2b). Neurons were exposed to a pharmaceutical inhibitor of ATM and ATR (ATM/ATRi) 
for 16 hours and this could effectively prevent p-ATM and p-Chk1 as well as p-TAU 
accumulation in Bmi1-/- neurons (Supplementary Fig. 2b). Using a competitive 
pharmaceutical inhibitor of ATM (ATMi) at a concentration showed to block ATM 
autophosphorylation 11, we found that p53 accumulation in Bmi1-null neurons could not 
be prevented (Supplementary Fig. 2b). In contrast, exposing Bmi1-null neurons to 
ATM/ATRi largely prevented p53 accumulation (Supplementary Fig. 2b), suggesting that 
the DDR machinery operates upstream of p53 and p-TAU in the neuropathological 
cascade. 
 
BMI1 deficiency, heterochromatin alterations and DDR in LOAD brains 
Considering the similarities between the Bmi1+/- mouse phenotype and AD, we 
investigated BMI1 expression in AD. The hippocampus is a brain region where severe 
neurodegeneration occurs in AD. By immunoblot analysis, we observed comparable 
BMI1 expression in the hippocampus of control brains (n = 3 brains, median age of 59 
year) and EOAD brains (n = 4 brains, median age of 61 year) (Fig. 7a, b, and 
Supplementary Table 1). In contrast, while BMI1 expression was present in the 
hippocampus of all elderly control brains (n = 3 brains, median age of 87 year), it was 
nearly absent in LOAD brains (n = 5 brains, median age of 82 year) (Fig. 7c, e, data not 
shown, and Supplementary Table 1). Since the hippocampus is highly affected in AD, we 
analyzed BMI1 expression in the frontal cortex, which is affected later and less severely. 
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Because BMI1 expression could only be detected in elderly control brains in regular 
immunoblot assays (n = 12 samples with two experiments, data not shown), blots were 
incubated with the BMI1 antibody for 3 days in order to increase sensitivity. This 
revealed the presence of a BMI1 triplet representing different phosphorylated forms of 
BMI1 (Fig. 7d) 33, 34. While BMI1 expression was detected in all control brains (n = 6 
brains, median age of 87 year), it was nearly absent in LOAD brains (n = 6 brains, 
median age of 87 year) (Fig. 7d, e, and Supplementary Table 1). BMI1 mRNA levels 
were also reduced by ~90% in LOAD samples when compared to elderly controls (not 
shown). Histone H2A is the main target of BMI1/RING1a/b activity 7, 8, and we found 
that Bmi1 hemi-deficiency is associated with reduced H3K9me3 levels in mice. Notably, 
H2Aub and H3K9me3 levels were significantly reduced in LOAD brains (Fig. 7c-e). In 
contrast, H2Aub and H3K9me3 levels were normal in EOAD brains (Fig. 7a, b), and in 
elderly control brains (Fig. 7c-e). To test for genomic instability, we analyzed the 
expression of DDR proteins. We observed accumulation of p-ATM, p-ATR and p-CHK1 
in all LOAD brains, but not in elderly control brains (Fig. 7d). In contrast, p-ATM, p-
ATR or p-CHK1 accumulation in EOAD and young control brains was not observed, 
with the exception of one EOAD sample presenting p-ATM accumulation (Fig. 7a). To 
investigate whether the LOAD chromatin phenotype was neuronal, we performed IHC on 
frontal cortex sections. We observed pyramidal neurons expressing BMI1 and NeuN in 
control brains, while neuronal BMI1 expression was reduced or absent in LOAD brains 
(Fig. 7f, and Supplementary Table 1). Likewise, large nuclei corresponding to that of 
pyramidal neurons had reduced or absent (~38% of all neurons) H3K9me3 nuclear staining 
and neuron’s chromocenters were smaller and more numerous in LOAD brains when 
compared to elderly controls (Fig. 7g-i). Furthermore, p-ATM accumulation in LOAD 
brains was found primarily in neurons (Fig. 7j). 
 
BMI1 is enriched at heterochromatin in healthy brains and DDR occurs at 
heterochromatin in LOAD brains 
To establish whether BMI1 was also enriched at heterochromatin in the human brain, we 
performed ChIP experiments on human frontal cortex samples. The b-GLOBIN locus was 
used as negative control and the HOXC13 locus as positive control for BMI1 binding to 
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chromatin 35. We observed BMI1 and H3K9me3 enrichment at pericentric heterochromatin 
in control brains, while BMI1 and H3K9me3 were depleted in LOAD brains (Fig. 8a). We 
also tested for DDR localization on the genome by ChIP. When compared to controls, 
there was predominant enrichment for p-ATR and gH2AX in LOAD at constitutive 
heterochromatin (SATIII, SATA and McBOX), but not facultative heterochromatin 
(HOXC13 and b-GLOBIN) or euchromatin (ACTIN) (Figure 8b, c). There was also a 
(non-significant) trend for p-ATM enrichment at constitutive heterochromatin in LOAD 
(Fig. 8b, c). These findings suggested predominant accumulation of DDR proteins at 
H3K9me3-dependent constitutive heterochromatin in LOAD brains. 
 
DISCUSSION 
 
 We demonstrated here that: 1) Bmi1+/- mice develop a behavioral, physiological, 
neuropathological and molecular phenotype resembling LOAD; 2) heterochromatin 
anomalies in Bmi1+/- neurons precede other pathological marks; 3) DDR in Bmi1-/- 
neurons works upstream of p53 and p-TAU and occurs at H3K9me3-associated 
heterochromatin; 4) Bmi1 co-localizes with H3K9me3 in neurons; 5) Bmi1 and H2Aub are 
enriched at H3K9me3-associated heterochromatin in mouse brains; 6) BMI1 expression is 
deficient in LOAD brains, together with that of H2Aub and H3K9me3; 7) BMI1 is enriched 
at H3K9me3-associated heterochromatin in human brains; 8) DDR also occurs at 
constitutive heterochromatin in LOAD brains. These results reveal striking molecular 
similarities between the Bmi1+/- mouse and LOAD phenotypes. They also provide 
evidences that Bmi1 is enriched at constitutive heterochromatin and required for 
heterochromatic genome stability. Most unexpectedly, they suggest that deficient BMI1 
expression and heterochromatic genome instability are hallmarks of LOAD. 
 The heterochromatin island hypothesis of aging stipulates that epigenome 
instability at the constitutive heterochromatin is a driving force of cellular aging 36, 37. 
Notably, perturbations of the nuclear matrix or inactivation of chromatin remodeling 
proteins, such as those of the NURD complex, result in DDR and cellular senescence that 
are preceded by heterochromatin alterations 25. Furthermore, modifications of constitutive 
heterochromatin in response to an acute stress can result in epigenome instability and 
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perturbation of gene expression program, which are hallmarks of cellular aging 22. In 
mice, deletion of the SUV39h1/h2 methyltransferases leads to reduced viability, loss of 
H3K9me3 and genomic instability 27. In Drosophila, perturbation of H3K9me2 levels 
through inactivation of Su(var)3-9 results in genomic instability and DDR at 
heterochromatin 26. We showed here that heterochromatin alterations in Bmi1+/- mice 
precede the other pathological marks and are present at the time of neurogenesis. 
Notably, this correlated with DDR at constitutive heterochromatin. The p53 protein is a 
critical mediator of neuronal cell death in multiple neurodegenerative disorders 38-40. 
Similarly, p-TAU mediates amyloid dependent and independent neurodegeneration and 
synaptic dysfunction 41-43. Using Bmi1-null neurons, we showed that a causal relationship 
could be established between DDR and accumulation of p53 and p-TAU, suggesting that 
persistent DDR in neurons is sufficient to cause neurodegeneration. Hence, over-
expression of Chk1 or Chk2 can exacerbate TAU toxicity in a Drosophila model of 
neurodegeneration through phosphorylation of human TAU at Ser262 44. Likewise, JNK 
activation may promote TAU hyper-phosphorylation 14. Taken together, these 
observations suggest that a sequential neuropathological cascade operates in Bmi1+/- mice 
and where deficient heterochromatin compaction initiates the disease process. 
There is overlooked evidence for PRC1 proteins localization, including BMI1, at 
pericentric heterochromatin in human cells 45. We have found that Bmi1 hemi-deficiency 
results in molecular alterations at constitutive heterochromatin characterized by reduced 
H2Aub and H3K9me3 deposition. This correlated with Bmi1 and H2Aub accumulation at 
constitutive heterochromatin and co-localization with H3K9me3 in neurons. By 
performing ChIP, we also established that BMI1 accumulates at H3K9me3–associated 
heterochromatin in healthy human brains, and that BMI1 and H3K9me3 were reduced at 
heterochromatin in LOAD brains. Taken together, these results suggest that Bmi1 
promotes heterochromatin formation by catalyzing H2Aub deposition at genomic 
repetitive sequences. Interestingly, a similar mechanism was proposed for BRCA1-
mediated heterochromatinization 46. How Bmi1/Ring1b-mediated H2Aub deposition at 
heterochromatin translates into H3K9me3 deposition and heterochromatin spreading 
remains an open question. Furthermore, whether confounding mechanisms are also 
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involved in the heterochromatin de-compaction phenotype observed in Bmi1+/- mice 
remains to be investigated. 
 We have found that enrichment for p-ATR and γH2AX in LOAD brains occurs 
preferentially at constitutive heterochromatin. The relatively weak accumulation of p-
ATM in LOAD brains as observed by ChIP (in contrast with immunoblot) suggests that a 
portion of the p-ATM pool is not chromatin-bound. This is consistent with p-ATM 
accumulation in both cytosolic and nuclear neuronal compartments (see Fig. 7). Why loss 
of heterochromatin compaction in LOAD brains and Bmi1+/- mouse brains is associated 
with DNA damage accumulation is unknown. It is possible that repetitive DNA 
sequences are intrinsically unstable upon loss of H3K9me3, and thus prone to de novo 
DNA damage formation 26. It is also possible that the efficiency of DNA repair is reduced 
upon BMI1 deficiency or that recognition of the H3K9me3 mark is important to activate 
the process of DNA repair 11, 12, 47. 
 There are mounting evidences supporting the possibility that epigenetic 
modifications are involved in LOAD 48, 49. Particularly, it was showed that genome-wide 
reductions in DNA methylation are characteristic of LOAD 50. We found deficient BMI1 
expression, loss of heterochromatin compaction and reduced histone H2Aub and H3K9me3 
levels in all LOAD samples tested. These anomalies were not present in elderly controls 
or EOAD samples, thus excluding brain aging or neurodegeneration as the primary cause. 
The molecular dichotomy observed between EOAD and LOAD further suggests that they 
represent distinct pathological entities 4. Why BMI1 expression is reduced in LOAD and 
whether this is a cause or a consequence of the human disease remains to be investigated. 
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FIGURE LEGENDS 
 
Figure 1. Bmi1+/− mice present neurological symptoms 
 (a) Photographs of 3-month old and old WT and Bmi1+/− mice. Note that old Bmi1+/− 
mice (n = 5) are smaller and exhibit hair loss (alopecia) compared to WT littermates (n = 
5). (b) Quantification representing the mean weight of 3-month (n = 6), 1-yr (n = 6) and 
old (n = 6) WT and Bmi1+/− mice, and where n = the number of mice/genotype. (c) 
Photographs showing the paw clasping reflex of old WT (n = 5) and Bmi1+/− mice (n = 
5). Note that the Bmi1+/− mouse pulls its fore limbs into its body rather than spreading 
them away from its trunk, and present asymmetry in the hind limbs’ position. (d) 
Analysis of SA b-galactosidase activity in the cortices of 24 month-old (24 M) WT and 
15 month-old (15 M) Bmi1+/− mice. Scale bar: 20µm. (e) Quantification of the number of 
SA b-galactosidase positive neurons/cortical section (n = 6), where n = number of brain 
sections/mouse. (f) Quantitative PCR analysis of p16Ink4a and p19Arf expression in the 
cortices of age-match 16 month-old WT (n = 3) and Bmi1+/− (n = 3) mice. All values are 
mean ± SEM. (*) P<0.05; (**)<0.01; Student’s t-test. 
 
Figure 2. Bmi1+/− mice display spatial memory deficit and reduced LTP 
(a-c) Healthy 15-month old WT (n = 5) and Bmi1+/− (n = 5) male mice were tested for 
behavioral changes associated with spatial memory formation deficit. (a) Results of 
Morris water maze probe test, showing mean swim speed, time spent in the target 
quadrant searching for the hidden platform, and mean time to reach the target platform 
(latency). (b) Charts representing mean latency and mean thigmotaxis of Morris water 
maze 4-day trials of WT and Bmi1+/− mice. (c) Histograms representative of Barnes maze 
test results including mean total errors and mean latency to reach the target probe. (d) 
LTP in 15-month old WT and Bmi1+/− mice. Scatter plots revealed changes in the slope 
of field excitatory postsynaptic potential (fEPSP) recorded from the hippocampal CA1 
region of WT and Bmi1+/− mice. LTP was induced by tetanus (100 Hz, 100 stimulation). 
Dotted line represents the baseline. (e) Representative traces of fEPSP recorded before 
(baseline) and 60 min after tetanus. Dotted lines represent baselines. (f) Histogram of 
fEPSP slope at 60 min after LTP induction. Normalized fEPSP slopes, recorded between 
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55-60 min after tetanus, were averaged for calculating percent potentiation. All values are 
mean ± SEM. (*) P< 0.05; (**) P< 0.01; Student’s t-test.  
 
Figure 3. Bmi1+/− mice present AD-like neurodegeneration 
(a) Western blot analysis of cortical extracts from 15-month old WT (n = 6) and Bmi1+/− 
(n = 6) mice, where n = the number of independent samples analyzed. (b) IHC for p-TAU 
(PHF1) on cortical sections of 20-month old WT (n = 3) and Bmi1+/− mice (n = 3), where 
n = the number of independent animals. (i) Low magnification. Scale bar: 20µm. Higher 
magnifications in (ii) revealed p-TAU deposits on ghost-like neurons and in (iii) p-TAU 
immunoreactivity in track fibers of the cortical white matter of Bmi1+/− mice. Scale bar: 
8µm. (c) Western blot analysis of cortical extracts from 24-month old WT (n = 3 mice) 
and 15-month old Bmi1+/− mice (n = 1 mouse), with 2 independent experiments. (d) 
Western blot (input) and IP (using DE2B4) of the soluble cellular fraction of 15-month 
old WT (n = 3) and Bmi1+/− (n = 3) cortices, and from a 6-month old APPTG mouse, all 
revealed with the FCA3542 antibody, with 2 independent experiments. (e) IHC on brain 
sections from 20 month-old WT (n = 3 mice) and Bmi1+/− (n = 3 mice) mice to analyze 
the expression of b-amyloid oligomers (DE2B4). Top images scale bar is 20µm; Lower 
images scale bar is 8µm. (f) Western blot analysis of cortical extracts from 24-month old 
WT (n = 3 mice), 15-month old Bmi1+/− (n = 1) and 12-month old APPTG  (n = 1) mice 
with the FCA3542 antibody, with 2 independent experiments. H3: histone H3. (g) 
Quantification of the number of NeuN+ cortical neurons in the frontal cortex of age-
match old WT (n = 5 mice) and Bmi1+/− (n = 5 mice) using IHC. (h) Quantification of the 
number of neurons positive for activated caspase-3 in the frontal cortex of age-match old 
WT (n = 5 mice) and Bmi1+/− (n = 5 mice) mice. All values are mean ± SEM. (*) P<0.05; 
Student’s t-test. 
 
Figure 4. Heterochromatin anomalies are present in cortical neurons of Bmi1+/− 
mice 
(a) Western blot analysis of cortical extracts from old WT (n = 6) and Bmi1+/− (n = 6) 
mice, where n = the number of independent animals. (b) Quantification of data presented 
in (a). (c, e) IHC was performed on cortical sections from old WT (n = 3) and Bmi1+/− (n 
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= 3) mice to reveal the expression of constitutive heterochromatin markers. Scale bar: 
20µm. Scale bar in the inset: 8µm. (d) Quantification of the number of H3K9me3 foci per 
nucleus in (c), and where 6 sections/sample were count. (f) Western blot analysis of 
cortical extracts from old WT (n = 3) and Bmi1+/− (n = 3) mice using antibodies against 
p-ATM and p-ATR. (g) IHC for gH2AX on cortical sections of old WT (n = 2) and 
Bmi1+/− (n = 2) mice. (h) Western blot on cortical extracts of 3-month old WT (n = 3) and 
Bmi1+/− (n = 3) mice. (i) Quantification of results obtained in (h). Scale bar: 20µm. All 
values are mean ± SEM. (*) P<0.05; (**)<0.01; Student’s t-test. 
 
Figure 5. BMI1 is enriched at heterochromatin and required to prevent DNA 
damage accumulation at pericentric and intergenic heterochromatin in Bmi1+/- 
mouse brains  
(a) ChIP analyses were performed on frontal cortex homogenates from 15-month old WT 
(n = 3) and Bmi1+/- (n = 3) mice. Quantitative PCR was performed in triplicate for each 
DNA sequence. All data are presented as fold of input. Bmi1 and H2Aub reduction (p < 
0.05), and p-ATR and gH2AX accumulation (p < 0.01) in Bmi1+/- mice are significant 
(Two-way ANOVA analysis). (b) Fold differences for gH2AX and p-ATR accumulation 
in Bmi1+/- mice were measured relative to WT levels for each DNA sequence. 
 
Figure 6. Bmi1 is required for normal H3K9me3 distribution and co-localizes with 
H3K9me3 in cortical neurons  
(a) Cortical slices from 45-day old mice were labeled with an H3K9me3 antibody, 
mounted with DAPI and analyzed by confocal microscopy, where n = 2 for the number of 
experiments. Areas showed are located in layers 2-3 of the frontal cortex. In WT mice, 
large pyramidal neurons are strongly labeled by the H3K9me3 antibody. Note the co-
localization of H3K9me3 with DAPI. In Bmi1+/- samples, large pyramidal neurons are 
weakly labeled by the H3K9me3 antibody and the H3K9me3 signal is fragmented. Note 
the poor co-localization of H3K9me3 with DAPI. (b, c) Quantification of the images 
showed in (a) revealing the normal distribution of the H3K9me3 signal in WT (b), but near 
bimodal (i) H3K9me3 distribution in the Bmi1+/- samples (c). Likewise, DAPI signal in the 
Bmi1+/- samples is compressed, enlarged and fragmented (ii). Note also the reduced 
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maximal intensity of the H3K9me3 signal in the Bmi1+/- samples (iii). (d) Cortical slices 
from 45-day old WT mice were labeled with Bmi1 and H3K9me3 antibodies, mounted 
with DAPI and analyzed by confocal microscopy, where n = 2 for the number of 
experiments. About 90-96% of the Bmi1 signal was found to co-localize with H3K9me3. 
 
Figure 7. BMI1 deficiency, neuronal heterochromatin loss and DDR in LOAD 
brains 
(a) Immunoblot on hippocampal extracts from young control and EOAD patients. (b) 
Quantification of the results in (a) relative to “healthy” controls. (c) Immunoblot on 
hippocampal extracts of aged control and LOAD patients. (d) Immunoblot on frontal 
cortex extracts from control and LOAD patients. (e) Quantification of the results in (c, d) 
relative to “healthy” controls. (f) IHC staining for BMI1 (black arrows) and NeuN (red 
arrows) on frontal cortex sections of age-match control and LOAD samples. Note the 
lipofuscin deposition (blue arrows). Scale bar: 8µm. (g) IHC staining for H3K9me3 on 
frontal cortex sections of “healthy” control and LOAD brains: (i) reduced peri-nucleolar 
heterochromatin in LOAD (arrows), (ii) chromocenters de-condensation in LOAD, and 
(iii) loss of H3K9me3 immunoreactivity in LOAD neurons. Scale bar: 5µm. (h) 
Quantification of the number of H3K9me3 foci/H3K9me3-positive neuron. H3K9me3-
negative neurons were excluded from the analysis. (i) Quantification of the number of 
H3K9me3-negative neurons, which were not found in aged controls. 6 full-fields at 630 
magnification/sample were counted, with n = 6 independent samples. (j) IHC staining for 
p-ATM on frontal cortex sections of “healthy” control and LOAD patients. p-ATM is 
predominant in LOAD neurons and accumulates in both cytosolic (blue arrowhead) and 
nuclear (black arrowhead) compartments. All values are mean ± SEM. (*) P<0.05; 
(**)<0.01; (***)<0.001; Student’s t-test. 
 
Figure 8. DNA damage accumulates at constitutive heterochromatin in LOAD 
brains  
(a, b) ChIP experiments were performed on frontal cortex extracts of age-match “healthy” 
control (n = 6 independent samples) and LOAD patients (n = 6 independent samples). All 
data are represented as fold of input. (a) BMI1 is enriched at constitutive heterochromatin 
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(McBOX, SATIII and SATA) together with H3K9me3 in control samples. BMI1 was also 
found at HOXC13. Note loss of BMI1 and H3K9me3 enrichment in LOAD samples. (b) 
Both p-ATR and gH2AX showed preferential enrichment at constitutive heterochromatin, 
but not elsewhere, in LOAD samples when compared to control samples. (c) Fold 
differences between “healthy” control and LOAD samples for p-ATM, p-ATR and 
gH2AX accumulation. Differences were more notable for p-ATR and gH2AX (bold 
numbers). All values are mean ± SEM. (*) P<0.05; (**)<0.01; Two way-ANOVA test 
was performed for multiple gene analysis and Student’s t-test for single gene analysis. 
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Figure 1 
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Figure 2 
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Figure 5 
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Figure 6 
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Figure 8 
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SUPPLEMENTARY FIGURE LEGENDS: 
 
Supplementary Figure 1. Heterochromatin anomalies in Bmi1+/- mice are present 
before the apparition of neuropathological marks 
(A)Western blot on cortical extracts from 3-month old WT (n=3) and Bmi1+/- (n=3) mice, 
and one old Bmi1+/- mouse (positive control). We used PHF1 for p-TAU and FCA3542 
for amyloid. (B) IHC for H3K9me3 on cortical sections of 3-month old WT (n=3) and 
Bmi1+/- (n=3) mice, Scale bar: 20µm, Scale bar in the inset: 8 µm. (C) Quantification of 
the total number of H3K9me3 foci per nucleus, as measured using IHC data obtained in 
(B) in neuronal layers 2 and 3 of the frontal cortex. All values are mean ±SEM. (*) 
P<0.05; Student’s t-test.  
 
Supplementary Figure 2. Bmi1 is required for heterochromatin formation and 
genomic stability in embryonic cortical neurons. 
ChIP analysis on 18.5 embryonic day WT (n=3) and Bmi1+/- (n=3) cortical neurons to 
evaluate the levels of H2Aub and H3K9me3 at the HoxA7, IAP1 (Interstitial A particles), 
and satellite repeats (Minor and Major Sat) loci. Quantitative PCR was performed in 
triplicate for each DNA sequence. All data are present as fold of input. Two-way 
ANOVA analysis exposed a highly significant decrease of Bmi1 (P<0.001), H2Aub 
(P<0.0001), and H3K9me3 (p<0.0001) accumulation at heterochromatin domains in 
Bmi1+/- neurons. (B) and (C) Immunoblot were performed on embryonic moue cortical 
neurons cultured for 7days in vitro. (B) DMSO or ATM/ATRi were added to the cultures 
16 hours prior to protein extraction. ATM/ATRi prevent p-ATM, p-CHK1 and p-TAU 
accumulation in Bmi1-/- neurons. (C) ATM/ATRi, but not ATMi, also largely prevented 
p53 accumulation in Bmi1-/- neurons. Numbers 1 and 2 in (C) represent two Bmi1-/- 
independent  neuronal samples.  
 
Supplementary Table 1. Human brain samples used in the study 
The Douglas hospital (DH) provided all western blot samples. The identification number 
(Id) of each sample is included but donor names are not known. The Hopital 
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Maisonneuve Rosemont (HMR) provided the IHC samples. The Id of each sample is 
included but donors are also anonymous.  
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Supplementary Figure 1  
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Supplementary Figure 2 
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Supplementary Table 1 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: 
 
In chapter 4, I discuss my results and correlate them with similar findings in the 
literature. In order to examine thoroughly the impact of the findings, I divided the chapter 
into three sections. In section 1, I explore the role of Bmi1 in the progression of 
Alzheimer’s disease. In section 2, I comment on the novel and important function of 
Bmi1 in the formation of constitutive heterochromatin. In the third section, I relate the 
three parameters i.e. Bmi1, AD, and constitutive heterochromatin together and suggest a 
new concept involving abnormal constitutive heterochromatin organization with 
development of neurodegeneration.  And finally, I discuss about future perspectives.  
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4.1. Bmi1 haploinsufficiency instigates neurodegeneration 
Aged Bmi1+/- mice display reduced median and maximal lifespan as well as 
enhanced onset of numerous ageing features at 15 month-old. These features include 
apparition of lens cataracts, alopecia, reduced body size, abnormal paw-clasping reflex, 
increased senescence-associated β-galactosidase activity, and significant upregulation of 
p16 expression.  Bmi1 is highly expressed in neurons and has been previously described 
as an “anti-progeroid” gene since mice lacking Bmi1 manifest an ageing phenotype 
similar to that of old Bmi1+/- mice, which appears however at very early stages when 
mice are approximately one-month old [1]. These findings indicate that Bmi1 activity is 
dosage sensitive, which may affect its molecular interactions and the stoichiometry of the 
protein complexes it constitutes. The observations that stem cell characteristics and 
cancer incidence in Bmi1+/- mice are similar but not as significant as those observed in 
Bmi1-/- mice also support the notion of Bmi1’s dosage sensitive function [2]. We 
previously demonstrated that Bmi1 expression decreases in the brain with advancing age 
[3]. One explanation for the enhanced ageing phenotype observed in Bmi1+/- mice is that 
the remaining Bmi1 allele of these mice displays decreased expression in the brain with 
ageing, which makes them eventually behave as Bmi1-/- mice but at later stages. This 
concept is similar to loss of heterozygosity of tumor suppressor genes in carcinogenesis 
where any hit affecting the remaining allele leads to its inactivation and favours cancer 
development. Therefore, Bmi1 could act as an ageing suppressor gene; however, loss of 
expression of the residual allele will promote ageing development.  
As mentioned in Chapter I, Bmi1 is the main repressor of the Ink4a/Arf locus that 
mediates the senescence pathway via p16 protein. Importantly, Ink4a/Arf locus 
upregulation is not only observed in senescing cultured cell lines, but is also detected in 
tissues of ageing animals and its expression correlated with enhanced SA-β-galactosidase 
activity [4]. We observed increased sensitivity for SA-β-galactosidase assay as well 
significant upregulation of p16 expression in cortical neurons of 15-month old Bmi1+/- 
mice when compared to those of 24-month old WT mice. This senescent phenotype could 
be caused by direct de-repression of the Ink4a/Arf locus in the neurons of Bmi1+/- mice. 
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Ageing is the main risk factor for progression of late-onset Alzheimer’s disease so 
we investigated if Bmi1+/- mice show any symptoms resembling AD. Spatial learning and 
memory formation are perturbed in mouse models of Alzheimer’s disease and 
interestingly Bmi1+/- mice were also impaired in this context exemplified by their poor 
performance in Morris water maze test and Barnes maze assay as well as by the 
significant reduction in LTP. These results imply a defective synaptic function and 
correlates with the observed severe decrease in the expression of synaptophysin in the 
cortices of these mice. Synaptophysin is a presynaptic vesicle that highly contributes to 
LTP formation and loss of its expression correlates with the cognitive decline in AD [5]. 
Accordingly, Cao et al. recently reported synaptophysin downregulation in one-month 
old Bmi1-/- mice cortices [6]. The severe synaptophysin reduction in Bmi1+/- mice could 
be explained by the degeneration of synapses due to expression of toxic proteins such as 
amyloid peptides in the neurons [7]. Another possibility is due to oxidative stress 
accumulation.  Old Bmi1+/- mice present elevated oxidative stress levels and evidence 
revealed that ROS can mediate synaptic degeneration (Our unpublished data)[6, 8]. 
Finally, microarray analysis exposed that Bmi1 regulates proteins involved in axonal 
guidance and neurite growth; hence loss of Bmi1 may initiate malformation of synapses 
[9].  
Our results reveal that Bmi1+/- mice present increased p53 activation, tau 
phosphorylation, and Aß expression. p53 protein is significantly elevated in brains of AD 
patients compared to healthy elderly controls [10]. Evidence of the pivotal role of p53 in 
neurodegeneration is provided by data from both in vitro and in vivo studies. Increased 
p53 immunoreactivity associated with neuronal death was observed in several models of 
brain injuries. Conversely, p53 inhibition prevents death in cultured neurons exposed to 
DNA-damaging agents and amyloid peptides [11]. DNA damage, oxidative stress and Arf 
are potent activators of p53 protein. Using cultured Bmi1-deficient neurons, we 
demonstrated that p53 activation in our model was neither due to increased oxidative 
stress nor de-repression of Ink4A/Arf locus, but due to activation of DDR kinases ATM 
and ATR (Annexe I, Figure 1), suggesting that DNA damage accumulation in Bmi1 
mutant neurons promotes p53 activation.  
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Surprisingly, Tau phosphorylation was also abrogated after treatment of Bmi1-/- 
neurons with inhibitors of ATM and ATR. Tau phosphorylation in our model could be 
caused by p53 upregulation. One study reported that p53 could induce Tau 
phosphorylation in vitro [10]. Other mechanistic possibility includes DDR kinases. 
Mendoza et al. demonstrated that the DNA-damage checkpoint kinases Chk1 and Chk2, 
which operate downstream of ATR and ATM respectively, phosphorylate tau protein at 
an AD-related site and enhance tau toxicity [12]. Moreover, tau can also be 
phosphorylated by the stress-activated JNK kinase, which is also upregulated in Bmi1+/- 
mice [13]. Thus, there are several possible ways in which Bmi1 may be regulating Tau 
phosphorylation downstream of DNA damage and it will be interesting to dissect to the 
contribution of each. 
Remarkably, the JNK pathway is also involved in oxidative stress-induced 
upregulation of ß-site APP cleaving enzyme 1 (BACE1), which expression is elevated in 
LOAD brains [14,15]. The lipid peroxidation metabolite 4-Hydroxynonenal induces 
BACE1 expression, linking JNK and ROS to Aβ metabolism [16]. We observed 
increased accumulation of amyloid-ß peptides, which correlated with BACE1 
upregulation, in the cortices of Bmi1+/- mice. Bmi1 mutation triggers ROS generation as 
well as elevated lipid peroxidation levels due to p53-mediated repression of antioxidant 
genes in the brain [1]. We detected that upon deletion of p53 in Bmi1-/- mice, amyloid 
accumulation is mitigated in the brain (Our unpublished data). Therefore, BACE1 
upregulation and amyloid deposition in our model could involve directly p53 pro-oxidant 
activity in neurons. On the other hand, since Bmi1 operates as a transcriptional silencer, it 
could also repress directly the expression of BACE1. The multifaceted ways in which 
Bmi1 affects amyloid accumulation, like other AD hallmarks, has yet to be scrutinized 
but the convergence of p53, ROS and JNK to BACE1 suggests that this enzyme may be 
an important mediator. 
Of note, some pathological marks such as p-TAU (S396) and SA b-galactosidase 
activity, although less abundant, were also detected in the brains of old WT mice. This 
finding correlates with a report showing that brains of some aged normal individuals 
display neurodegenerative hallmarks such as S396-tau neurofibrillary tangles [17]. 
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Nonetheless, p-TAU (S202), p-JNK and amyloid expression were not yet observed in 24-
month old WT mice but were present in 15-month Bmi1+/- mice, indicating that these 
features are associated with pathological AD-like ageing and not with physiological 
ageing. Better characterization of hallmarks of AD vs normal ageing is important not 
only for proper identification of Alzheimer’s patients, but also in order to develop proper 
strategies for targeting the causative dysfunctional pathways. 
A critical question that remains unresolved in all currently available animal 
models of AD, is how well do they model the disease where there are no mutations in 
either APP or tau. Therefore, development of animal models mimicking the 
neuropathology of AD that are not based upon overexpression of mutant human proteins, 
as this does not reflect LOAD, is significantly needed. In our study, we describe a novel 
mouse model for LOAD pathology and we show that mice heterozygous for Bmi1 
manifest, with advancing age, AD-like phenotypic features. Surprisingly, we also found 
that 6 month-old mice, which are both transgenic for APP and heterozygous for Bmi1, 
acquire a higher level of tau phosphorylation and amyloid burden indicating a synergistic 
interaction between APP and Bmi1 in contributing to AD pathology (Annexe I, Figure 2). 
In conclusion, Bmi1+/- mouse model can greatly serve in AD research providing new 
insight in understanding the neuropathology that is different from the classical amyloid 
hypothesis and hence promoting novel ways of targeting therapies. 
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4.2. BMI1 is enriched at constitutive heterochromatin and its function is redundant 
with BRCA-1 mediated heterochromatinization 
PRC1 complex is enriched at facultative heterochromatin and is recruited by the 
PRC2-mediated H3K27me3 repressive mark [18]. Our in vitro studies demonstrate that the 
PRC1 member BMI1 is also enriched at constitutive pericentric and intergenic 
heterochromatin where it colocalizes with the repressive H3K9me3 mark and its 
accumulation was independent of PRC2-mediated H3K27me3, indicating a novel way for 
BMI1 to target chromatin that is different from the classical polycomb recruitment 
process. Consistently, our cell -fractionation assay revealed that a large portion of the 
BMI1 protein pool is bound to the SDS chromatin fraction, which is predicted to 
correspond to constitutive heterochromatin. Moreover, our ChIP analyses on cortices of 
WT mice as well as on brains of healthy individuals confirmed the enrichment of Bmi1 at 
constitutive heterochromatin domains in vivo. Furthermore, our findings indicate that 
Bmi1-mediated repression through H2A ubiquitylation is required for maintenance of 
constitutive heterochromatic regions. Though little evidence in the literature hints at 
localization of PcG proteins such as Bmi1 at constitutive heterochromatin, a few studies 
support our findings. Bernstein et al. showed that not all PcG chromodomain proteins 
bind preferentially to H3K27me3; instead some display greater affinity to H3K9me3 [19]. 
Inactivation of PcG proteins Ring1b and eed in mouse embryonic cells resulted in 
reactivation of major satellite repeats [20]. Saurin et al. reported that BMI1 is localized at 
pericentromeric chromatin in human cells and suggested that the preferential 1qh 
association of BMI1 is mediated by speciﬁc protein interaction with a repeated sequence 
motif occurring in chromosome 1-speciﬁc α-satellite DNA [21]. Van Lohuizen group 
found that the DNA methylase DNMT1 is required for BMI1 recruitment to pericentric 
regions, since its downregulation led to diffuse distribution of the BMI1 fluorescence 
throughout the nucleus [22]. This finding corroborates a study analyzing genome-wide 
Bmi1-mediated H2Aub localization and showing that enrichment of H2Aub is not limited 
to regions containing the PRC2-H3K27me3 mark but is linked instead to DNA 
methylation patterns [23].  
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The question raised is how Bmi1-mediated H2Aub deposition at constitutive 
heterochromatin translates into H3K9me3 deposition and heterochromatin spreading. 
Studies defined the mechanism by which H2Bub, a mark associated with active 
transcription, regulates other histone modifications including trimethylation of K4 and 
K79 of histone H3 by the histone methyltransferases COMPASS and Dot1, respectively 
[24]. This trans-histone crosstalk is unidirectional meaning that defects in the histone 
methylation of H3 have no reciprocal effect on the upstream ubiquitylation event [24]. 
One study revealed trans-histone crosstalk between H2Aub and H3 methylation. The 
authors found that H2A ubiquitylation inhibited H3K4 trimethylation through MLL3 
methylase and suggested that H2Aub might change the substrate specificity of MLL3 [25]. 
According to the crystal structure of the nucleosome, the C terminus of H2A and the N 
terminus of H3 are close together and form the entrance for the DNA [26]. Hence, one 
mechanistic insight is that H2Aub induces allosteric changes and enhances the affinity of 
the histone 3 substrate to H3K9 methylases such as Su(VAR) proteins. Another 
mechanism may involve p53 activity. A recent report by Mungamuri et al. revealed that 
p53 downregulates the H3K9 methylase SUV39H1 leading to heterochromatin 
reorganization [28]. On the other hand, Zhen et al. found that p53 directly induces the 
expression of the H3K9 demethylase JMJD2b through promoter binding [29]. Our 
preliminary data demonstrate that Bmi1-/-;p53-/- neurons show a rescue of the disrupted 
heterochromatin phenotype (Unpublished data).  Further delineation of this pathway is 
imminent. Other mechanistic possibility involves the RNAi pathway. As discussed 
earlier, the RNAi process is required for nucleation and spreading of constitutive 
heterochromatin by SUV39H1-HP1 pathway. Evidence also includes RNA interference 
pathway for polycomb targeting to chromatin [30].  Findings from Bishof group show 
that lncRNAs are required for BMI1/RING1B mediated gene silencing (Unpublished 
data). Therefore, the RNA interference pathway may bridge Bmi1-mediated H2Aub with 
SUV39H1-HP1 system to methylate H3K9, thus providing more binding site for HP1 to 
spread heterochromatin formation.  
 On the other hand, Bmi1-mediated H2Aub deposition can also promote 
heterochromatin compaction independent of H3K9me3. Crystallography analysis of the 
nucleosome core revealed that the C-terminal tail of H2Aub could reach the linker histone 
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H1, which is associated with high-ordered structure of chromatin and nucleosomal 
compaction. Moreover, immunoprecipitation of nucleosomes containing WT or its 
ubiquitination mutant, K119R, revealed that H1 preferentially associated with WT H2A, 
suggesting that ubiquitination of H2A facilitates interaction with H1 promoting 
heterochromatin condensation [24]. One last possibility involves the positive charge 
domain of interacting polycomb proteins such as the chromodomain protein M33 [31]. 
RYBP is an H2Aub-binding protein that interacts with RING1A/B and M33/CBX2, 
functioning as a potential link between H2Aub and condensation of nucleosomes. 
Therefore, from all these observations, we can suggest four mechanisms to delineate the 
role of Bmi1 in constitutive heterochromatin formation in our model: 1) Bmi1/Ring1b 
recruitment at constitutive heterochromatin is DNMT1-dependent promoting H2A 
ubiquitylation favouring increased affinity of H3K9 substrate to HMTases. 2) Bmi1 
represses the protein p53, which mediates heterochromatin reorganization and 
demethylation of H3K9 either via downregulation of HMTase or upregulation of histone 
demethylase. 3) Bmi1/Ring1b is targeted to constitutive heterochromatin via the RNAi 
pathway, which will also target H3K9 methyltransferases leading to constitutive 
heterochromatin initiation and spreading. And 4) Bmi1/Ring1b-mediated nucleosomal 
condensation at constitutive heterochromatin could be directly involving the conserved 
positive domains of interacting polycomb proteins and/or facilitating the binding of linker 
histone H1.   
Similarly to BMI1, BRCA1 protein also catalyzes H2A ubiquitylation and was reported 
to mediate heterochromatinization in mouse neurons. Comparably to Bmi1 heterozygous 
mice, absence of Brca1 full-length isoform causes p53-mediated accelerated ageing in 
adult mice, including decreased lifespan, reduced body fat deposition, osteoporosis, and 
skin atrophy [32]. All these findings propose that Bmi1 and Brca1 promote similar 
effects. We report that co-inactivation of BMI1 and BRCA1 in human cells triggers a 
more rigorous depletion of H2Aub, H3K9me3 and HP1 at constitutive heterochromatin 
than single BMI1 or BRCA1 deficiencies, and that BMI1 overexpression could rescue the 
BRCA1-deficient heterochromatin phenotype. These observations suggest that BMI1 and 
BRCA1 are functionally redundant for H2Aub deposition at constitutive heterochromatin. 
The observation that BMI1 and BRCA1 proteins accumulation is mutually independent 
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and that BMI1 levels are increased in BRCA1-deficient cells (and reciprocally), also 
suggest that both proteins possibly bind to the same substrate to catalyze H2Aub 
deposition.  
In conclusion, we provided substantial data demonstrating that BMI1 is associated with 
constitutive heterochromatin and that it is essential for heterochromatin maintenance in 
mouse and human cells. BMI1 also displayed functional redundancy with BRCA1 in 
heterochromatinization and was sufficient to rescue the BRCA1-deficient 
heterochromatin phenotype. 
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4.3. Significant reduction in Bmi1 expression, perturbed constitutive 
heterochromatin, and increased genomic instability at repetitive sequences in 
Bmi1+/- and LOAD, but not EOAD, brains   
In light of recent studies, epigenetic modification has emerged as one of the 
possible pathogenic mechanisms of AD [33,34]. DNA methylation is associated with 
H3K9me3, is tightly linked to heterochromatinization, is catalyzed by DNA 
methyltransferases (Dnmts), and recruits proteins known as methyl–binding domain 
proteins (MBDs) that are associated with chromatin compaction [35]. 
Immunohistochemical studies in the entorhinal cortex of AD patients revealed genome-
wide reduction in the DNA methylation marker 5-methylcytosine (5-mC) and decreased 
expression of variety of proteins involved in the process of DNA methylation, such as 
Dnmt1 and methyl-CpG–binding protein 2 (MeCP2). The group analyzed monozygotic 
twins and demonstrated substantial DNA hypomethylation in the neocortex of an LOAD 
twin compared to his non-AD identical twin pair, strengthening the role of gene-
environment interactions and epigenetics in AD progression [36]. Consistent with these 
findings, a recent study by Chouliaras et al. also showed a global robust decrease in 5-mC 
levels in the hippocampus of AD brains, which is the region of the brain associated with 
memory [37]. An emerging literature has established that the expression of certain 
transposable elements, such as some LINE, SINE and LTR transposons, is elevated in the 
brain of individuals affected with several neurodegenerative disorders including the rett 
syndrome, amyotrophic lateral sclerosis (ALS), aged-related macular degeneration, and 
sporadic Creutzfeldt-Jakob disease [38]. As mentioned earlier, transposable elements are 
highly abundant mobile genetic elements that can insert into new genomic locations, 
presenting a massive endogenous reservoir of genomic instability and cellular toxicity. 
The effects of these parasitic genetic elements are normally stifled by potent cellular 
mechanisms involving small interfering RNAs that act via the RNA induced silencing 
complex (RISC). Indeed, mutations in Drosophila Argonaute 2 (Ago2) resulted in 
exacerbated transposon expression in the brain, progressive and age-dependent memory 
impairment, and reduced lifespan [39]. Moreover, DICER-1 loss promotes Alu RNA 
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toxicity in age related macular degeneration [40]. Overall, these findings indicate that 
transposon de-repression may contribute to age-dependent loss of neuronal function.  
Bmi1+/- mice cortices and LOAD hippocampi and frontal cortices present 
significant Bmi1 and H2Aub downregulation as well as perturbed constitutive 
heterochromatin de-compaction characterized by severe reduction or nearly absence of 
H3K9me3 in neurons. One mechanism to explain this phenomenon is the fact that folate 
metabolism is required for the production of S-adenosyl-methyonine (SAM), the 
universal donor for DNA and histone methylation reactions. Interestingly, perturbations 
of the folate metabolism and SAM levels are common features in LOAD [41]. In 
Caenorhabditis elegans embryos, inhibition of SAM-synthetase results in preferential 
reduction of H3K9me3, heterochromatin de-repression and release from the nuclear 
periphery [42]. PcG proteins have been reported to play a role in SAM production, as the 
PRC1 protein CBX4 was shown to sumoylate cystathionine β-synthase (CBS), an 
enzyme involved in the conversion of homocysteine to cysteine. Sumoylation of CBS 
inhibited its enzymatic activity resulting in altered homocysteine to cysteine conversion, 
which is an important step in the synthesis of SAM [43]. In mammals, SAM is generated 
by the methionine adenosyltransferase isozyme MATIIa, which interacts in the nucleus 
with multiple chromatin remodeling complexes, including NURD and Polycomb 
Repressive Complex1 (RING1A/RING1B) [44]. Remarkably, the MATIIa-deficient 
heterochromatin phenotype cannot be rescued by SAM supplementation, indicating that 
interaction between MATIIa, chromatin and histone methyltransferases is required for 
H3K9 trimethylation and H3K9me3 loading [45]. Therefore it would be interesting to 
analyze if folate or SAM supplementation would mitigate the loss-of-Bmi1 phenotype or 
if Bmi1 is physically required, like MATIIa, in order to rescue the phenotype. This is 
pertinent in terms of evaluation if folate can be used as a treatment for LOAD or if it is 
useless in LOAD characterized by BMI1 deficiency.  
Since the main role of constitutive heterochromatin is to repress transcription, the 
observed heterochromatin decondensation in Bmi1+/- and LOAD brains may affect gene 
expression patterns and hence affect the integrity of the transcriptome. Heterochromatin 
maintenance is essential for silencing ribosomal RNA transcription; hence it would be 
intriguing to link the heterochromatin status, ribosomal RNA synthesis, and Alzheimer’s 
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disease by taking into account the energy metabolism. That is, ribosomal RNA 
transcription is a rate-limiting step in protein synthesis and hence increased RNA 
transcription would promote growth and accelerate ageing. 
Abundant reports suggested that constitutive heterochromatin is refractory to 
DNA damage; however, this notion was revisited by Chiolo et al. who demonstrated that 
γH2A and p-ATR foci are formed in heterochromatin upon DSBs [46]. Two reports 
revealed that disrupted heterochromatin induces the rate of spontaneous DSBs, leads to 
the expansion of DNA repeat arrays, and is correlated with genomic instability as well as 
reduced viability. In their model, Drosophila flies lacking the Su(var)3-9 H3K9 
methyltransferase present reduced lifespan, muscle degeneration, and significantly 
elevated frequencies of spontaneous DNA damage in heterochromatin that occur in both 
somatic and germ-line cells. DNA repair proteins and mitotic checkpoints were also 
activated in mutant flies. Similar phenotype was also observed in flies that are deficient 
of RNA interference pathway component Dcr2, indicating that H3K9 methylation and 
RNAi processes are essential for heterochromatin stability [47]. Concomitantly, deletion 
of SUV39h1/h2 methyltransferases in mice also leads to reduced viability, loss of 
H3K9me3 and genomic instability [48]. Knockdown of the chromatin remodeling complex 
NoRC, which is known to silence heterochromatic structures at centromeres and 
telomeres, leads to relaxation of heterochromatin and enhanced chromosomal instability 
[49]. Haider et al. recently reported that satellite repeat elements were significantly 
hypomethylated and upregulated in end-stage cardiomyopathic hearts relative to healthy 
normal controls. They suggest that satellite overexpression correlates with the widespread 
DNA damage observed in post-mitotic cardiomyocytes, highlighting that SAT expression 
may be a potential link between genomic damage and heart failure disease progression 
[50]. Consistent with all these findings, we show that Bmi1+/- mice cortices and LOAD 
brains show enrichment of DDR machinery, i.e. p-ATR and γH2AX, preferentially at 
constitutive heterochromatin domains. The relatively weak accumulation of p-ATM in 
LOAD brains as detected by ChIP, which is contradictory to immunoblot and 
immunohistochemistry results, suggests that a portion of the p-ATM pool is not 
chromatin-bound. This is consistent with p-ATM accumulation in both cytosolic and 
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nuclear neuronal compartments in Bmi1+/- cortices and LOAD brains (Annexe I Figure 3 
and Figure 6E) [51].  
The question is how the loss of heterochromatin compaction in LOAD and 
Bmi1+/- mice triggers DNA damage accumulation. 1) First possibility is that repetitive 
DNA sequences are intrinsically unstable upon loss of heterochromatin compaction and 
thus prone to de novo DNA damage formation. De novo mutations arise spontaneously 
and have recently been identified as contributors to neurodevelopmental disorders such as 
autism spectrum disorders, schizophrenia and mental retardation [52]. 2) Another 
explanation could involve the repetitive sequences of constitutive heterochromatin, where 
loss of chromatin condensation can lead to abnormal recombination of such sequences 
and thus genome rearrangement.  3) It is also probable that the efficacy of DNA repair is 
reduced upon BMI1 deficiency or that recognition of H3K9me3 mark and HP1 is 
important to activate the process of DNA repair in constitutive heterochromatin [53]. 
Indeed, several studies correlate HP1 with efficient DNA repair activity at 
heterochromatin sites [54]. 4) Another mechanism could involve the RNA interference 
pathway. Francia et al. identified that small RNA produced by DICER and DROSHA, 
two RNases type III enzymes that process non-coding RNA, are required to activate DDR 
and efficiently repair DNA at the damaged sites of heterochromatin. The DICER- and 
DROSHA-dependent small RNA products have the sequence of the damaged locus, and 
can restore DDR in RNase-treated cells [55]. These findings are highly important since 
they directly link RNAi-mediated heterochromatin formation with DNA repair. 5) 
Finally, it could be that the repair of damaged lesions at heterochromatin is not efficient. 
In fact, several studies reported that DNA repair at constitutive heterochromatin is 
problematic being less effective and occurring with slower kinetics [56]. A delay in repair 
of heterochromatic DSBs was observed in human cells. Moreover, DSBs occurring in 
heterochromatin are repaired by HR pathway, which leads to abnormal genome 
rearrangements in the presence of the closely clustered repeats contributing to human 
diseases such as cancer and infertility [56]. In all four cases, which are mutually non-
exclusive, persistent and prolonged exposure to cumulative neuronal DNA damage 
causes neurons to senesce, re-enter the cell cycle and/or atrophy, and ultimately 
degenerate.  
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An everlasting debate was the question is which one comes first? Do the DNA 
damage and the DDR lead to chromatin defects and thus neurodegeneration? Or it is that 
loss of chromatin structure makes the cell more susceptible to DNA damage, increases 
genome instability, and therefore promotes neuropathology? A study by Pegoraro et al. 
endorses that chromatin anomalies occur prior to DNA damage. They reported that 
knocking down of the chromatin remodeling complex NURD, involved in establishment 
of heterochromatin, leads to aberrant chromatin structure indicated by loss of H3K9me3 
foci about 50h earlier than DNA damage characterized by γH2AX foci presence [57]. 
Our findings also support that heterochromatin defects largely precede DNA damage 
accumulation and the ensuing neuropathology. Embryonic Bmi1+/- neurons and 3-month 
old Bmi1+/- mice display reduced levels of H2Aub and H3K9me3 as well as diffused 
distribution of HP1 protein, which largely preceded ATM/Chk2 and ATR/Chk1 
activation as well as expression of neuropathological proteins. Using Bmi1-deficient 
neurons, we show that a causal relationship could be established between activation of 
ATM/ATR and accumulation of the pathological proteins p53 and p-TAU, strengthening 
further the notion that persistent DDR in post-mitotic neurons is sufficient to favour 
neurodegeneration. Overall, these observations suggest that epigenetic and chromatin 
structure changes are in the upstream of DNA damage events.   
Our data revealed critical differences between familial and spontaneous AD. 
Heterochromatin anomalies were not present in EOAD samples, thus excluding 
neurodegeneration as the primary cause. We also found a molecular dichotomy between 
EOAD and LOAD at the level of BMI1 expression and DDR activation. This suggests 
that EOAD and LOAD represent two pathologies that are triggered by distinct 
mechanisms that ultimately result in the same neuropathology i.e. amyloid deposition and 
tau phosphorylation. It has been proposed that the amyloid hypothesis may only hold for 
familial forms of the disease but that the situation is much more complex in late-onset 
forms. Clinical findings from a growing number of Aβ-reducing drug trials in LOAD 
show that this strategy is not potent. Therefore, these observations may have important 
consequences in developing alternative therapies for LOAD such as upregulating BMI1 
in neurons by gene therapy [58].  
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Bmi1 protein levels in the cortices of 15-month old Bmi1+/- mice and LOAD 
brains, as measured by Western blot and ChIP analyses, were severely reduced or even 
nonexistent in some LOAD cases. One possibility is that the Bmi1 protein, alone or in 
complex with Ring1b, binds to its own product (i.e. H2Aub) or to H3K9me3, thus creating 
a self-enforcing loop to amplify H2Aub deposition and heterochromatin formation [43]. 
Sub-optimal self-enforcing mechanism and the ensuing loss of chromatin association 
would result in Bmi1 protein destabilization and degradation. Another possibility 
involves miRNA-218, which was shown to promote apoptosis by downregulating BMI1 
in colon cancer. Interestingly, miRNA-218 gene is localized at intergenic 
heterochromatin and is enriched in aged mouse cortex and hippocampus [59]. It would be 
interesting to analyze if miRNA-218 also targets BMI1 in the brain and regulates its 
decreased expression with age and AD. This suggestion could be illustrated by a 
regulating cycle where BMI1 represses the expression of this miRNA through its 
heterochromatin mediated compaction; however decreased dosage of BMI1 would favour 
de-repression of the miRNA-218 gene and hence lead to further BMI1 downregulation. 
So far, only one reported polymorphism (C18Y) in the RING domain of BMI1 gene was 
associated with a significant decrease in BMI1 levels in humans, inducing elevated 
ubiquitination and proteasomal degradation [60]. It would be interesting to evaluate if 
LOAD patients present this polymorphism.  
 
In conclusion, our study is greatly pertinent in Alzheimer’s disease research and 
in delineating the function of Bmi1 in genomic stability (Figure 1). We provided three 
main novel tools and concepts. 
1- Aged Bmi1 heterozygous mice could be an interesting model for LOAD 
research. To our knowledge, there are no models recapitulating this form of the disease. It 
would be interesting to examine if Bmi1 re-expression in neurons could rescue the 
pathological phenotype.   
2- Bmi1 was previously reported to associate with facultative heterochromatin. 
We are first to demonstrate that it is also enriched at constitutive intergenic and 
pericentric heterochromatin and that this association is H3K27me3 independent, 
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suggesting other mechanisms for polycomb chromatin targeting. Moreover, loss of Bmi1 
enrichment correlates with increased genomic instability at heterochromatic regions.  
3- We also observed that BMI1 deficiency and constitutive heterochromatic 
genome instability in human brains are hallmarks of LOAD but not of EOAD. This 
finding indicates that these two disorders differ in their triggering mechanisms however 
the final neuropathology is similar in both.  
 
In order to mechanistically recapitulate the whole pathological process, treatment 
of WT cortical neurons with drugs that induce heterochromatin decompaction such as 
HDAC inhibitors is required. Conversely, treatment of Bmi1-/- cortical neurons with 
inhibitors of the histone demethylase Jumonji should rescue the phenotype. Furthermore, 
in order to demonstrate our proof of principle relating Bmi1 loss with progression of 
LOAD in humans, overexpression or knocking down of Bmi1 in LOAD and healthy 
cortical neurons is required. Subsequently, we can evaluate if Bmi1 overexpression 
rescues the pathological phenotype in LOAD neurons or if Bmi1 knock-down in healthy 
neurons promotes heterochromatin decondensation and neurodegeneration. Human 
cortical neurons of LOAD or healthy individuals can be obtained from differentiated iPS 
cells. It is also highly important to evaluate if Bmi1 deficiency and reduced H3K9me3 
levels can also be detected in the lymphocytes of Bmi1+/- mice and LOAD patients. This 
is highly pertinent in terms of development of biomarkers for LOAD.  
Our study opens the door to potential treatments and diagnostic biomarkers for 
age-related Alzheimer’s disease… the question that remains is whether we can delineate 
the process well enough so that we can actually develop a molecular fountain of youth. 
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Figure 1: Working model describing the process by which epigenetic modifications of 
constitutive heterochromatin lead to LOAD progression. Disrupted heterochromatin 
results in genomic instability as well as activation of the DNA damage and chromatin 
stress sensors ATM and ATR. These kinases, working at the apex of the cascade, can 
subsequently activate p53 and the Chk1 and Chk2 kinases. This pathological cascade is 
sufficient, at least in mice, to induce beta-Amyloid and p-TAU accumulation, hallmarks 
of LOAD. 
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Figure 1: A. Treatment of Bmi1-/- cortical neurons with the ROS scavenger NAC did not 
inhibit p53 activation. B. DKO Bmi1-/-;INK4A/Arf-/- cortical neurons did not rescue the 
pathological accumulation of p53. C. Quantification of the results in B. D. p53 was still 
upregulated in Bmi1-/- neurons even after treatment with an ATM inhibitor. E. 
Quantification of the results in D. 
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Figure 2: Genetic cooperation between Bmi1 and APP. A. 6-month old APP; Bmi1+/- 
mice present a significant reduction in median lifespan. B. & D. 6-month old APP; 
Bmi1+/- mice show significant formation of p-Tau tangles and amyloid plaques deposition 
in several cortical sections, compared to APP mice cortices alone. C. &. E. 
Quantification of B. & D. 
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Figure 3: Immunohistochemistry on cortical sections of old WT and Bmi1+/- reveals 
important accumulation of p-ATM in the nucleus and cytosol of aged Bmi1+/- neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
